CN1835948B - 2-酰基氨基噻唑衍生物或其盐 - Google Patents
2-酰基氨基噻唑衍生物或其盐 Download PDFInfo
- Publication number
- CN1835948B CN1835948B CN2004800204978A CN200480020497A CN1835948B CN 1835948 B CN1835948 B CN 1835948B CN 2004800204978 A CN2004800204978 A CN 2004800204978A CN 200480020497 A CN200480020497 A CN 200480020497A CN 1835948 B CN1835948 B CN 1835948B
- Authority
- CN
- China
- Prior art keywords
- alkyl
- unsubstituted
- group
- replace
- methyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Epidemiology (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
基于良好的人c-mpl-Ba/F3细胞增殖作用及巨核细胞集落形成促进作用而具有血小板增多活性的2-酰基氨基噻唑衍生物或其盐。对血小板减少症的治疗有用。
Description
技术领域
本发明涉及作为药剂,尤其血小板减少症治疗剂有用的新颖的2-酰基氨基噻唑衍生物或其盐,还涉及包含一种或多种所述化合物作为活性成分的药剂。
背景技术
血小板是对生理止血及病理性血栓的形成起主要作用的无核血细胞。在体内,血小板由作为前体细胞的巨核细胞不断产生。血小板的产生与其它血细胞一样来自于多能干细胞,多能干细胞转变为巨核细胞系的前体细胞,再由此转变为原始巨核细胞、幼稚巨核细胞、巨核细胞。该巨核细胞的成熟过程中,未成熟的巨核细胞仅进行不伴随细胞分裂的DNA合成,形成多倍体。其后,细胞质开始成熟,形成血小板分离膜,细胞质分裂,血小板被释放出来。
另一方面,贫血、骨髓发育不良综合征或恶性肿瘤的化学疗法、放射疗法等时的各种造血障碍导致的血小板减少会引发出血倾向等严重的症状,所以正在尝试进行以治疗这些疾病为目的的使血小板增多的各种技术的开发。现在,血小板减少症治疗的有力手段是输血小板,但尚不能供给足够量的血小板,并且输入的血小板的寿命很短。因而很难充分改善血小板减少症。此外,输血小板存在病毒感染、同种抗体的产生和移植物抗宿主病(Graft Versus Host Disease(GVHD))等问题。因此,希望开发出缓解由各种疾病或疗法所引起的造血机能的抑制状态,促进血小板数目的恢复的药物制剂。
这些情况中,有报道与巨核细胞系细胞的分裂有关的主要因子,作为c-Mpl配体的血小板生成素(以下称为TPO)已被克隆,可刺激巨核细胞系细胞的分裂和增殖,刺激血小板的产生(Kaushansky K.等,Nature,369,568-571,1994:非专利文献1)。TPO作为血小板增多剂已被进行临床试验,确认其对人的有用性和耐受性。但是,作为TPO的一种的PEG-rHuMGDF(TPO的N末端开始的第163号氨基酸被聚乙二醇修饰的物质)的临床试验中,确认了有中和抗体出现(Li J.等,Blood,98,3241-3248,2001:非专利文献2,以及Basser R.L.等,Blood,99,2599-2602,2002:非专利文献3),所以担心TPO有免疫原性。此外,由于TPO为蛋白质,所以会在消化管内被分解,作为口服制剂并不实用。基于同样的理由,低分子肽作为口服制剂也不实用。这种情况下,以血小板减少症的治疗为目的进行着免疫原性小、可口服的非肽性c-Mpl配体的开发。
上述化合物已知有苯并二氮杂衍生物(专利文献1)、酰基腙衍生物(专利文献2)、重氮萘衍生物(专利文献3)、吡咯并咔唑衍生物(专利文献4)、吡咯并菲啶衍生物(专利文献5)、吡咯并邻苯二甲酰亚胺衍生物(专利文献6)。
国际公开WO 01/07423号(专利文献7)记载了以下的通式(VII)表示的化合物具有血小板增多作用。
(式中符号含义参照该公报)
该公报中记载了X1为可被取代的噻唑,Y1为-NHCO-的化合物。但是本发明化合物中的R3未被该公报中的具有如噻唑基的A1取代基取代。而且,该公报中的实施例及其它地方对噻唑5位上被由氮原子取代的低级烷基取代的化合物无具体记载。
国际公开WO 01/53267号(专利文献8)记载了以下通式(VIII)表示的化合物具有血小板增多作用。
X1-Y1-Z1-W1 (VIII)
(式中符号含义参照该公报)
该公报中,有关于X1为可被取代的噻唑,Y1为-NHCO-的化合物的记载。但是本发明化合物中的R3未被该公报中的具有W1的取代基取代。而且,该公报中的实施例及其它地方对噻唑5位上被由氮原子取代的低级烷基取代的化合物无具体记载。
国际公开WO 02/62775(专利文献9)记载了以下通式(IX)表示的化合物具有血小板增多作用。
(式中符号含义参照该公报)
该公报中,有2-酰基氨基噻唑的5-位直接被氮原子取代的化合物的记载。但是,没有描述本发明的噻唑5-位上被由氮原子取代的低级烷基取代的化合物。
国际公开WO 03/062233(专利文献10)记载了以下通式(X)表示的化合物具有血小板增多作用。
(式中符号含义参照该公报)
该公报中,有2-酰基氨基噻唑的5-位直接被氮原子取代的化合物的记载。但是,没有描述本发明的噻唑5-位上被由氮原子取代的低级烷基取代的化合物。
除了上述专利文献7-10之外,2-酰基氨基噻唑化合物在专利3199451号(专利文献11)中作为缩胆囊素及胃泌素受体拮抗剂,或在Chemical andPharmaceutical Bulletin,25,9,2292-2299,1977(非专利文献4)中作为具有抗炎症特性的化合物被揭示,但均未触及本发明的血小板增多作用。
上述情况下,希望以血小板减少症的治疗为目的,进行免疫原性小、可口服的非肽性c-Mpl配体的开发。
[专利文献1]JP-A-11-152276
[专利文献2]WO 99/11262小册子
[专利文献3]WO 00/35446小册子
[专利文献4]WO 98/09967小册子
[专利文献5]JP-A-10-212289
[专利文献6]JP-A-2000-44562
[专利文献7]WO 01/07423小册子
[专利文献8]WO 01/53267
[专利文献9]WO 02/62775小册子
[专利文献10]WO 03/062233小册子
[专利文献11]专利No.3199451
[非专利文献1]Nature,1994,No.369,p.568-571
[非专利文献2]Blood,2001,vol.98,p.3241-3248
[非专利文献3]Blood,2002,vol.99,p.2599-2602
[非专利文献4]Chemical and Pharmaceutical Bulletin,1977,vol.25,No.9,p.2292-2299
发明内容
本发明者对具有血小板增多作用的化合物进行认真研究后发现了新颖的2-酰基氨基噻唑衍生物具有良好的血小板增多作用,从而完成了本发明。
即,本发明提供了以下(1)~(15)。
(1)包含式(I)表示的2-酰基氨基噻唑衍生物或其药学上可接受的盐为有效成分的血小板增多剂。
式中符号具有以下含义:
A:低级亚烷基
R1:式(II)表示的基团或可被取代的环状胺基。
式中符号具有以下含义:
R11:H、可被取代的低级烷基或可被取代的环烷基。当A表示亚甲基时,R11可以是桥接到R2表示的噻吩基或苯基的亚甲基。当A表示亚甲基时,R11可以是可被取代并在A表示的亚甲基上闭合形成环的低级亚烷基。
R12:低级烷基、环烷基或非芳族杂环,它们各自可以被取代。
R2:噻吩基或苯基,它们各自可以被取代。
R3:芳族杂环、芳基或环状胺基,它们各自可以被取代。
(2)(1)所述的药物组合物,其中A是亚甲基。
(3)(2)所述的药物组合物,其中R2是噻吩基或苯基,它们各自被一个或多个选自可被一个或多个卤素取代的低级烷基以及卤素的基团取代。
(4)(1)至(3)中任一项所述的药物组合物,是一种血小板减少症治疗剂。
(5)(1)至(3)中任一项所述的药物组合物,是一种c-Mpl配体。
(6)由化学式(III)表示的2-酰基氨基噻唑衍生物或其药学上可接受的盐。
式中符号具有以下含义:
B:按照(1)中的A表示的基团。
R4:按照(1)中的R1表示的基团。
R5:按照(1)中的R2表示的基团。
R6:按照(1)中的R3表示的基团,条件是不包括未取代的苯基和可被取代的吲哚。
(7)(6)所述的化合物,其中B是亚甲基。
(8)(7)所述的化合物,其中R5是噻吩基或苯基,它们各自被一个或多个选自可被一个或多个卤索取代的低级烷基以及卤素的基团取代。
(9)(8)所述的化合物,其中R6是可被取代的吡啶基或被取代的苯基。
(10)(8)所述的化合物,其中R6是吡啶-3-基,其5-位被选自氯和氟的基团取代,且其6-位被取代,或者苯基,其3-位被选自氯和氟的基团取代,其5-被选自-H、氯和氟的基团取代,且其4-位被取代。
(11)(6)所述的化合物中,选自化合物组X及化合物组Y的化合物或其药学上可接受的盐,较好的是选自化合物组X的化合物,
这里,“化合物组X”为
1-{3-氯-5-[(4-(4-氯噻吩-2-基)-5-{[环丁基(甲基)氨基]甲基}噻唑-2-基)氨基甲酰基]-2-吡啶基}哌啶-4-羧酸,
1-(5-{[5-{[丁基(甲基)氨基]甲基}-4-(4-氯噻吩-2-基)噻唑-2-基]氨基甲酰基}-3-氯-2-吡啶基)哌啶-4-羧酸,
1-{5-[(4-(4-氯噻吩-2-基)-5-{[(2R)-2-甲基吡咯烷-1-基]甲基}噻唑-2-基)氨基甲酰基]-3-氟-2-吡啶基}哌啶-4-羧酸,
1-{3-氯-5-[(4-(4-氯噻吩-2-基)-5-{[(2S)-2-甲基吡咯烷-1-基]甲基}噻唑-2-基)氨基甲酰基]-2-吡啶基}哌啶-4-羧酸,
1-(3-氯-5-{[4-(4-氯噻吩-2-基)-5-(二甲基氨基甲基)噻唑-2-基]氨基甲酰基}-2-吡啶基)哌啶-4-羧酸,
1-{3-氯-5-[(4-(4-氯噻吩-2-基)-5-{[异丙基(甲基)氨基]甲基}噻唑-2-基)氨基甲酰基]-2-吡啶基}哌啶-4-羧酸,
4-[{3-氯-5-[(4-(4-氯噻吩-2-基)-5-{[异丙基(甲基)氨基]甲基}噻唑-2-基)氨基甲酰基]-2-吡啶基}(甲基)氨基]丁酸,
1-{3-氯-5-[(4-(4-氯噻吩-2-基)-5-{[(3S)-3-甲基吡咯烷-1-基]甲基}噻唑-2-基)氨基甲酰基]-2-吡啶基}哌啶-4-羧酸,
1-{3-氯-5-[(4-(4-氯噻吩-2-基)-5-{[[(2S)-2-甲氧基丙基](甲基)氨基]甲基}噻唑-2-基)氨基甲酰基]-2-吡啶基}哌啶-4-羧酸,
N-[5-{[丁基(甲基)氨基]甲基}-4-(4-氯噻吩-2-基)噻唑-2-基]-5-氯-6-[(3-羟基丙基)氨基]烟酰胺,
N-[5-{[丁基(甲基)氨基]甲基}-4-(4-氯噻吩-2-基)噻唑-2-基]-5-氯-6-(3-氧代哌嗪-1-基)烟酰胺和
N-[5-{[丁基(甲基)氨基]甲基}-4-(4-氯噻吩-2-基)噻唑-2-基]-5-氯-6-[4-(羟甲基)哌啶子基]烟酰胺,以及
其药学上可减少的盐;
“化合物组Y”为
1-{3-氯-5-[(4-(4-氯噻吩-2-基)-5-{[(2R)-2-甲基吡咯烷-1-基]甲基}噻唑-2-基)氨基甲酰基]-2-吡啶基}哌啶-4-羧酸,
4-[{3-氯-5-[(4-(4-氯噻吩-2-基)-5-{[(2R)-2-甲基吡咯烷-1-基]甲基}噻唑-2-基)氨基甲酰基]-2-吡啶基}(甲基)氨基]丁酸,
4-[{3-氯-5-[(4-(4-氯噻吩-2-基)-5-{[(2S)-2-甲基吡咯烷-1-基]甲基}噻唑-2-基)氨基甲酰基]-2-吡啶基}(甲基)氨基]丁酸,
1-{5-[(4-(4-氯噻吩-2-基)-5-{[(2S)-2-甲基吡咯烷-1-基]甲基}噻唑-2-基)氨基甲酰基]-3-氟-2-吡啶基}哌啶-4-羧酸,
(1-{3-氯-5-[(4-(4-氯噻吩-2-基)-5-{[(2R)-2-甲基吡咯烷-1-基]甲基}噻唑-2-基)氨基甲酰基]-2-吡啶基}氮杂环丁烷-3-基)乙酸,
(1-{3-氯-5-[(4-(4-氯噻吩-2-基)-5-{[(2S)-2-甲基吡咯烷-1-基]甲基}噻唑-2-基)氨基甲酰基]-2-吡啶基}氮杂环丁烷-3-基)乙酸,
1-(3-氯-5-{[5-{[异丙基(甲基)氨基]甲基}-4-(4-甲基噻吩-2-基)噻唑-2-基]氨基甲酰基}-2-吡啶基)哌啶-4-羧酸,
1-{3-氯-5-[(4-(4-氯噻吩-2-基)-5-{[(3R)-3-甲基吡咯烷-1-基]甲基}噻唑-2-基)氨基甲酰基]-2-吡啶基}哌啶-4-羧酸,
1-{3-氯-5-[(4-(4-氯噻吩-2-基)-5-{[[(2R)-2-甲氧基丙基](甲基)氨基]甲基}噻唑-2-基)氨基甲酰基]-2-吡啶基}哌啶-4-羧酸,
1-(5-{[5-(氮杂环庚烷(azepan)-1-基甲基)-4-(4-氯噻吩-2-基)噻唑-2-基]氨基甲酰基}-3-氯-2-吡啶基)哌啶-4-羧酸,
1-{3-氯-5-[(4-(4-氯噻吩-2-基)-5-{[(2-甲氧基乙基)(甲基)氨基]甲基}噻唑-2-基)氨基甲酰基]-2-吡啶基}哌啶-4-羧酸,
1-(5-{[5-氮杂环辛烷(azocan)-1-基甲基)-4-(4-氯噻吩-2-基)噻唑-2-基]氨基甲酰基}-3-氯-2-吡啶基)哌啶-4-羧酸,
1-{3-氯-5-[(4-(4-氯噻吩-2-基)-5-{[环己基(甲基)氨基]甲基}噻唑-2-基)氨基甲酰基]-2-吡啶基}哌啶-4-羧酸,和
1-{3-氯-5-[(4-(4-氯噻吩-2-基)-5-{[环丙基(甲基)氨基]甲基}噻唑-2-基)氨基甲酰基]-2-吡啶基}哌啶-4-羧酸,以及
其药学上可减少的盐。
(12)一种药物组合物,包含(6)-(10)中任一项所述的化合物作为活性成分。
(13)(11)所述的药物组合物,是血小板增多剂。
(14)(11)所述的药物组合物,是血小板减少症治疗剂。
(15)(11)所述的药物组合物,是c-Mpl配体。
由化学式(I)表示的化合物中的A和由化学式(III)表示的化合物中的B较好是亚甲基。
由化学式(I)表示的化合物中的R1和由化学式(III)表示的化合物中的R4较好是由化学式(II)表示的基团,其中,R11是低级烷基,R12是可被分别取代的低级烷基或环烷基,或可被低级烷基取代的环状胺基;更好是由化学式(II)表示的基团,其中R11是甲基,R12是低级烷基或环烷基,它们可被分别取代,或可被甲基取代的环状胺基。
由化学式(I)表示的化合物中的R2和由化学式(III)表示的化合物中的R5较好是可被取代的噻吩基;更好是被一个或多个选自被一个或多个卤素取代的低级烷基以及卤素的基团取代的噻吩基;最好是被一个或多个选自氯和甲基的基团取代的噻吩基;尤其是4-氯噻吩-2-基或4-甲基噻吩-2-基。在另一个实施方式中,由化学式(I)表示的化合物中的R2和由化学式(III)表示的化合物中的R5较好可以是可被取代的苯基;更好是被一个或多个选自被一个或多个卤素取代的低级烷基以及卤素的基团取代的苯基;最好是被一个或多个选自三氟甲基、氯和氟的基团取代的苯基;尤其是3-三氟甲基苯基、4-氟苯基或3-氯苯基。
由化学式(I)表示的化合物中的R3和由化学式(III)表示的化合物中的R6较好是可被取代的吡啶基;更好是被至少一个卤素取代的吡啶基;最好是吡啶-3-基,且其5-位被选自氯和氟的基团取代,且其6-位被取代。其中,优选其6-位被选自哌啶-1-基或哌嗪-1-基的基团取代的吡啶-3-基,所述哌啶-1-基或哌嗪-1-基各自被一个或多个选自以下的基团取代:被取代基W取代的低级烷基、取代基W和氧代、-O-低级烷基、-NH-低级烷基或-N(低级烷基)-低级烷基,它们可以分别被一个或多个选自取代基W的基团取代,且其5-被选自氯和氟的基团取代。
本文中,“取代基W”指以下的基团:-OH、-O-RZ、-OCO-RZ、羧基、-CO2-RZ、-CO-RZ和可被一个或两个RZ取代的氨基甲酰基(当氨基甲酰基被两个RZ取代时,它们可以相同或不同)、氰基、可被一个或两个RZ取代的氨基(当氨基被两个RZ取代时,它们可以相同或不同)、-NHCO-RZ、-NHSO2-RZ、可被一个或两个RZ取代的氨磺酰基(当氨磺酰基被两个RZ取代时,它们可以相同或不同)、-SO3H、-P(O)(OH)2、-P(O)(OH)(ORZ)、-P(O)(ORZ)2、芳族杂环、非芳族杂环和RZ。“RZ”表示低级烷基、环烷基或非芳族杂环,它们各自可以被一个或多个选自以下的基团取代:-OH、-O-低级烷基(此低级烷基可以被一个或多个选自-OH、-O-低级烷基和氨基的取代基取代)、-OCO-低级烷基、羧基、-CO2-低级烷基、-CO-低级烷基、可被一个或两个低级烷基取代的氨基甲酰基(当氨基甲酰基被两个低级烷基取代时,它们可以相同或不同),氰基、可被一个或两个低级烷基取代的氨基(当氨基被两个低级烷基取代时,它们可以相同或不同),-NHCO-低级烷基、-NHSO2-低级烷基、可被一个或两个低级烷基取代的氨磺酰基(当氨磺酰基被两个低级烷基取代时,它们可以相同或不同)、-SO3H、-P(O)(OH)2、-P(O)(OH)(O-低级烷基)、-P(O)(O-低级烷基)2、芳族杂环、非芳族杂环和卤素(这适用于下面)。
在另一个实施方式中,由化学式(I)表示的化合物中的R3和由化学式(III)表示的化合物中的R6较好是可被取代的苯基;更好是被至少一个卤素取代的苯基;最好是其3-位被选自氯和氟的基团取代,其5-位被选自-H、氯和氟的基团取代,且其4-被取代的苯基。其中,优选其4-位被选自哌啶-1-基或哌嗪-1-基的基团取代,其3-位被选自氯和氟的基团取代,其5-位被选自-H、氯和氟的基团取代的苯基,所述哌啶-1-基和哌嗪-1-基各自被一个或多个选自以下的基团取代:被取代基W取代的低级烷基、取代基W和氧代、-O-低级烷基、-NH-低级烷基或可分别被一个或多个选自取代基W的基团取代的-N(低级烷基)-低级烷基。
在R11中,“当A表示亚甲基时,R11可以是桥接到R2表示的噻吩基或苯基的亚甲基”具体指例如表30所示化合物的一部分结构。
在R11中,“当A表示亚甲基时,R11可以是可被取代并在A表示的亚甲基上闭合形成环的低级亚烷基”具体指例如在表33所示化合物的一部分结构。
本发明的化合物的化学结构上的特征在于是2-位被酰基氨基取代、5-位被由氮原子取代的低级烷基取代的2-酰基氨基噻唑衍生物。本发明化合物显现出人c-mpl-Ba/F3细胞增殖活性,促进人CD34+细胞分裂成巨核细胞活性,以及小鼠口服试验中的良好的口服活性,其结果是,本发明化合物具有显现血小板增多作用的药理学性能。
下面,进一步说明本发明的化合物。
本说明书中,对“低级”一词如无特别说明,表示碳原子数1-6的直链或支链碳链。
因此,“低级烷基”表示C1-6烷基,具体例子包括甲基、乙基、丙基、异丙基、丁基、异丁基、仲丁基、叔丁基、戊基、新戊基、己基等,较好为作为C1-3烷基的甲基、乙基、丙基、异丙基。
“低级-亚烷基”表示C1-6烷基的二价基团,较好为作为C1-4亚烷基的亚甲基、亚乙基、三亚甲基、甲基亚乙基、四亚甲基、二甲基亚甲基和二甲基亚乙基。更好为是亚甲基和亚乙基,最好是亚甲基。
“环烷基”表示C3-8的碳环,它们可部分具有一个或多个不饱和键。因此,具体例子包括环丙基、环丁基、环戊基、环己基、环辛基、环丁烯基、环己烯基、环辛二烯基等。
“芳基”表示C6-14的单环至三环的芳香环,较好为苯基、萘基,更好为苯基。
“环状胺基”表示3-至8-元非芳香族环状胺的单价基团,具有至少一个氮原子,并还可具有一个或多个选自氮、氧和硫的杂原子,当有多个杂原子时,它们可以相同或不同,并且至少一个氮原子具有成键位点。具体例子包括:氮杂环丁烷、吡咯烷、哌啶、氮杂环庚烷(azepane)、氮杂环辛烷(azocane)、氮杂环壬烷(azonane)、氮杂环癸烷(azecane)、哌嗪、高哌嗪、吗啉和硫代吗啉(thiomorpholine)等的单价基团。
“非芳族杂环”表示具有一个或多个选自氮、氧和硫的杂原子的非芳族杂环的单价基团,当有多个杂原子时,它们可以相同或不同。具体例子包括四氢呋喃、四氢吡喃、四氢噻吩、四氢噻喃、氧杂环丁烷、氮杂环丁烷、吡咯烷、哌啶、氮杂环庚烷、哌嗪、高哌嗪、吗啉和硫代吗啉等的单价基团。
“芳族杂环”表示具有一个或多个选自氮、氧和硫的杂原子的5-或6-元芳族杂环的单价基团,当有多个杂原子时,它们可以相同或不同,或该杂环被部分氢化。具体例子包括吡啶、吡嗪、嘧啶、哒嗪、吡咯、咪唑、恶唑、噻唑、噻吩和呋喃的单价基团。这些杂环可以与苯环稠合。
“卤素”的例子包括氟、氯、溴和碘,较好是氟和氯。
本说明书中,对于“可被取代”和“取代的”词语所允许的取代基,可以是任何取代基,只要是通常用作各基团的取代基。这些取代基中的一个或多个可存在于各基团中。
对于在R1和R4中的“可被取代的环状胺基”,R11中的“可被取代的环烷基”、R12中的“可分别被取代的环烷基或非芳族杂环”和R2和R5中的“可被取代的噻吩基或苯基”中所允许的取代基,可例举以下的(a)~(h)所示的基团。
(a)卤原子;
(b)-OH、-O-RZ、-O-芳基、-OCO-RZ、氧代基(=O);
(c)-SH、-S-RZ、-S-芳基、-SO-RZ、-SO-芳基、-SO2-RZ、-SO2-芳基、可被1个或2个RZ取代的氨磺酰基;
(d)可被1个或2个RZ取代的氨基、-NHCO-RZ、-NHCO-芳基、-NHCO2-RZ、-NHCONH2、-NHSO2-RZ、-NHSO2-芳基、-NHSO2NH2、硝基;
(e)-CHO、-CO-RZ、-CO2H、-CO2-RZ、可被1个或2个RZ取代的氨基甲酰基、氰基;
(f)可被一个或多个选自-OH、-O-低级烷基、可被1个或2个低级烷基取代的氨基、卤原子及RZ的基团分别取代的芳基或环烷基;
(g)可被一个或多个选自-OH、-O-低级烷基、可被1个或2个低级烷基取代的氨基、卤原子及RZ的基团分别取代的芳族杂环或非芳族杂环;
(h)可被一个或多个选自上述(a)~(g)所示的取代基的基团取代的低级烷基。
R11中的“可被取代的低级烷基”和“可被取代的低级亚烷基”以及R12中的“可被取代的低级烷基”中所允许的取代基包括在(a)至(g)中列出的基团。
R3和R6中的“可分别被取代的芳族杂环、芳基或环状胺基”中所允许的取代基的例子包括卤素、可被一个或多个卤素取代的低级烷基、-OH、-O-RZ、氧代、可被1个或2个RZ取代的氨基以及化学式(III)表示的基团。当取代基是被2个RZ取代的氨基时,两个RZ可以相同或不同。
-X-Y-Z (III)
式中符号具有以下含义:
X:环胺二基,可被一个或多个选自-OH、-O-低级烷基、卤素、氧代和RZ的基团取代。
Y:单键、-O-低级亚烷基或-N(低级烷基)-低级亚烷基。
Z:取代基W、-环胺二基-取代基W或-CO-环胺二基-取代基W。
“环胺二基”指3-至8-元非芳族环状胺的二价基团,可有至少一个氮原子,还可有一个或多个选自氮、氧和硫的杂原子,有多个杂原子时,它们可以相同或不同,并且至少一个氮原子有键合位点。具体例子包括氮杂环丁烷、吡咯烷、哌啶、氮杂环庚烷、氮杂环辛烷、氮杂环壬烷、氮杂环癸烷、哌嗪、高哌嗪、吗啉和硫代吗啉的二价基团。
为本发明药剂的活性成分的化学式(I)表示的化合物或为本发明化合物的化学式(III)表示的化合物有时因取代基的种类而含有手性碳原子,可存在基于此的光学异构体。本发明包含所有这些光学异构体的混合物和分离的光学异构体。此外,本发明化合物有时还存在互变异构体,本发明包括分离的互变异构体或其混合物。此外,本发明包括标记化合物,即,有一个或多个被放射性同位素或非放射性同位素取代的原子的本发明化合物。
本发明的化合物有时可形成盐,所述盐只要是药学上可接受的盐即可,也包括在本发明的范围内。具体例子包括与无机酸如盐酸、氢溴酸、氢碘酸、硫酸、硝酸、磷酸等的加成盐,与有机酸如甲酸、乙酸、丙酸、草酸、丙二酸、琥珀酸、富马酸、马来酸、乳酸、苹果酸、酒石酸、柠檬酸、甲磺酸、乙磺酸、对甲苯磺酸、天冬氨酸和谷氨酸等的加成盐,与包含钠、钾、钙、镁等金属的无机碱,甲胺、乙胺、乙醇胺、赖氨酸、鸟氨酸等有机碱形成的盐和铵盐等。本发明还包括本发明化合物及其药学上可接受的盐的各种水合物、溶剂合物及具有多晶形的物质。本发明还包括所有在体内被代谢而转变为具有前述通式(I)或(III)的化合物或其盐的化合物,即所谓前体药物。形成本发明的前体药物的基团可例举Prog.Med.5:2157-2161(1985)记载的基团,和在Hirokawa Shoten,1990,″Iyakuhin noKaihatsu″,vol.7,Bunshi Shekkei pp.163-198记载的基团。
(方法)
本发明化合物及其药学上可接受的盐可利用基于其基本结构或取代基的种类的特征,采用各种公知的合成方法制得。以下对其典型的制法进行描述。某些类型的官能团在原料或中间体的阶段被适当保护基即容易转化为该官能团的基团取代,所述保护基在制备技术上是有效的。然后,根据需要除去保护基,就能够获得所需的化合物。这种官能团的例子包括羟基、羧基、氨基等。这些保护基可例举Greene及Wuts著《Protective Groups in Organic Synthesis(third edition)》中记载的保护基,可根据反应条件适当采用之。
(第一方法)
(式中,R7代表前面化学式(II)表示的且其中的R11是H、可被取代的低级烷基或可被取代的环烷基的基团,或代表可被取代的环状胺基;R8代表由R2或R5代表的前述基团;R9代表由R3或R6代表的前述基团或由普通技术人员采用常规方法能转变为R3或R6的基团。下同。)
本方法是制备由化学式(I)或(III)表示的本发明化合物之一的方法,其中A是亚甲基,R1和R2(或R4和R5)不交联,R1或R4和A不闭合成环。
(步骤A)
这一步骤是按照常规方法使化合物(1a)或其盐与化合物(1b)或其反应性衍生物酰胺化,再根据需要除去保护基,制得化合物(1c)的步骤。
作为此步骤中的酰胺化,可采用技术人员通常采用的酰胺化。尤其可方便采用的方法有,在吡啶溶剂中使用磷酰氯的方法,在1-羟基苯并三唑(HOBt)存在下使用缩合剂如盐酸1-乙基-3-(3-二甲基氨基丙基)碳二亚胺(WSC.HCl)、二环己基碳二亚胺、羰基二咪唑、二苯基磷酰叠氮(diphenylphosphorylazide)或二乙基磷酰腈(diethylphosphorylcyanide)的方法。
该反应随所用的反应性衍生物或缩合剂而不同。通常,反应在对该反应惰性的有机溶剂中,在冷却下、冷却至室温或室温至加热下进行,有机溶剂的例子包括卤代烃类如二氯甲烷、二氯乙烷和氯仿,芳烃如苯、甲苯和二甲苯,醚类如乙醚和四氢呋喃(THF),酯类如乙酸乙酯(EtOAc),乙腈、N,N-二甲基甲酰胺(DMF)或二甲亚砜(DMSO)等。
(步骤B)
此步骤是制备本发明化合物(I)或(III)的步骤,采用化合物(1e)的Mannich反应在化合物(1c)的噻唑的5-位引入氨基甲基。可以采用Altertson,N.F.;J Am ChemSoc 1948,70,669或Bhargava,P.N.;Sharma,S.C.;Bull Chem Soc Jpn 1965,38,909所述方法或相应的方法。
(步骤C,步骤D)
这些步骤是制备本发明化合物(I)或(III)的方法,在化合物(1c)噻唑的5-位引入乙酰氧基甲基,然后在碱性条件下与化合物(1e)进行亲核取代反应。
步骤C中的乙酰氧基甲基化可以在室温至加热或在室温至回流下,使化合物(1c)与甲醛水溶液或p-甲醛在乙酸溶剂中反应。该反应可以通过替代乙酸溶剂而将乙酸加入对该反应惰性的溶剂如卤化烃、芳烃或醚中进行。这种情况下,反应活性会下降。此外,该反应可通过加入乙酸酐进行。
步骤D中的亲核取代反应可通过使化合物(1d)与化合物(1e)在对该反应惰性的有机溶剂如卤化烃、芳烃、醚、酯、乙腈、DMF或DMSO中,在有机碱如三乙安或二异丙基乙胺和/或无机碱如碳酸钾、碳酸钠、碳酸铯或碳酸氢钠中进行。为加速该反应,可以使用催化剂如二甲基氨基吡啶。可以使用大量化合物(1e)来替代有机碱和/或无机碱。该反应因所用的碱而不同。可以在冷却至室温、室温至加热或室温至回流下进行。
(第二方法)
(式中,X表示离去基如卤素;Y表示低级烷基;n表示1-6的整数。下同)
此方法是制备由化学式(I)或(III)表示的本发明化合物之一的方法,其中A或B是除亚甲基外的低级亚烷基,R1和R2或R4和R5不交联,R1和A或R4和B不闭合成环。
(步骤A)
此步骤是通过缩合化合物(2a)和化合物(2b)来制备(2c)的步骤。可采用HAND,E.S.;JOHNSON,S.C.;BAKER,D.C.;J Org Chem 1997,62(5),1348-1355中所述的方法或相应的方法。
(步骤B)
此步骤是化合物(2c)的酮的α-位被卤化,然后该化合物与硫脲反应形成噻唑环的步骤。可采用Org.Syn.Coll.Vol.II,1943,32-32.,和Maruzen,1992,″Dai 4han Jikken Kagaku Koza 19″,pp.431-435中所述的方法或其相应的方法。
(步骤C)
此步骤是化合物(2d)或按照需要进行水解的羧酸化合物按照第一方法的步骤A进行酰胺化,然后通过还原反应使酰胺键转变为氨基亚甲基键的步骤。可采用在Maruzen,1992,″Dai 4han Jikken Kagaku Koza 26″,pp.227-228中所述方法或其相应的方法。
(步骤D)
此步骤是通过化合物(2e)与化合物(1b)酰胺化来制备本发明化合物(I)或(III)的步骤。该可以按照第一方法的步骤A进行。
(第三方法)
(式中R12代表前述基团。下同)
此方法是制备由化学式(I)或(III)表示的本发明化合物之一的方法,其中R1和R2(或R4和R5)被R11交联。当A或B是亚甲基,R1或R4是按照前面定义的化学式(II)表示的基团时,R11以亚甲基在R2或R5上交联。
(步骤A)
此步骤是采用与化合物(1c)的Mannich反应在化合物(1c)的噻唑的5-位引入氨基甲基,并使R2代表的苯基或噻吩基亲核攻击通过随后第二阶段Mannich反应形成的亚铵,得到为本发明化合物的三环化合物。此步骤可以按照第一方法的步骤B进行。
(第四方法)
(式中,m表示1-6的整数。下同)
此方法是制备由化学式(I)或(III)表示的本发明化合物之一的方法,其中R1和A(或R4和B)被R11交联。当A或B是亚甲基,且R1或R4是按照前面定义的化学式(II)表示的基团时,R11是可被取代并在A或B上闭环的亚甲基。
(步骤A)
此步骤按照Van Tamelin,E.E.;Knapp,G.C.;J.Am.Chem.Soc.,77,1860,
在第一至第四方法中,下一个进行的步骤是在前一步骤的适当时间转化R9成R3或R6表示的基团。作为转化方法,可采用例如在步骤A所述的方法,引入5,6-二氯吡啶-3-基或3,4,5-二氟苯基作为R9,在适当时间例如第一方法中步骤B之前、步骤C之前或步骤D之前,通过亲核反应进行ipso取代反应,将R9转变为R3或R6,本发明化合物的一部分结构。
此外,化学式(I)或(III)表示的某些化合物可由前述方法获得的本发明的化合物,通过任意组合技术人员通常采用的步骤如公知的烷基化、酰化、取代反应、氧化、还原和水解而制备。
以上制得的本发明化合物可以分离和纯化为游离形式或按照常规方法进行成盐处理得到其盐。分离纯化可采用萃取、浓缩、蒸馏、结晶、过滤、重结晶、各种色谱法等常规的化学操作进行。
各种异构体可按照常规方法利用异构体间的物理化学性质的差异进行分离。例如,外消旋混合物,例如可形成与酒石酸等一般的光学活性酸的非对映异构体盐,通过光学拆分的方法等常用的外消旋体拆分法获得光学纯的异构体。此外,非对映异构体混合物例如可通过分步结晶或各种色谱法等进行分离。光学活性化合物也可采用适当的光学活性原料制得。
工业应用
本发明化合物及其盐具有良好的血小板增多作用。因此,本发明化合物对贫血,骨髓发育不良综合征时的血小板减少症,恶性肿瘤的化学疗法,放射疗法引起的血小板减少症,特发性血小板减少性紫癜病,肝病时的血小板减少症,HIV引起的血小板减少症等各种血小板减少症的治疗及/或预防有用。在采用化学疗法和放射疗法可能导致血小板减少的情况下,可在实施这些疗法之前预先给予本发明化合物。
本发明化合物的药理作用通过以下的试验确认。
(i)人c-mpl-Ba/F3细胞增殖试验
在96孔的微型板中,于37℃在添加了各浓度的测试化合物的含有10%胎牛血清的RPMI1640培养基(100μl/孔)中对2×105细胞/ml的人c-mpl-Ba/F3细胞进行培养。培养开始24小时后以10μl/孔添加WST-1/1-甲氧基PMS(细胞计数盒,Dojin)。添加后立刻及2小时后,用微型板读数计(Model3350:Bio-Rad)测定A450/A650的吸光度,将2小时的吸光度的增加作为各被验化合物的增殖活性,其结果示于表1。
表中的符号的含义如下所示。
pot:促进细胞增殖为化合物A(化合物A及rhTPO中的rhTPO)的最大细胞增殖活性值的30%时的测试化合物浓度。
Efficacy:化合物A(化合物A及rhTPO中的rhTPO)的最大细胞增殖活性值作为100%时的测试化合物的最大细胞增殖活性值。
化合物A指前述专利文献10的实施例9的化合物。
(表1)
人c-mpl-Ba/F3细胞增殖活性
表1中,比较化合物1是前述专利文献7中记载的化合物编号A-1的化合物;比较化合物2是前述专利文献8中记载的化合物编号A-14的化合物;比较化合物3是前述专利文献8中记载的化合物编号J-14的化合物;比较化合物4是前述专利文献9的实施例2的化合物。比较化合物1至4和化合物A的结构如下。
从上述结果可确认本发明化合物具有通过c-Mpl引起的Ba/F3细胞增殖作用。
(ii)测定巨核细胞集落形成促进作用的试验
于37℃,用MegaCultTM-C(StemCell Technologies公司),在测试物质存在下,通过2-孔室载玻片对人CD34+细胞进行10~14天的培养。按照所附说明书进行脱水和固定后,用抗糖蛋白IIb/IIIa抗体进行染色。将3个以上被染色的巨核细胞的群体作为1个集落,用显微镜测定每1个孔中的集落数。通过剂量曲线算出各被验化合物的EC30值。
其结果是,本发明化合物的EC30值,实施例71的化合物的EC30值为20nM,实施例100的化合物的EC30值为34nM,实施例104的化合物的EC30值为36nM。实施例106的化合物的EC30值为23nM,实施例315的化合物的EC30值为45nM。从以上结果可确认,本发明化合物具有良好的巨核细胞集落形成促进作用。
(iii)小鼠口服试验
以3mg/kg或10mg/kg(比较化合物1至3以100mg/kg)给雄性ICR小鼠口服测试化合物溶解或悬浮于0.5%甲基纤维素水溶液而形成的化合物混合液。口服2小时后,用1/10容积的3.8%柠檬酸钠为抗凝剂从腹下大静脉采血,以12000rpm进行3分钟的离心分离,于56℃对所得血浆进行30分钟的保温,将保温后的血浆加入(i)记载的人c-mpl-Ba/F3细胞增殖试验系统中,使最终浓度达到0.3%、1%或3%(比较化合物1至3为10%)血浆,测定细胞增殖活性。求出各被验化合物的最大细胞增殖活性作为100%时的各血浆的细胞增殖活性(%)。其结果示于表2。
(表2)
口服后的血浆的人c-mpl-Ba/F3细胞增殖活性
测试化合物 | 剂量[mg/kg p.o.] | 稀释率[%] | 细胞增殖活性[%] |
实施例65 | 3 | 3 | ≥80 |
实施例71 | 3 | 3 | ≥80 |
实施例84 | 3 | 1 | ≥80 |
实施例85 | 3 | 1 | ≥80 |
实施例90 | 3 | 0.3 | ≥80 |
实施例100 | 3 | 3 | ≥80 |
实施例101 | 3 | 1 | 76 |
实施例104 | 3 | 1 | 63 |
实施例106 | 3 | 1 | 63 |
实施例109 | 3 | 1 | 59 |
实施例150 | 3 | 0.3 | 28 |
实施例151 | 10 | 3 | 24 |
实施例153 | 10 | 3 | 29 |
实施例314 | 3 | 3 | 52 |
比较化合物1 | 100 | 10 | <10 |
比较化合物2 | 100 | 10 | <10 |
比较化合物3 | 100 | 10 | <10 |
表2中比较化合物1至3分别与表1中的比较化合物1至3相同。
从以上结果可确认,本发明化合物对小鼠具有口服活性。尤其是发现,比较化合物甚至“100mg/kg-10%稀释条件下”的也几乎未显现出口服活性,而本发明化合物甚至“以3mg/kg或10mg/kg的低剂量-3%或更高低浓度的高度稀释条件下”也具有良好的口服活性。这是未预料的,可以认为是在噻唑5-位引入有氨基作为取代基的低级亚烷基而实现的。比较化合物2及比较化合物3中在较低剂量(10mg/kg p.o.)其细胞增殖活性<10%。
对移植人的造血干细胞后,认为产生了人血小板的小鼠给予本发明化合物,可确认其血小板增多活性。
本发明的药剂可通过常用的方法,由本发明化学式(I)或(III)表示的至少一种和常用于制剂化的药剂用载体、赋形剂及其它添加剂配制。给药可采用片剂、丸剂、胶囊剂、颗粒剂、散剂、溶液剂等方式口服,或静注、肌注等注射剂或栓剂、经鼻、经粘膜、经皮等非口服方式中的任一种。
本发明的口服的固体组合物采用片剂、散剂、颗粒剂等。这种固体组合物中混合了1种或2种以上的活性物质和至少1种惰性稀释剂,例如,乳糖、甘露糖醇、葡萄糖、羟丙纤维素、微晶纤维素、淀粉、聚乙烯吡咯烷酮、硅铝酸镁等。组合物中利用常规方法可含有惰性稀释剂以外的添加剂,例如,硬脂酸镁等润滑剂,羧甲纤维素钙等崩解剂,稳定剂和助溶剂等。片剂或丸剂可根据需要用蔗糖、明胶、羟丙纤维素、羟丙甲基纤维素邻苯二甲酸酯等糖衣或胃溶性或肠溶性薄膜包衣。
口服液体组合物含有药物制剂中允许的乳化剂、溶液剂、悬浮剂、糖浆剂、酏剂等,包含常用的惰性稀释剂,例如纯化水和乙醇(EtOH)。该组合物除了惰性稀释剂以外还含有湿润剂和悬浮剂等助剂,甜味剂,矫味剂,芳香剂和防腐剂。
非口服的注射剂含有无菌的水性或非水性溶液剂、悬浮剂、乳剂。水性溶液剂、悬浮剂例如含有注射用蒸馏水及生理食盐水。非水性溶液剂、悬浮剂例如有丙二醇、聚乙二醇、橄榄油等植物油、乙醇等醇类、吐温80等。该组合物还可含有防腐剂,湿润剂,乳化剂,分散剂,稳定剂和助溶剂等助剂。它们例如可通过除菌滤器过滤、配合杀菌剂或照射而灭菌。此外,也可制造无菌的固体组合物,在使用前以无菌水或无菌的注射用溶剂溶解后使用。
通常口服的情况下,1天的给药量按照体重约0.0001~50mg/kg,较好约为0.001~10mg/kg,更好为0.01~1mg/kg,可1次或分2~4次给药。静脉给药时,1天的给药量按照体重约为0.0001~1mg/kg,较好约为0.0001~0.1mg/kg,1天1次或分多次给药。给药量可根据患者症状、年龄、性别等作适当决定。
实施发明的最佳方式
以下,通过实施例对本发明进行具体说明,但本发明并不仅限于这些实施例。实施例中所用的原料化合物中也包含新物质,作为参考例对从公知物获得这种原料化合物的制备方法进行说明。
参考例1
在3,4,5-三氟苯甲酸的DMF溶液中中加入碳酸钾和烯丙基溴,搅拌该混合物过夜,制得粗烯丙酯。在粗烯丙酯和4-哌啶甲酸乙酯的DMF溶液中加入碳酸钾,室温搅拌该混合物过夜,获得哌啶取代产物。在该哌啶取代产物的THF溶液中加入吗啉和四(三苯基膦)钯(催化量),60℃搅拌混合物2小时,室温搅拌4天。蒸除溶剂后,加入乙醚和EtOAc,混合物用饱和碳酸氢钠水溶液洗涤10次。在收集的水层加入浓盐酸,过滤收集产生的沉淀,获得4-[4-(乙氧基羰基)哌啶-1-基]-3,5-二氟苯甲酸。
参考例2
在3-氯-5-氟-4-羟基苯甲酸乙酯的DMF溶液中加入碳酸钾和3-(叔丁基二甲基甲硅烷氧基)丙基溴,50℃搅拌该混合物,制得4-[3-(叔丁基二甲基甲硅烷氧基)丙氧基]-3-氯-5-氟苯甲酸乙酯。
表3中所示的参考例3和4中的化合物按照与参考例2相同的方式,各自用相应的原料制备。
参考例5
将无水哌嗪加到3,4-二氟苯甲酸甲酯的THF溶液中,混合物在60℃搅拌18小时,制得3-氟-4-哌嗪-1-基苯甲酸甲酯。
参考例6
将二碳酸二-叔丁酯和4-二甲基氨基吡啶加到参考例5的化合物的1,2-二氯乙烷溶液中,室温搅拌该混合物10分钟制得4-[2-氟-4-(甲氧基羰基)苯基]哌嗪-1-羧酸叔丁酯。
参考例7
将N-氯琥珀酰亚胺加到参考例6的化合物的DMF溶液中,室温搅拌该混合物3小时,制得4-[2-氯-6-氟-4-(甲氧基羰基)苯基]哌嗪-1-羧酸叔丁酯。
参考例8
将1M NaOH水溶液加到参考例2的化合物的MeOH-THF混合溶液中,室温搅拌该混合物16小时,制得4-[3-(叔丁基二甲基甲硅烷氧基)丙氧基]-3-氯-5-氟苯甲酸。
表3中所示的参考例9至11中的化合物按照与参考例8相同的方式,各自用相应的原料制备。
参考例12
将亚硫酰氯加到参考例11的化合物的MeOH溶液中,室温搅拌该混合物22小时,制得4-[3-(甲氧基羰基)丙氧基]-3-氟苯甲酸。
表中符号具有以下含义(下同)。
Rf:参考例编号,
Data:物理学数据(MS:FAB-MS(M+H)+,MN:FAB-MS(M-H)-,MM:FAB-MS(M)+,
R、R1、R2、R3、R4、X、Y:通式中的取代基(Me:甲基,Et:乙基,iPr:异丙基,cPr:环丙基,nBu:正丁基,iBu:异丁基,tBu:叔丁基,Ph:苯基,Py:吡啶基,Boc:叔丁氧基羰基,The:噻吩基,azet.氮杂环丁烷-1-基,pyrr:吡咯烷-1-基,pipe:哌啶-1-基,pipa:哌嗪-1-基,mor:吗啉-4-基,TBS:叔丁基二甲基甲硅烷基,di:二。取代基前的数字表示取代位置,例如,3,5-diF-4-(4-Et02C-pipe)Ph指3,5-二氟-4-(4-乙氧基羰基哌啶-1-基)苯基,4-Me-2-The指4-甲基噻吩-2-基)。
(表3)
Rf | R<sup>1</sup>,R<sup>2</sup>,R<sup>3</sup>,R | Data |
1 | R<sup>1</sup>=F,R<sup>2</sup>=4-EtO<sub>2</sub>C-pipe,R<sup>3</sup>=F,R=H | MS;314. |
2 | R<sup>1</sup>=Cl,R<sup>2</sup>=TBSO(CH<sub>2</sub>)<sub>3</sub>O-,R<sup>3</sup>=F,R=Et | MS;391. |
3 | R<sup>1</sup>=OMe,R<sup>2</sup>=TBSO(CH<sub>2</sub>)<sub>2</sub>O-,R<sup>3</sup>=H,R=Et | MS;355. |
4 | R<sup>1</sup>=F,R<sup>2</sup>=EtO<sub>2</sub>C(CH<sub>2</sub>)<sub>3</sub>O-,R<sup>3</sup>=H,R=Me | MS;285. |
5 | R<sup>1</sup>=F,R<sup>2</sup>=pipa,R<sup>3</sup>=H,R=Me | MS;239. |
6 | R<sup>1</sup>=F,R<sup>2</sup>=4-Boc-pipa,R<sup>3</sup>=H,R=Me | MS;339. |
7 | R<sup>1</sup>=Cl,R<sup>2</sup>=4-Boc-pipa,R<sup>3</sup>=F,R=Me | MS;373. |
8 | R<sup>1</sup>=Cl,R<sup>2</sup>=TBSO(CH<sub>2</sub>)<sub>3</sub>O-,R<sup>3</sup>=F,R=H | MS;363. |
9 | R<sup>1</sup>=Cl,R<sup>2</sup>=4-Boc-pipa,R<sup>3</sup>=F,R=H | MS;359. |
10 | R<sup>1</sup>=OMe,R<sup>2</sup>=TBSO(CH<sub>2</sub>)<sub>2</sub>O-,R<sup>3</sup>=H,R=H | MS;327. |
11 | R<sup>1</sup>=F,R<sup>2</sup>=HO<sub>2</sub>C(CH<sub>2</sub>)<sub>3</sub>O-,R<sup>3</sup>=H,R=H | MN;241. |
12 | R<sup>1</sup>=F,R<sup>2</sup>=MeO<sub>2</sub>C(CH<sub>2</sub>)<sub>3</sub>O-,R<sup>3</sup>=H,R=H | MS;257. |
参考例13
冰冷却下,在4-氯-2-乙酰基噻吩的醚溶液中加入溴,室温搅拌该混合物2小时,制得溴化的化合物。室温,在该溴化化合物的EtOH溶液加入硫脲,80℃搅拌混合物过夜,制得2-氨基-4-(4-氯噻吩-2-基)噻唑。
4中所示的参考例14中的化合物按照与参考例13相同的方式,用相应的原料制备。
(表4)
Rf | R | Data |
13 | Cl | MS;217. |
14 | Me | MS;197. |
参考例15
将磷酰氯加到参考例13的化合物和5,6-二氯烟酸的吡啶悬浮液中。逐步升高温度,室温搅拌混合物过夜,制得5,6-二氯-N-[4-(4-氯噻吩-2-基)噻唑-2-基]烟酰胺。
表5中所示的参考例16至22的化合物按照与参考例15相同的方式,各自用相应的原料制备。
(表5)
Rf | R | Data |
15 | 5,6-diCl-3-Py | MS;390. |
16 | 2-MeO-4-Py | MS;352. |
17 | 3,5-diF-4-(4-EtO<sub>2</sub>C-pipe)Ph | MS;512. |
18 | 3-Cl-5-F-4-TBSO(CH<sub>2</sub>)<sub>3</sub>O-Ph | MS;561. |
19 | 3-Cl-5-F-4-(4-Boc-pipa)Ph | MS;557. |
20 | 3-Cl-4-MeOCH<sub>2</sub>O-Ph | MS;415. |
21 | 3-MeO-4-TBSO(CH<sub>2</sub>)<sub>2</sub>O-Ph | MS;624. |
22 | 3-F-4-MeO<sub>2</sub>C(CH<sub>2</sub>)<sub>3</sub>O-Ph | MS;455. |
参考例23
将吡啶、三乙胺和4-哌啶甲酸乙酯加到参考例15的化合物中,70℃搅拌混合物16小时,制得1-(3-氯-5-{[4-(4-氯噻吩-2-基)噻唑-2-基]氨基甲酰基}-2-吡啶基)哌啶-4-羧酸乙酯。
表6中所示的参考例24至31的化合物按照与参考例23相同的方式,各自用相应的原料制备。
(表6)
Rf | R | Data |
23 | 4-EtO<sub>2</sub>C-pipe | MS;511. |
24 | 3-EtO<sub>2</sub>C-pipe | MS;511. |
25 | 3-MeO<sub>2</sub>C-pyrr | MS;483. |
26 | (R)-3-MeO<sub>2</sub>CCH<sub>2</sub>O-pyrr | MS;513. |
27 | 4-EtO<sub>2</sub>CCH<sub>2</sub>-pipe | MS;525. |
28 | 2-EtO<sub>2</sub>C-mor | MS;513. |
29 | (S)-3-MeO<sub>2</sub>C-pyrr | MS;483. |
30 | 3-EtO<sub>2</sub>C-azet | MS;483. |
31 | 4-tBuO<sub>2</sub>CCH<sub>2</sub>O-pipe | MS;569. |
参考例32
将乙酸和甲醛水溶液(36%)加到参考例23的化合物中,100℃搅拌混合物过夜,制得1-(5-乙酰氧基甲基-4-(4-氯噻吩-2-基)噻唑-2-基)氨基甲酰基)-3-氯-2-吡啶基)哌啶-4-羧酸乙酯。
表7中所示的参考例33中的化合物按照与参考例32相同的方式,用相应的原料制备。
(表7)
Rf | X,Y | Data |
32 | X=N,Y=C-Cl | MS;583. |
33 | X=C-F,Y=C-F | MS;584. |
表8中所示的参考例34和35中的化合物按照与下面将描述的实施例1相同的方式,各自用相应的原料制备。
(表8)
Rf | R | Data |
34 | pipe | MS;487. |
35 | nBuN(Me) | MS;489. |
参考例36
冰冷却下,将4M HCl-EtOAc溶液加到参考例19的化合物的氯仿-EtOH混合溶液中,室温搅拌该混合物17小时,制得盐酸3-氯-N-[4-(4-氯噻吩-2-基)噻唑-2-基]-5-氟-4-哌嗪-1-基苯甲酰胺。
参考例37
将碳酸钾和溴乙酸乙酯加到参考例36的化合物的DMF溶液中,室温搅拌该混合物23小时,制得[4-(2-氯-4-{[4-(4-氯噻吩-2-基)噻唑-2-基]氨基甲酰基}-6-氟苯基)哌嗪-1-基]乙酸乙酯。
(表9)
Rf | R | Data |
36 | H | MS;457. |
Rf | R | Data |
37 | EtO<sub>2</sub>CCH<sub>2</sub> | MS;543. |
参考例38
-30℃,将磷酰氯加到2-氨基-4-[3-(三氟甲基)苯基]噻唑和5,6-二氯烟酸的吡啶悬浮液中。逐步升高温度,室温搅拌混合物过夜。减压蒸除溶剂后,加入吡啶和EtOH,50℃搅拌混合物30分钟。室温加入三乙胺和3-哌啶甲酸乙酯,80℃搅拌该溶液15小时,制得1-[3-氯-5-({4-[3-三氟甲基]苯基}噻唑-2-基)氨基甲酰基]-2-吡啶基]哌啶-4-羧酸乙酯。
表10中所示的参考例39和40的化合物按照与参考例38相同的方式,各自用相应的原料制备。
(表10)
Rf | R | Data |
38 | 3-F<sub>3</sub>C-Ph | MS;539. |
39 | 4-F-Ph | MS;489. |
40 | 4-Me-2-The | MS;491. |
表11中所示的参考例41中的化合物按照与参考例8相同的方式,参考例42的化合物按照与下面将描述的实施例8相同的方式,各用相应的原料制备。
(表11)
Rf | R | Data |
41 | HO | MS;483. |
42 | MeO<sub>2</sub>CCH<sub>2</sub>NH | MS;554. |
参考例43
将氯甲酸苯基酯和吡啶加到参考例13的化合物的THF溶液中,室温搅拌该混合物1.5小时,制得N-[4-(4-氯噻吩-2-基)噻唑-2-基]氨基甲酸苯基酯。
参考例44
将盐酸N-(哌啶-4-基)-4-哌啶甲酸乙酯和N-(哌啶-4-基)-4-哌啶甲酸异丙酯以及三乙胺的混合物加到参考例43的化合物的DMF溶液中,80℃搅拌混合物12小时,制得酯的混合物。将该酯混合物溶于MeOH,加入三乙胺和乙醇钠。从室温至50℃搅拌该溶液18小时,制得1′-{[4-(4-氯噻吩-2-基)噻唑-2-基]氨基甲酰基}-1,4′-联哌啶-4-羧酸甲酯。
(表12)
Rf | R | Data |
43 | PhO | MS;337. |
44 | 4-(4-MeO<sub>2</sub>C-pipe)pipe | MS;469. |
参考例45
表13中所示的参考例45的化合物按照与参考例13相同的方式,用4-(4-氯噻吩-2-基)-4-氧代丁酸酯(甲酯∶乙酯的3∶2混合物)作为原料制备。
参考例46
表13中所示的参考例46的化合物按照与参考例8相同的方式,用相应的原料制备。
参考例47
将丁基甲胺、WSC.HCl、HOBt和三乙胺加到参考例46的化合物的DMF溶液中,室温搅拌该混合物18小时,制得N-丁基-N-甲基-[2-氨基-4-(4-氯噻吩-2-基)噻唑-5-基]乙酰胺。
参考例48
将参考例47的化合物的THF溶液加到氢化铝锂的THF悬浮液中,该混合物回流下搅拌3小时,制得2-氨基-5-{2-[丁基(甲基)氨基]乙基}-4-(4-氯噻吩-2-基)噻唑。
参考例49
表13中所示的参考例49的化合物按照与参考例15相同的方式,用相应的原料制备。
(表13)
Rf | R<sup>1</sup>,R<sup>2</sup> | Data |
45 | R<sup>1</sup>=RO<sub>2</sub>CCH<sub>2</sub>(R;Me∶Et=3∶2),R<sup>2</sup>=H | GC-MS;288,302. |
46 | R<sup>1</sup>=HO<sub>2</sub>CCH<sub>2</sub>,R<sup>2</sup>=H | MS;275. |
47 | R<sup>1</sup>=nBuN(Me)COCH<sub>2</sub>,R<sup>2</sup>=H | MS;344. |
48 | R<sup>1</sup>=nBuN(Me)(CH<sub>2</sub>)<sub>2</sub>,R<sup>2</sup>=H | MS;330. |
49 | R<sup>1</sup>=nBuN(Me)(CH<sub>2</sub>)<sub>2</sub>,R<sup>2</sup>=5,6-diCl-3-Py-CO- | MN;501,503. |
参考例50
将4-哌啶甲酸乙酯加到2,6-二氯-5-氟烟酸的DMF溶液中,80℃搅拌该混合物,制得2-氯-6-[4-(乙氧基羰基)哌啶-1-基]-5-氟烟酸。
参考例51
将三乙胺和10%负载在碳上的钯加到参考例50的化合物的THF-EtOH溶液中,室温,4个大气压的氢气氛中搅拌该混合物,制得6-[4-(乙氧基羰基)哌啶-1-基]-5-氟烟酸。
(表14)
Rf | R | Data |
50 | Cl | MS;331. |
51 | H | MS;297. |
表15中所示的参考例52和53的化合物按照与下面将描述的实施例3相同的方式,表15中所示的参考例54至56的化合物按照与参考例15相同的方式,表15中所示的参考例57至64的化合物按照与下面将描述的实施例1相同的方式,各自用相应的原料制备。
(表15)
Rf | R<sup>1</sup> | R<sup>2</sup> | R<sup>3</sup> | Data |
52 | H | 4-Cl-2-The | 5-Cl-6-(MeO<sub>2</sub>C(CH<sub>2</sub>)<sub>2</sub>N(Me))-3-Py | MN;471. |
53 | H | 4-Cl-2-The | 5-Cl-6-(MeO<sub>2</sub>C(CH<sub>2</sub>)<sub>3</sub>N(Me))-3-Py | MN;483. |
54 | H | 4-Cl-2-The | 5-F-6-(4-EtO<sub>2</sub>C-pipe)-3-Py | MS;495. |
55 | H | 4-Cl-2-The | 3-F<sub>3</sub>C-4-Me-Ph | MS;403. |
56 | H | 4-Me-2-The | 5,6-diCl-3-Py | MS;370. |
57 | iPrN(Me)- | 4-Cl-2-The | 5,6-diCl-3-Py | MS;475,477. |
58 | iBuN(Me)- | 4-Cl-2-The | 5,6-diCl-3-Py | MS;491. |
59 | 2-Me-pyrr- | 4-C l-2-The | 5,6-diCl-3-Py | MS;487. |
60 | (S)-2-Me-pyrr- | 4-Cl-2-The | 5,6-diCl-3-Py | MS;487. |
61 | (R)-2-Me-pyrr- | 4-C l-2-The | 5,6-diCl-3-Py | MS;487. |
62 | iBuN(Me)- | 4-Me-2-The | 5,6-diCl-3-Py | MS;469. |
63 | cBuCH<sub>2</sub>N(Me)- | 4-Me-2-The | 5,6-diCl-3-Py | MS;481. |
64 | 2-Me-pyrr- | 4-Me-2-The | 5,6-diCl-3-Py | MS;467. |
实施例1
将3ml乙酸、24μl甲醛水溶液(36%)和47μl N-丁基-N-甲基胺加到150mg1-(3-氯-5-{[4-(4-氯噻吩-2-基)噻唑-2-基]氨基甲酰基}-2-吡啶基)哌啶-4-羧酸乙酯中,90℃搅拌该混合物18小时。减压蒸除溶剂后,加入饱和碳酸氢钠水溶液。该混合物用氯仿萃取,用硫酸镁干燥。减压蒸除溶剂,产生的残余物通过硅胶柱层析用己烷∶EtOAc(7∶1至5∶1)为洗脱溶剂进行纯化,获得147mg 1-(5-{[5-{[丁基(甲基)氨基]甲基}-4-(4-氯噻吩-2-基)噻唑-2-基]氨基甲酰基}-3-氯-2-吡啶基)哌啶-4-羧酸乙酯。
实施例2
将39μl N-(2-甲氧基乙基)甲胺、51μl三乙胺和23mg 4-(二甲基氨基)吡啶加到107mg 1-(5-{[5-[(乙酰氧基)甲基]-4-(4-氯噻吩-2-基)噻唑-2-基]氨基甲酰基}-3-氯-2-吡啶基)哌啶-4-羧酸乙酯在6ml EtOH的悬浮液中,50℃搅拌混合物2小时。蒸除溶剂后,加入饱和碳酸氢钠水溶液,混合物用EtOAc萃取,用水和盐水(饱和氯化钠水溶液)洗涤。形成的产物用硫酸镁干燥,然后减压蒸除溶剂。产生的残余物通过硅胶柱层析,用己烷∶EtOAc(10∶1至3.5∶1)作为洗脱溶剂纯化,获得90mg1-{3-氯-5-[(4-(4-氯噻吩-2-基)-5-{[(2-甲氧基乙基)(甲基)氨基]甲基}噻唑-2-基)氨基甲酰基]-2-吡啶基}哌啶-4-羧酸乙酯。
实施例3
将110μl甲醛水溶液(35%)和76μl乙酸加到79mg 1-[3-氯-5-({4-(4-氯噻吩-2-基)-5-[(环丁基氨基)甲基]噻唑-2-基}氨基甲酰基)-2-吡啶基]哌啶-4-羧酸乙酯的2ml 1,2-二氯乙烷溶液,室温搅拌该混合物1小时。随后,加入45mg NaBH(OAc)3,室温搅拌该溶液1小时。在反应溶液中加入氯仿,有机层用饱和碳酸氢钠水溶液、用水和盐水洗涤,然后用硫酸钠干燥。蒸除溶剂后,残余物通过硅胶柱层析纯化(己烷∶EtOAc=4∶1至2∶1),获得58mg 1-{3-氯-5-[(4-(4-氯噻吩-2-基)-5-{[环丁基(甲基)氨基]甲基}噻唑-2-基)氨基甲酰基]-2-吡啶基}哌啶-4-羧酸乙酯。
实施例4
将1.3ml 4-哌啶甲酸乙酯加到413mg 5,6-二氯-N-[4-(4-氯噻吩-2-基)-5-(哌啶-1-基甲基)-1,3-噻唑-2-基]烟酰胺的5ml THF溶液中,搅拌该混合物5天。减压蒸除溶剂后,加入饱和碳酸氢钠水溶液,过滤收集产生的沉淀。将沉淀溶于氯仿,加入饱和碳酸氢钠水溶液。混合物用氯仿萃取,用硫酸镁干燥。减压蒸除溶剂,产生的残余物通过硅胶柱层析,用己烷∶EtOAc(4∶1至3∶1)作为洗脱溶剂纯化,获得468mg 1-(3-氯-5-{[4-(4-氯噻吩-2-基)-5-(哌啶子基甲基)噻唑-2-基]氨基甲酰基}-2-吡啶基)哌啶-4-羧酸乙酯。
实施例5
将0.4ml1M氢氧化钠水溶液加到76mg 1-{3-氯-5-[(4-(4-氯噻吩-2-基)-5-{[(2-甲氧基乙基)(甲基)氨基]甲基}噻唑-2-基)氨基甲酰基]-2-吡啶基}哌啶-4-羧酸乙酯在1.5ml EtOH的悬浮液中,60℃搅拌混合物2小时。室温加入0.6ml1M盐酸和0.5ml水,过滤收集产生的沉淀,用50%乙醇水洗涤,减压干燥,获得73mg盐酸1-{3-氯-5-[(4-(4-氯噻吩-2-基)-5-{[(2-甲氧基乙基)(甲基)氨基]甲基}噻唑-2-基)氨基甲酰基]-2-吡啶基}哌啶-4-羧酸。
实施例6
将19mg硼氢化钠加到128mg[4-(5-{5-{[丁基(甲基)氨基]甲基}-4-(4-氯噻吩-2-基)噻唑-2-基}氨基甲酰基)-3-氯-2-吡啶基]-2-氧代哌嗪-1-基]乙酸乙酯的5mlTHF溶液中,回流下搅拌该混合物。在混合物中缓慢滴加128mg MeOH的2mlTHF溶液,回流下搅拌混合物1小时。反应溶液用冰冷却,然后加入水。溶液用氯仿萃取,用盐水洗涤,然后用硫酸镁干燥。减压蒸除溶剂,产生的残余物通过硅胶柱层析,用氯仿∶MeOH(99∶1to 98∶2)作为洗脱溶剂纯化。将形成的粗产物悬浮于甲醇中,过滤除去不溶物。然后减压蒸除溶剂。将获得的残余物溶于EtOAc,加入4M HCl-EtOAc溶液,随后搅拌。然后过滤收集形成的沉淀,减压干燥,获得15mg盐酸N-[5-{[丁基(甲基)氨基]甲基}-4-(4-氯噻吩-2-基)噻唑-2-基]-5-氯-6-[4-(2-羟乙基)-3-氧代哌嗪-1-基]烟酰胺。
实施例7
将40mg实施例132的化合物溶于6ml MeOH,加入1.6ml浓盐酸,随后搅拌2小时。然后进行浓缩,过滤出沉淀,用EtOAc洗涤,获得32mg盐酸N-[5-{[丁基(甲基)氨基]甲基}-4-(4-氯噻吩-2-基)噻唑-2-基]-4-(2-羟基甲氧基)-3-甲氧基苯甲酰胺。
实施例8
将30μl三乙胺、30μl吗啉、45mg WSC·HCl和30mg HOBt加到52mg盐酸1-{3-氯-5-[(4-(4-氯噻吩-2-基)-5-{[(3-甲氧基丙基)(甲基)氨基]甲基}噻唑-2-基)氨基甲酰基]-2-吡啶基}哌啶-4-羧酸在2ml THF中的溶液中,室温搅拌混合物过夜。在反应溶液中加入氯仿。有机层用饱和碳酸氢钠水溶液、用水和盐水洗涤,然后用硫酸钠干燥。蒸除溶剂后,残余物通过硅胶柱层析纯化(洗脱液:氯仿∶MeOH=100∶1至50∶1,己烷∶EtOAc=2∶1,然后氯仿∶MeOH=20∶1),并悬浮于2ml二乙醚中。加入2ml 4M HCl-EtOAc,过滤收集沉淀,获得25mg盐酸5-氯-N-(4-(4-氯噻吩-2-基)-5-{[(3-甲氧基丙基)(甲基)氨基]甲基}噻唑-2-基)-6-[4-(吗啉代羰基)哌啶子基]烟酰胺。
实施例9
将3ml 4M HCl-二恶烷溶液加到188mg实施例190的化合物中,50℃搅拌混合物18小时。反应溶液于室温冷却,然后过滤出固体沉淀,获得160mg盐酸[(1-{3-氯-5-[(4-(4-氯噻吩-2-基)-5-{[(2-甲氧基乙基)(甲基)氨基]甲基}噻唑-2-基)氨基甲酰基]-2-吡啶基}-4-哌啶基)氧]乙酸。
实施例10
将200mg参考例23的化合物溶于5ml甲酸,加入37μl甲氧基乙胺和92μl甲醛水溶液(35%),随后70℃搅拌15小时。反应溶液浓缩后,加入氯仿,有机层用饱和碳酸氢钠水溶液、用水和盐水洗涤,随后用硫酸钠干燥。蒸除溶剂后,残余物通过硅胶柱层析纯化(己烷∶EtOAc=5∶1至3∶1),获得110mg 1-{3-氯-5-{[7-氯-5-(2-甲氧基乙基)-5,6-二氢-4H-噻唑并[5,4-c]噻吩并[2,3-e]氮杂-2-基]氨基甲酰基}-2-吡啶}-4-羧酸乙酯。
实施例11
将100mg三盐酸6-[(2-氨基乙基)氨基]-N-[5-{[丁基(甲基)氨基]甲基}-4-(4-氯噻吩-2-基)噻唑-2-基]-5-氯烟酰胺悬浮于5ml THF中,加入85μl三乙胺。随后冷却至0℃。在该溶液中加入13μl甲磺酰氯,室温搅拌该混合物2小时。将该反应溶液倒入水中,用氯仿萃取。有机层用水和盐水洗涤,然后用硫酸镁干燥。蒸除溶剂后,残余物通过硅胶柱层析纯化(氯仿∶MeOH=10∶1),获得75mg N-[5-{[丁基(甲基)氨基]甲基}-4-(4-氯噻吩-2-基)噻唑-2-基]-5-氯-6-({2-[(甲基磺酰基)氨基]乙基}氨基)烟酰胺。
以下的表16-26所示为实施例化合物的结构和物理数据。表中符号的含义如下所述(下同)。
Ex:实施例编号(Ex栏中只记载实施例编号时,表示该化合物为游离化合物,实施例编号后有斜线(/)和“HCl”时,表示此实施例化合物为盐酸盐)。
Syn:制备方法(数字表示化合物按照编号与作为实施例编号相同的实施例化合物的同样方式用相应的原料合成)。
R:通式中的取代基(nPr:正丙基,cBu:环丁基,cHex:环己基,MOM:甲氧基甲基,Ac:乙酰基,Ms:甲磺酰基,THF:四氢呋喃基,THP:四氢吡喃基)。
(表16)
Ex | Syn | R | Data |
1 | 1 | nBuN(Me)- | MS;610. |
2 | 2 | MeO(CH<sub>2</sub>)<sub>2</sub>N(Me)- | MS;612. |
3 | 3 | cBuN(Me)- | MS;608. |
4 | 4 | pipe- | MS;608. |
12 | 1 | Me<sub>2</sub>N- | MS;568. |
13 | 1 | pyrr- | MS;594. |
14 | 1 | mor- | MS;610. |
15 | 1 | 4-Me-pipa- | MS;623. |
16 | 1 | 4-cHex-pipa- | MS;691. |
17 | 1 | Et<sub>2</sub>N- | MS;650. |
18 | 1 | EtO(CH<sub>2</sub>)<sub>2</sub>N(Me)- | MS;626. |
19 | 1 | (2-THF)CH<sub>2</sub>N(Me)- | MS;638. |
20 | 1 | nPrO(CH<sub>2</sub>)<sub>2</sub>N(Me)- | MS;640. |
Ex | Syn | R | Data |
21 | 1 | EtO(CH<sub>2</sub>)<sub>2</sub>N(Et)- | MS;640. |
22 | 1 | iPrO(CH<sub>2</sub>)<sub>2</sub>N(Me)- | MS;640. |
23 | 1 | 4-(3-F-pyrr)pipe- | MS;694. |
24 | 1 | MeO(CH<sub>2</sub>)<sub>3</sub>N(Me)- | MS;625. |
25 | 1 | MeO(CH<sub>2</sub>)<sub>2</sub>N(Et)- | MS;626 |
26 | 1 | (2S,6R)-2,6-diMe-mor- | MS;638 |
27 | 1 | 4-EtO<sub>2</sub>C-pipe- | MN;678. |
28 | 1 | iPrN(Me)- | MS;596. |
29 | 1 | 2-Me-pyrr- | MS;608. |
30 | 1 | (S)-2-Me-pyrr- | MS;608. |
31 | 1 | (R)-2-Me-pyrr- | MS;608. |
32 | 1 | (R)-3-Me-pyrr- | MS;608. |
33 | 1 | (S)-3-Me-pyrr- | MS;608. |
34 | 1 | 3-EtO-pyrr- | MS;638. |
35 | 1 | 4-MeO-pipe- | MS;638. |
36 | 1 | 3-MeO-pipe- | MS;638. |
37 | 1 | (S)-2-MeOCH<sub>2</sub>-pyrr- | MS;638. |
38 | 1 | (R)-2-MeOCH<sub>2</sub>-pyrr- | MS;638. |
39 | 2 | (R)-MeOCH<sub>2</sub>CH(Me)N(Me) | MS;626. |
40 | 2 | (S)-MeOCH<sub>2</sub>CH(Me)N(Me) | MS;626. |
Ex | Syn | R | Data |
41 | 2 | azet- | MS;580. |
42 | 2 | 氮杂环庚烷-1-基 | MS;622. |
43 | 2 | 氮杂环辛烷-1-基 | MS;636. |
44 | 2 | 氮杂环壬烷-1-基 | MS;650. |
(表16,续)
Ex | Syn | R | Data |
45 | 2 | 氮杂环癸烷-1-基 | MS;664. |
46 | 2 | (2R,6S)-2,6-diMe-pipe | MS;636. |
47 | 2 | Me<sub>2</sub>N(CH<sub>2</sub>)<sub>2</sub>N(Me)- | MS;625. |
48 | 2 | cHexN(Me)- | MS;636. |
49 | 2 | MeO(CH<sub>2</sub>)<sub>2</sub>NH- | MS;597. |
50 | 2 | cPrNH- | MS;580. |
51 | 2 | cBuNH- | MS;594. |
52 | 2 | cHexNH- | MS;622. |
53 | 2 | iPrNH- | MS;582. |
54 | 2 | tBuNH- | MS;596. |
55 | 2 | (4-THP)NH- | MS;624. |
56 | 2 | (3-THF)NH- | MS;610. |
57 | 2 | MeOCH<sub>2</sub>CH(Me)NH- | MS;612. |
58 | 3 | (4-THP)N(Me)- | MS;638. |
Ex | Syn | R | Data |
59 | 3 | (3-THF)N(Me)- | MS;624. |
60 | 3 | MeOCH<sub>2</sub>CH(Me)N(Me)- | MS;626. |
61 | 3 | cPrN(Me)- | MS;594. |
62 | 3 | iBuN(Me)- | MS;610. |
63 | 10 | (R)-(MeO)(Me)CHCH<sub>2</sub>N(Me)- | MS;626. |
64 | 10 | (S)-(MeO)(Me)CHCH<sub>2</sub>N(Me)- | MS;626. |
(表17)
Ex | Syn | R | Data |
5/HCl | 5 | MeO(CH<sub>2</sub>)<sub>2</sub>N(Me)- | MS;584. |
65/HCl | 5 | Me<sub>2</sub>N- | MS;540. |
66/HCl | 5 | pyrr- | MS;566. |
67/HCl | 5 | mor- | MN;580. |
68/HCl | 5 | 4-Me-pipa- | MS;595. |
69/HCl | 5 | 4-cHex-pipa- | MS;663. |
70/HCl | 5 | Et<sub>2</sub>N- | MS;568. |
71/HCl | 5 | nBuN(Me)- | MS;582. |
72/HCl | 5 | EtO(CH<sub>2</sub>)<sub>2</sub>N(Me)- | MS;598. |
Ex | Syn | R | Data |
73/HCl | 5 | (2-THF)CH<sub>2</sub>N(Me)- | MS;610. |
74/HCl | 5 | nPrO(CH<sub>2</sub>)<sub>2</sub>N(Me)- | MS;612. |
75/HCl | 5 | EtO(CH<sub>2</sub>)<sub>2</sub>N(Et)- | MS;612. |
76/HCl | 5 | iPrO(CH<sub>2</sub>)<sub>2</sub>N(Me)- | MS;612. |
77/HCl | 5 | 4-(3-F-pyrr)pipe- | MS;667. |
(表17,续)
Ex | Syn | R | Data |
78/HCl | 5 | MeO(CH<sub>2</sub>)<sub>3</sub>N(Me)- | MN;596. |
79/HCl | 5 | MeO(CH<sub>2</sub>)<sub>2</sub>N(Et)- | MS;598. |
80 | 5 | (2S,6R)-2,6-diMe-mor- | MN;608. |
81/HCl | 5 | (R)-MeOCH<sub>2</sub>CH(Me)N(Me)- | MS;598. |
82/HCl | 5 | (S)-MeOCH<sub>2</sub>CH(Me)N(Me)- | MS;598. |
83/HCl | 5 | azet- | MS;552. |
84/HCl | 5 | 氮杂环庚烷-1-基 | MS;594. |
85/HCl | 5 | 氮杂环辛烷-1-基 | MS;608. |
86/HCl | 5 | 氮杂环壬烷-1-基 | MS;622. |
87/HCl | 5 | 氮杂环癸烷-1-基 | MS;636. |
88/HCl | 5 | (2R,6S)-2,6-diMe-pipe- | MS;608. |
89/HCl | 5 | Me<sub>2</sub>N(CH<sub>2</sub>)<sub>2</sub>N(Me)- | MS;597. |
90/HCl | 5 | cHexN(Me)- | MS;608. |
Ex | Syn | R | Data |
91/HCl | 5 | MeO(CH<sub>2</sub>)<sub>2</sub>NH- | MS;569. |
92/HCl | 5 | cPrNH- | MN;550. |
93/HCl | 5 | cBuNH- | MN;564. |
94/HCl | 5 | cHex-NH- | MN;592. |
95/HCl | 5 | iPrNH- | MN;552. |
96/HCl | 5 | tBuNH- | MN;566. |
97/HCl | 5 | (4-THP)N(Me)- | MS;610. |
98/HCl | 5 | (3-THF)N(Me)- | MS;596. |
99/HCl | 5 | MeOCH<sub>2</sub>CH(Me)N(Me)- | MS;598. |
100/HCl | 5 | cBuN(Me)- | MS;580. |
101/HCl | 5 | cPrN(Me)- | MS;566. |
102/HCl | 5 | pipe- | MN;578. |
103/HCl | 5 | iBuN(Me)- | MS;582. |
104/HCl | 5 | iPrN(Me)- | MS;568. |
105/HCl | 5 | 2-Me-pyrr- | MS;580. |
106/HCl | 5 | (S)-2-Me-pyrr- | MS;580. |
107/HCl | 5 | (R)-2-Me-pyrr- | MS;580. |
108/HCl | 5 | (R)-3-Me-pyrr- | MS;580. |
109/HCl | 5 | (S)-3-Me-pyrr- | MS;580. |
110/HCl | 5 | (R)-MeOCH(Me)CH<sub>2</sub>N(Me)- | MS;598. |
Ex | Syn | R | Data |
111/HCl | 5 | (S)-MeOCH(Me)CH<sub>2</sub>N(Me)- | MS;598. |
112/HCl | 5 | 3-EtO-pyrr- | MS;610. |
113/HCl | 5 | 4-MeO-pipe- | MS;610. |
114/HCl | 5 | 3-MeO-pipe- | MS;610. |
115/HCl | 5 | (S)-2-MeOCH<sub>2</sub>-pyrr- | MS;610. |
116/HCl | 5 | (R)-2-MeOCH<sub>2</sub>-pyrr- | MS;610. |
(表18)
Ex | Syn | R<sup>1</sup> | R<sup>2</sup> | R<sup>3</sup> | Data |
117 | 1 | MeO(CH<sub>2</sub>)<sub>2</sub>N(Me)- | 4-(EtO<sub>2</sub>CCH<sub>2</sub>)pipa- | Cl | MS;644. |
118 | 1 | nBuN(Me)- | 4-(EtO<sub>2</sub>CCH<sub>2</sub>)pipa- | Cl | MS;642. |
119/HCl | 1 | nBuN(Me)- | HO(CH<sub>2</sub>)<sub>3</sub>O- | Cl | MS;546. |
120/HCl | 1 | nBuN(Me)- | AcO(CH<sub>2</sub>)<sub>3</sub>O- | Cl | MS;588. |
121 | 1 | iBuN(Me)- | MeO<sub>2</sub>C(CH<sub>2</sub>)<sub>3</sub>O- | H | MM:554. |
122 | 2 | 氮杂环辛烷-1-基 | 4-EtO<sub>2</sub>C-pipe | F | MS;637. |
123 | 2 | nBuN(Me)- | 4-EtO<sub>2</sub>C-pipe | F | MS;611. |
124/HCl | 5 | MeO(CH<sub>2</sub>)<sub>2</sub>N(Me)- | 4-(HO<sub>2</sub>CCH<sub>2</sub>)pipa- | Cl | MN;614. |
125/HCl | 5 | nBuN(Me)- | 4-(HO<sub>2</sub>CCH<sub>2</sub>)pipa- | Cl | MS;614. |
Ex | Syn | R<sup>1</sup> | R<sup>2</sup> | R<sup>3</sup> | Data |
126/HCl | 5 | 氮杂环辛烷-1-基 | 4-HO<sub>2</sub>C-pipe | F | MS;609. |
127/HCl | 5 | nBuN(Me)- | 4-HO<sub>2</sub>C-pipe | F | MS;583. |
128/HCl | 5 | iBuN(Me)- | HO<sub>2</sub>C(CH<sub>2</sub>)<sub>3</sub>O- | H | MN;538. |
(表19)
Ex | Syn | R<sup>1</sup> | R<sup>2</sup> | R<sup>3</sup> | Data |
7/HCl | 7 | nBuN(Me)- | HO(CH<sub>2</sub>)<sub>2</sub>O- | OMe | MS;510 |
129 | 1 | nBuN(Me)- | OMOM | Cl | MS;514. |
130/HCl | 1 | nBuN(Me)- | OH | Cl | MS;470. |
131 | 1 | nBuN(Me)- | MeO<sub>2</sub>C(CH<sub>2</sub>)<sub>3</sub>O- | F | MS;554. |
132 | 1 | nBuN(Me)- | TBSO(CH<sub>2</sub>)<sub>2</sub>O- | OMe | MS;624. |
133 | 1 | nBuN(Me)- | Me | CF<sub>3</sub> | MS;502. |
134/HCl | 5 | nBuN(Me)- | HO<sub>2</sub>C(CH<sub>2</sub>)<sub>3</sub>O- | F | MS;540. |
(表20)
Ex | Syn | R<sup>1</sup> | R<sup>2</sup> | Data |
6/HCl | 6 | nBu | 3-氧代-4-HO(CH<sub>2</sub>)<sub>2</sub>-pipa- | MS;597. |
11/HCl | 11 | nBu | MsHN(CH<sub>2</sub>)<sub>2</sub>NH- | MS;591. |
135 | 1 | nBu | 3-MeO<sub>2</sub>C-pyrr | MS;582. |
136 | 1 | nBu | (R)-3-(MeO<sub>2</sub>CCH<sub>2</sub>O)pyrr- | MS;612. |
137 | 1 | nBu | (S)-3-MeO<sub>2</sub>C-pyrr- | MS;582. |
138 | 1 | nBu | 3-EtO<sub>2</sub>C-azet- | MS;582. |
139 | 1 | nBu | 4-(tBuO<sub>2</sub>CCH<sub>2</sub>O)pipe- | MS;668. |
140 | 1 | nBu | 2-EtO<sub>2</sub>C-mor- | MS;612. |
141 | 1 | nBu | 4-(MeO<sub>2</sub>CCH<sub>2</sub>NHCO)pipe- | MS;653. |
142 | 3 | nBu | 4-OH-4-EtO<sub>2</sub>C-pipe- | MS;626. |
143 | 3 | nBu | tBuO<sub>2</sub>C(CH<sub>2</sub>)<sub>2</sub>NH- | MS;598. |
144 | 3 | iBu | 3-(EtO<sub>2</sub>CCH<sub>2</sub>)azet- | MS;596. |
145 | 3 | iBu | EtO<sub>2</sub>C(CH<sub>2</sub>)<sub>3</sub>NH- | MS;584. |
146 | 3 | iBu | tBuO<sub>2</sub>C(CH<sub>2</sub>)<sub>2</sub>NH- | MS;598. |
147 | 3 | iBu | MeO<sub>2</sub>C(CH<sub>2</sub>)<sub>3</sub>N(Me)- | MS;584. |
148 | 3 | iBu | EtO<sub>2</sub>C(CH<sub>2</sub>)<sub>2</sub>N(Me)- | MS;584. |
149 | 3 | iBu | EtO<sub>2</sub>CCH<sub>2</sub>N(Me)- | MS;570. |
150/HCl | 4 | nBu | 4-HOCH<sub>2</sub>-pipe- | MS;568. |
151/HCl | 4 | nBu | HO(CH<sub>2</sub>)<sub>3</sub>NH- | MS;528. |
152/HCl | 4 | nBu | MeO(CH<sub>2</sub>)<sub>2</sub>O(CH<sub>2</sub>)<sub>2</sub>NH- | MS;572. |
Ex | Syn | R<sup>1</sup> | R<sup>2</sup> | Data |
153/HCl | 4 | nBu | 3-氧代-pipa- | MS;553. |
154/HCl | 4 | nBu | H<sub>2</sub>N(CH<sub>2</sub>)<sub>2</sub>NH- | MS;513. |
155 | 4 | nBu | 4-(4-MeO<sub>2</sub>C-pipe)-pipe- | MS;679. |
156 | 4 | nBu | 3-氧代-4-EtO<sub>2</sub>CCH<sub>2</sub>-pipa- | MS;639. |
157 | 4 | nBu | EtO<sub>2</sub>C(CH<sub>2</sub>)<sub>3</sub>NH- | MS;584. |
158/HCl | 5 | nBu | HO<sub>2</sub>C(CH<sub>2</sub>)<sub>3</sub>NH- | MS;556. |
159/HCl | 5 | nBu | 4-(4-HO<sub>2</sub>C-pipe)-pipe- | MN;663. |
160/HCl | 5 | nBu | 3-氧代-4-HO<sub>2</sub>CCH<sub>2</sub>-pipa- | MS;611. |
161/HCl | 5 | nBu | 3-HO<sub>2</sub>C-pyrr- | MS;568. |
162/HCl | 5 | nBu | (R)-3-(HO<sub>2</sub>CCH<sub>2</sub>O)-pyrr- | MN;596. |
163/HCl | 5 | nBu | (S)-3-HO<sub>2</sub>C-pyrr- | MS;568. |
164/HCl | 5 | nBu | 3-HO<sub>2</sub>C-azet- | MS;554. |
165/HCl | 5 | nBu | 2-HO<sub>2</sub>C-mor- | MS;584. |
166/HCl | 5 | nBu | 4-(3-HO<sub>2</sub>C-azet-CO)pipe- | MN;663. |
167/HCl | 5 | nBu | 4-(HO<sub>2</sub>C(CH<sub>2</sub>)<sub>2</sub>NHCO)pipe- | MS;653. |
(表20,续)
Ex | Syn | R<sup>1</sup> | R<sup>2</sup> | Data |
168/HCl | 5 | nBu | 4-(HO<sub>2</sub>CCH<sub>2</sub>NHCO)pipe- | MS;639. |
169/HCl | 5 | nBu | 4-HO-4-HO<sub>2</sub>C-pipe- | MS;598. |
170/HCl | 5 | iBu | 3-(HO<sub>2</sub>CCH<sub>2</sub>)azet- | MS;568. |
Ex | Syn | R<sup>1</sup> | R<sup>2</sup> | Data |
171/HCl | 5 | iBu | HO<sub>2</sub>C(CH<sub>2</sub>)<sub>3</sub>NH- | MS;556. |
172/HCl | 5 | iBu | HO<sub>2</sub>C(CH<sub>2</sub>)<sub>3</sub>N(Me)- | MS;570. |
173/HCl | 5 | iBu | HO<sub>2</sub>C(CH<sub>2</sub>)<sub>2</sub>N(Me)- | MS;556. |
174/HCl | 5 | iBu | HO<sub>2</sub>CCH<sub>2</sub>N(Me)- | MS;542. |
175 | 8 | nBu | 4-(3-EtO<sub>2</sub>C-azet-CO)pipe | MS;693. |
176/HCl | 8 | nBu | 4-(MeO(CH<sub>2</sub>)<sub>2</sub>NHCO)pipe | MS;639. |
177/HCl | 8 | nBu | 4-(H<sub>2</sub>NCOCH<sub>2</sub>NHCO)pipe | MS;638. |
178/HCl | 8 | nBu | 4-(MeO(CH<sub>2</sub>)<sub>2</sub>O(CH<sub>2</sub>)<sub>2</sub>NHCO)pipe- | MS;683. |
179 | 8 | nBu | 4-(EtO<sub>2</sub>C(CH<sub>2</sub>)<sub>2</sub>NHCO)pipe- | MS;681. |
180 | 8 | nBu | 4-(HO(CH<sub>2</sub>)<sub>2</sub>NHCO)pipe- | MS;625. |
181/HCl | 9 | nBu | 4-HO<sub>2</sub>CCH<sub>2</sub>O-pipe- | MS;612. |
182/HCl | 9 | nBu | HO<sub>2</sub>C(CH<sub>2</sub>)<sub>2</sub>NH- | MS;542. |
183/HCl | 9 | iBu | HO<sub>2</sub>C(CH<sub>2</sub>)<sub>2</sub>NH- | MS;542. |
(表21)
Ex | Syn | R | Data |
9/HCl | 9 | 4-(HO<sub>2</sub>CCH<sub>2</sub>O)pipe- | MN;612. |
184 | 1 | 3-EtO<sub>2</sub>C-pipe- | MS;612. |
Ex | Syn | R | Data |
185 | 1 | 3-MeO<sub>2</sub>C-pyrr- | MS;584. |
186 | 1 | (R)-3-(MeO<sub>2</sub>CCH<sub>2</sub>O)pyrr- | MS;614. |
187 | 1 | 4-EtO<sub>2</sub>CCH<sub>2</sub>-pipe- | MS;626. |
188 | 1 | 2-EtO<sub>2</sub>C-mor- | MN;612. |
189 | 1 | 3-EtO<sub>2</sub>C-azet- | MS;584. |
190 | 1 | 4-(tBuO<sub>2</sub>CCH<sub>2</sub>O)-pipe- | MS;670. |
191/HCl | 5 | 3-HO<sub>2</sub>C-pipe- | MS;584. |
192/HCl | 5 | 3-HO<sub>2</sub>C-pyrr | MS;570. |
193/HCl | 5 | (R)-3-(HO<sub>2</sub>CCH<sub>2</sub>O)pyrr- | MS;600. |
194/HCl | 5 | 4-HO<sub>2</sub>CCH<sub>2</sub>-pipe- | MS;598. |
195/HCl | 5 | 2-HO<sub>2</sub>C-mor- | MS;586. |
196/HCl | 5 | 3-HO<sub>2</sub>C-azet- | MS;556. |
(表22)
Ex | Syn | R<sup>1</sup> | R<sup>2</sup> | Data |
8/HCl | 8 | MeO(CH<sub>2</sub>)<sub>3</sub>N(Me)- | 4-(mor-CO)pipe- | MS;667. |
197 | 8 | MeO(CH<sub>2</sub>)<sub>3</sub>N(Me)- | 4-(MeO(CH<sub>2</sub>)<sub>2</sub>NHCO)pipe- | MS;655. |
198 | 1 | Me<sub>2</sub>N- | 3-MeO<sub>2</sub>C-pyrr- | MN;538. |
Ex | Syn | R<sup>1</sup> | R<sup>2</sup> | Data |
199 | 1 | (S)-2-Me-pyrr- | MeO<sub>2</sub>C(CH<sub>2</sub>)<sub>3</sub>N(Me)- | MS;582. |
200 | 1 | (R)-2-Me-pyrr- | MeO<sub>2</sub>C(CH<sub>2</sub>)<sub>3</sub>N(Me)- | MS;582. |
201 | 1 | Et<sub>2</sub>CHN(Me)- | MeO<sub>2</sub>C(CH<sub>2</sub>)<sub>3</sub>N(Me)- | MS;598. |
202 | 1 | (S)-3-Me-Pyrr- | MeO<sub>2</sub>C(CH<sub>2</sub>)<sub>3</sub>N(Me)- | MS;582. |
203 | 1 | 2-Me-pyrr- | MeO<sub>2</sub>C(CH<sub>2</sub>)<sub>2</sub>N(Me)- | MS;568. |
204 | 1 | iPrN(Me)- | MeO<sub>2</sub>C(CH<sub>2</sub>)<sub>2</sub>N(Me)- | MS;556. |
205 | 1 | (nPr)(Me)CHN(Me)- | MeO<sub>2</sub>C(CH<sub>2</sub>)<sub>2</sub>N(Me)- | MS;584. |
206 | 1 | (S)-3-Me-pyrr- | MeO<sub>2</sub>C(CH<sub>2</sub>)<sub>2</sub>N(Me)- | MS;568. |
207 | 1 | iPrN(Me)- | (S)-MeO<sub>2</sub>C-pyrr- | MS;568. |
208 | 3 | 2-Me-pyrr- | 3-(EtO<sub>2</sub>CCH<sub>2</sub>)azet- | MS;594. |
209 | 3 | (S)-2-Me-pyrr- | 3-(EtO<sub>2</sub>CCH<sub>2</sub>)azet- | MS;594. |
210 | 3 | (R)-2-Me-pyrr- | 3-(EtO<sub>2</sub>CCH<sub>2</sub>)azet- | MS;594. |
211 | 3 | iPrN(Me)- | 3-(EtO<sub>2</sub>CCH<sub>2</sub>)azet- | MS;582. |
212 | 3 | 2-Me-pyrr- | MeO<sub>2</sub>C(CH<sub>2</sub>)<sub>3</sub>N(Me)- | MS;582. |
213 | 3 | iPrN(Me)- | MeO<sub>2</sub>C(CH<sub>2</sub>)<sub>3</sub>N(Me)- | MS;570. |
214 | 3 | 2-Me-pyrr- | EtO<sub>2</sub>C(CH<sub>2</sub>)<sub>3</sub>NH- | MS;582. |
215 | 3 | (S)-2-Me-pyrr- | EtO<sub>2</sub>C(CH<sub>2</sub>)<sub>3</sub>NH- | MS;582. |
216 | 3 | (R)-2-Me-pyrr- | EtO<sub>2</sub>C(CH<sub>2</sub>)<sub>3</sub>NH- | MS;582. |
217 | 3 | 2-Me-pyrr- | tBuO<sub>2</sub>C(CH<sub>2</sub>)<sub>2</sub>NH- | MS;596. |
218/HCl | 4 | pipe- | 4-H<sub>2</sub>NOC-pipe- | MN;579. |
Ex | Syn | R<sup>1</sup> | R<sup>2</sup> | Data |
219/HCl | 5 | Me<sub>2</sub>N- | 3-HO<sub>2</sub>C-pyrr- | MS;526. |
220/HCl | 5 | 2-Me-pyrr- | 3-(HO<sub>2</sub>CCH<sub>2</sub>)azet- | MN;564. |
221/HCl | 5 | (S)-2-Me-pyrr- | 3-(HO<sub>2</sub>CCH<sub>2</sub>)azet- | MN;564. |
222/HCl | 5 | (R)-2-Me-pyrr- | 3-(HO<sub>2</sub>CCH<sub>2</sub>)azet- | MN;564. |
223/HCl | 5 | iPrN(Me)- | 3-(HO<sub>2</sub>CCH<sub>2</sub>)azet- | MN;552. |
224/HCl | 5 | 2-Me-pyrr- | HO<sub>2</sub>C(CH<sub>2</sub>)<sub>3</sub>N(Me)- | MS;568. |
225/HCl | 5 | (S)-2-Me-pyrr- | HO<sub>2</sub>C(CH<sub>2</sub>)<sub>3</sub>N(Me)- | MS;568. |
226/HCl | 5 | (R)-2-Me-pyrr- | HO<sub>2</sub>C(CH<sub>2</sub>)<sub>3</sub>N(Me)- | MS;568. |
227/HCl | 5 | iPrN(Me)- | HO<sub>2</sub>C(CH<sub>2</sub>)<sub>3</sub>N(Me)- | MS;556. |
228/HCl | 5 | Et<sub>2</sub>CHN(Me)- | HO<sub>2</sub>C(CH<sub>2</sub>)<sub>3</sub>N(Me)- | MS;584. |
229/HCl | 5 | (S)-3-Me-pyrr- | HO<sub>2</sub>C(CH<sub>2</sub>)<sub>3</sub>N(Me)- | MN;566. |
230/HCl | 5 | 2-Me-pyrr- | HO<sub>2</sub>C(CH<sub>2</sub>)<sub>2</sub>N(Me)- | MS;554. |
231/HCl | 5 | iPrN(Me)- | HO<sub>2</sub>C(CH<sub>2</sub>)<sub>2</sub>N(Me)- | MN;540. |
(表22,续)
Ex | Syn | R<sup>1</sup> | R<sup>2</sup> | Data |
232/HCl | 5 | (nPr)(Me)CHN(Me)- | HO<sub>2</sub>C(CH<sub>2</sub>)<sub>2</sub>N(Me)- | MS;570. |
233/HCl | 5 | (S)-3-Me-pyrr- | HO<sub>2</sub>C(CH<sub>2</sub>)<sub>2</sub>N(Me)- | MS;554. |
234/HCl | 5 | 2-Me-pyrr- | HO<sub>2</sub>C(CH<sub>2</sub>)<sub>3</sub>NH- | MS;554. |
235/HCl | 5 | (S)-2-Me-pyrr- | HO<sub>2</sub>C(CH<sub>2</sub>)<sub>3</sub>NH- | MN;552. |
236/HCl | 5 | (R)-2-Me-pyrr- | HO<sub>2</sub>C(CH<sub>2</sub>)<sub>3</sub>NH- | MN;552. |
Ex | Syn | R<sup>1</sup> | R<sup>2</sup> | Data |
237/HCl | 5 | iPrN(Me)- | (S)-3-HO<sub>2</sub>C-pyrr- | MN;552. |
238/HCl | 9 | 2-Me-pyrr- | HO<sub>2</sub>C(CH<sub>2</sub>)<sub>2</sub>NH- | MN;538. |
(表23)
Ex | Syn | R<sup>1</sup> | R<sup>2</sup> | Data |
239 | 1 | nBuN(Me)- | 4-EtO<sub>2</sub>C-pipe- | MN;588. |
240 | 1 | Me<sub>2</sub>N- | 4-EtO<sub>2</sub>C-pipe- | MS;588. |
241 | 1 | iBuN(Me)- | 4-EtO<sub>2</sub>C-pipe- | MN;588. |
242 | 1 | cHexN(Me)- | 4-EtO<sub>2</sub>C-pipe- | MS;588. |
243 | 1 | iPrN(Me)- | 4-EtO<sub>2</sub>C-pipe- | MN;588. |
244 | 1 | cBuN(Me)- | 4-EtO<sub>2</sub>C-pipe- | MN;687. |
245 | 1 | Et<sub>2</sub>CHN(Me)- | 4-EtO<sub>2</sub>C-pipe- | MN;687. |
246 | 1 | (nPr)(Me)CHN(Me)- | 4-EtO<sub>2</sub>C-pipe- | MS;604. |
247 | 1 | (iPr)(Me)CHN(Me)- | 4-EtO<sub>2</sub>C-pipe- | MS;604. |
248 | 1 | tBuN(Me)- | 4-EtO<sub>2</sub>C-pipe- | MS;590. |
249 | 1 | cBuCH<sub>2</sub>N(Me)- | 4-EtO<sub>2</sub>C-pipe- | MS;602. |
250 | 1 | 氮杂环庚烷-1-基 | 4-EtO<sub>2</sub>C-pipe- | MS;602. |
251 | 1 | 4-Me-pipe- | 4-EtO<sub>2</sub>C-pipe- | MS;602. |
Ex | Syn | R<sup>1</sup> | R<sup>2</sup> | Data |
252 | 1 | 3-Me-pipe- | 4-EtO<sub>2</sub>C-pipe- | MS;602. |
253 | 1 | 2-Me-pipe- | 4-EtO<sub>2</sub>C-pipe- | MS;602. |
254 | 1 | 2-Me-pyrr- | 4-EtO<sub>2</sub>C-pipe- | MS;588. |
255 | 1 | (S)-2-Me-pyrr- | 4-EtO<sub>2</sub>C-pipe- | MS;588. |
256 | 1 | (R)-2-Me-pyrr- | 4-EtO<sub>2</sub>C-pipe- | MS;588. |
257 | 1 | (R)-3-Me-pyrr- | 4-EtO<sub>2</sub>C-pipe- | MS;588. |
258 | 1 | (S)-3-Me-pyrr- | 4-EtO<sub>2</sub>C-pipe- | MS;588. |
259 | 1 | 3,3-diMe-pyrr- | 4-EtO<sub>2</sub>C-pipe- | MN;600. |
260 | 3 | iBuN(Me)- | 4-HO-4-EtO<sub>2</sub>C-pipe- | MS;606. |
261 | 3 | iBuN(Me)- | EtO<sub>2</sub>C(CH<sub>2</sub>)<sub>3</sub>NH- | MS;564. |
262 | 3 | iBuN(Me)- | MeO<sub>2</sub>C(CH<sub>2</sub>)<sub>3</sub>N(Me)- | MS;564. |
263 | 3 | cBuCH<sub>2</sub>N(Me)- | 4-HO-4-EtO<sub>2</sub>C-pipe- | ESI-MS(Pos);618. |
264 | 3 | 2-Me-pyrr- | 4-HO-4-EtO<sub>2</sub>C-pipe- | MS;604. |
(表23,续)
Ex | Syn | R<sup>1</sup> | R<sup>2</sup> | Data |
265 | 3 | 2-Me-pyrr- | EtO<sub>2</sub>C(CH<sub>2</sub>)<sub>3</sub>NH- | MS;562. |
266 | 3 | 2-Me-pyrr- | MeO<sub>2</sub>C(CH<sub>2</sub>)<sub>3</sub>N(Me)- | ESI-MS(Pos);562. |
267/HCl | 5 | nBuN(Me)- | 4-HO<sub>2</sub>C-pipe- | MS;562. |
268/HCl | 5 | Me<sub>2</sub>N- | 4-HO<sub>2</sub>C-pipe- | MS;520. |
269/HCl | 5 | iBuN(Me)- | 4-HO<sub>2</sub>C-pipe- | MS;562. |
Ex | Syn | R<sup>1</sup> | R<sup>2</sup> | Data |
270/HCl | 5 | cHexN(Me)- | 4-HO<sub>2</sub>C-pipe- | MS;588. |
271/HCl | 5 | iPrN(Me)- | 4-HO<sub>2</sub>C-pipe- | MS;548. |
272/HCl | 5 | cBuN(Me)- | 4-HO<sub>2</sub>C-pipe- | MS;560. |
273/HCl | 5 | Et<sub>2</sub>CHN(Me)- | 4-HO<sub>2</sub>C-pipe- | MS;576. |
274/HCl | 5 | (nPr)(Me)CHN(Me)- | 4-HO<sub>2</sub>C-pipe- | MS;576. |
275/HCl | 5 | (iPr)(Me)CHN(Me)- | 4-HO<sub>2</sub>C-pipe- | MS;576. |
276/HCl | 5 | cBuCH<sub>2</sub>N(Me)- | 4-HO<sub>2</sub>C-pipe- | MS;574. |
277/HCl | 5 | 氮杂环庚烷-1-基 | 4-HO<sub>2</sub>C-pipe- | MS;574. |
278/HCl | 5 | 4-Me-pipe- | 4-HO<sub>2</sub>C-pipe- | MS;574. |
279/HCl | 5 | 3-Me-pipe- | 4-HO<sub>2</sub>C-pipe- | MS;574. |
280/HCl | 5 | 2-Me-pipe- | 4-HO<sub>2</sub>C-pipe- | MS;574. |
281/HCl | 5 | 2-Me-pyrr- | 4-HO<sub>2</sub>C-pipe- | MN;558. |
282/HCl | 5 | (S)-2-Me-pyrr- | 4-HO<sub>2</sub>C-pipe- | MS;560. |
283/HCl | 5 | (R)-2-Me-pyrr- | 4-HO<sub>2</sub>C-pipe- | MS;560. |
284/HCl | 5 | (R)-3-Me-pyrr- | 4-HO<sub>2</sub>C-pipe- | MN;558. |
285/HCl | 5 | (S)-3-Me-pyrr- | 4-HO<sub>2</sub>C-pipe- | MN;558. |
286/HCl | 5 | 3,3-diMe-pyrr- | 4-HO<sub>2</sub>C-pipe- | MS;574. |
287/HCl | 5 | iBuN(Me)- | 4-HO-4-HO<sub>2</sub>C-pipe- | MS;578. |
288/HCl | 5 | iBuN(Me)- | HO<sub>2</sub>C(CH<sub>2</sub>)<sub>3</sub>NH- | MS;536. |
289/HCl | 5 | iBuN(Me)- | HO<sub>2</sub>C(CH<sub>2</sub>)<sub>3</sub>N(Me)- | MS;550. |
Ex | Syn | R<sup>1</sup> | R<sup>2</sup> | Data |
290/HCl | 5 | cBuCH<sub>2</sub>N(Me)- | 4-HO-4-HO<sub>2</sub>C-pipe- | MS;590. |
291/HCl | 5 | 2-Me-pyrr- | 4-HO-4-HO<sub>2</sub>C-pipe- | MS;576. |
292/HCl | 5 | 2-Me-pyrr- | HO<sub>2</sub>C(CH<sub>2</sub>)<sub>3</sub>NH- | MS;534. |
293/HCl | 5 | 2-Me-pyrr- | HO<sub>2</sub>C(CH<sub>2</sub>)<sub>3</sub>N(Me)- | MS;548. |
(表24)
Ex | Syn | R<sup>1</sup> | R<sup>2</sup> | R<sup>3</sup> | Data |
294 | 1 | pipe | 4-F-Ph- | 4-EtO<sub>2</sub>C-pipe- | MS;586. |
295 | 1 | pipe | 3-F<sub>3</sub>C-Ph- | 4-EtO<sub>2</sub>C-pipe- | MS;636. |
296 | 1 | nBuN(Me)- | 4-F-Ph- | 4-EtO<sub>2</sub>C-pipe- | MS;588. |
297 | 1 | nBuN(Me)- | 4-Me-5-(nBuN(Me)CH<sub>2</sub>)-2-The- | 4-EtO<sub>2</sub>C-pipe- | MN;687. |
298/HCl | 5 | pipe | 4-F-Ph- | 4-HO<sub>2</sub>C-pipe- | MS;558. |
299/HCl | 5 | pipe | 3-F<sub>3</sub>C-Ph- | 4-HO<sub>2</sub>C-pipe- | MS;608. |
300/HCl | 5 | nBuN(Me)- | 4-F-Ph- | 4-HO<sub>2</sub>C-pipe- | MS;560. |
(表25)
Ex | Syn | R<sup>1</sup> | R<sup>2</sup> | Data |
301/HCl | 1 | pipe | 2-MeO-4-Py | MS;449. |
302 | 1 | nBuN(Me)- | 4-(4-MeO<sub>2</sub>C-pipe)pipe | MS;568. |
303 | 1 | nBuN(Me)CH<sub>2</sub>- | 5-Cl-6-(4-EtO<sub>2</sub>C-pipe)-3-Py | MS;624. |
304 | 1 | nPrN(Me)- | 5-F-6-(4-EtO<sub>2</sub>C-pipe)-3-Py | MS;580. |
305 | 1 | iBuN(Me)- | 5-F-6-(4-EtO<sub>2</sub>C-pipe)-3-Py | MS;594. |
306 | 1 | 2-Me-pyrr- | 5-F-6-(4-EtO<sub>2</sub>C-pipe)-3-Py | MS;592. |
307 | 1 | (S)-2-Me-pyrr- | 5-F-6-(4-EtO<sub>2</sub>C-pipe)-3-Py | MS;592. |
308 | 1 | (R)-2-Me-pyrr- | 5-F-6-(4-EtO<sub>2</sub>C-pipe)-3-Py | MS;592. |
309 | 1 | iPrN(Me)- | 5-F-6-(4-EtO<sub>2</sub>C-pipe)-3-Py | MS;580. |
310/HCl | 5 | nBuN(Me)CH<sub>2</sub>- | 5-Cl-6-(4-HO<sub>2</sub>C-pipe)-3-Py | MS;596. |
311/HCl | 5 | nPrN(Me)- | 5-F-6-(4-HO<sub>2</sub>C-pipe)-3-Py | MS;552. |
312/HCl | 5 | iBuN(Me)- | 5-F-6-(4-HO<sub>2</sub>C-pipe)-3-Py | MS;566. |
313/HCl | 5 | 2-Me-pyrr- | 5-F-6-(4-HO<sub>2</sub>C-pipe)-3-Py | MS;564. |
314/HCl | 5 | (S)-2-Me-pyrr- | 5-F-6-(4-HO<sub>2</sub>C-pipe)-3-Py | MN:562. |
315/HCl | 5 | (R)-2-Me-pyrr- | 5-F-6-(4-HO<sub>2</sub>C-pipe)-3-Py | MS;564. |
316/HCl | 5 | iPrN(Me)- | 5-F-6-(4-HO<sub>2</sub>C-pipe)-3-Py | MN:550. |
(表26)
Ex | Syn | R<sup>1</sup> | R<sup>2</sup> | R<sup>3</sup> | Data |
10 | 10 | MeO(CH<sub>2</sub>)<sub>2</sub>- | EtO<sub>2</sub>C- | Cl | MS;610. |
317/HCl | 5 | cBu | HO<sub>2</sub>C- | Cl | MS;578. |
318/HCl | 5 | MeO(CH<sub>2</sub>)<sub>2</sub>- | HO<sub>2</sub>C- | Cl | MS;582. |
319/HCl | 5 | (R)-(MeO)(Me)CHCH<sub>2</sub>- | HO<sub>2</sub>C- | Cl | MS;596. |
320/HCl | 5 | (S)-(MeO)(Me)CHCH<sub>2</sub>- | HO<sub>2</sub>C- | Cl | MS;596. |
321 | 5 | Me | HO<sub>2</sub>C- | Cl | ESI-MS(Pos);538. |
322/HCl | 5 | Me | HO<sub>2</sub>C- | Me | MS;518. |
323 | 10 | cBu | EtO<sub>2</sub>C- | Cl | MS;606. |
324 | 10 | (R)-(MeO)(Me)CHCH<sub>2</sub>- | EtO<sub>2</sub>C- | Cl | MS;624. |
325 | 10 | (S)-(MeO)(Me)CHCH<sub>2</sub>- | EtO<sub>2</sub>C- | Cl | MS;624. |
326 | 10 | Et | EtO<sub>2</sub>C- | Cl | MN;578. |
327 | 10 | Me | EtO<sub>2</sub>C- | Cl | ESI-MS(Pos);566. |
328 | 10 | Me | EtO<sub>2</sub>C- | Me | MS;546. |
下面表27列出选定的实施例化合物的NMR数据。除非特别指出,各数据所示为用四甲基硅烷为内标和DMSO-δ6为测定溶剂的1H-NMR中的峰δ(ppm)。
(表27)
Ex | Data |
5 | 1.62-1.74(2H,m),1.90-1.98(2H,m),2.52-2.58(1H,m),2.81(3H,s),3.05(2H,t,J=11.2Hz),3.34(5H,s),3.72(2H,brs),4.00(2H,d,J=13.2Hz),4.60-4.90(2H,m),7.65(1H,s),7.73(1H,s),8.43(1H,d,J=1.9Hz),8.87(1H,d,J=2.4Hz),10.33(1H,brs),12.28(1H,brs),13.00(1H,s). |
65 | 1.61-1.73(2H,m),1.90-1.99(2H,m),2.51-2.54(1H,m),2.81(6H,m),3.05(2H,t,J=11.3Hz),4.01(2H,d,J=13.2Hz),4.74(2H,brs),7.69(1H,s),7.72(1H,s),8.43(1H,d,J=1.5Hz),8.87(1H,d,J=1.9Hz),9.95(1H,brs),12.27(1H,brs),12.99(1H,s). |
71 | 0.87(3H,t,J=7.4Hz),1.18-1.32(2H,m),1.58-1.74(4H,m),1.90-1.99(2H,m),2.51-2.57(1H,m),2.74(3H,d,J=3.9Hz),2.98-3.17(4H,m),4.01(2H,d,J=13.2Hz),4.63-4.84(2H,m),7.69(1H,s),7.74(1H,s),8.43(1H,d,J=2.4Hz),8.87(1H,d,J=1.9Hz),10.33(1H,brs),12.28(1H,brs),13.00(1H,s). |
Ex | Data |
84 | 1.52-1.98(12H,m),2.52-2.58(1H,m),3.05(2H,t,J=11.2Hz),3.13-3.24(2H,m),3.30-3.43(2H,m),4.00(2H,d,J=12.7Hz),4.74(2H,d,J=5.4Hz),7.65(1H,s),7.73(1H,s),8.42(1H,d,J=2.0Hz),8.87(1H,d,J=1.9Hz),10.18(1H,brs),12.27(1H,brs),12.99(1H,s). |
(表27,续)
Ex | Data |
85 | 1.48-1.77(10H,m),1.82-1.99(4H,m),2.52-2.59(1H,m),3.05(2H,t,J=11.3Hz),3.16-3.43(4H,m),4.00(2H,d,J=12.7Hz),4.74(2H,d,J=4.9Hz),7.65(1H,d,J=0.9Hz),7.74(1H,d,J=1.0Hz),8.43(1H,d,J=1.5Hz),8.87(1H,d,J=1.9Hz),9.98(1H,brs),12.29(1H,brs),12.99(1H,s). |
90 | 1.03-2.07(14H,m),2.52-2.57(1H,m),2.69(3H,d,J=4.4Hz),3.05(2H,t,J=11.5Hz),3.11-3.22(1H,m),4.01(2H,d,J=13.2Hz),4.58-4.89(2H,m),7.66(1H,s),7.75(1H,s),8.42(1H,d,J=2.0Hz),8.87(1H,d,J=2.0Hz),10.11(1H,brs),12.27(1H,brs),13.01(1H,s). |
100 | 1.60-1.77(4H,m),1.89-2.00(2H,m),2.01-2.20(2H,m),2.18-2.36(2H,m),2.50-2.58(1H,m),2.59-2.63(3H,d,J=4.4Hz),3.05(2H,t,J=11.7Hz),3.72-3.84(1H,m),3.95-4.05(2H,m),4.51-4.62(1H,m),4.65-4.75(1H,m),7.69(1H,s),7.74(1H,s),8.42(1H,d,J=2.2Hz),8.87(1H,d,J=2.2Hz),10.51(1H,brs),12.28(1H,brs),13.02(1H,brs) |
101 | 0.50-1.10(4H,m),1.62-1.75(2H,m),1.89-2.05(2H,m),2.50-2.58(1H,m),2.87(3H,brs),3.05(2H,t,J=11.2Hz),3.11-3.15(1H,m),3.92-4.06(2H,m),4.64-5.08(2H,m),7.62-7.83(2H,m),8.42(1H,d,J=2.0Hz),8.86(1H,d,J=2.0Hz),10.25(1H,brs),12.25(1H,brs),13.00(1H,brs). |
104 | 1.22(3H,d,J=6.9Hz),1.30(3H,d,J=6.8Hz),1.60-1.74(2H,m),1.90-2.00(2H,m),2.50-2.58(1H,m),2.67(3H,d,J=4.9Hz),3.05(2H,t,J=11.3Hz),3.30-3.45(1H,m),4.00(2H,d,J=3.2Hz),4.55-4.65(1H,m),4.72-4.82(1H,m),7.65(1H,s),7.74(1H,d,J=1.5Hz),8.42(1H,d,J=1.9Hz),8.87(1H,d,J=2.0Hz),10.05-10.25(1H,brs),12.97(1H,s,). |
106 | 1.42(3H,d,J=,6.3Hz),1.61-1.73(3H,m),1.87-1.96(4H,m),2.20-2.23(1H,m),2.49-2.57(1H,m),3.03-3.08(2H,m),3.13-3.22(1H,m),3.48-3.64(2H,m),4.01(2H,d,J=13.2Hz),4.62-4.68(2H,m),4.95(1H,d,J=11.8Hz)7.66(1H,d,J=1.0Hz),7.74(1H,d,J=1.0Hz),8.43(1H,d,J=2.0Hz),8.87(1H,d,J=2.4Hz),10.21(1H,brs),13.01(1H,s). |
107 | 1.42(3H,d,J=,6.3Hz),1.61-1.72(3H,m),1.88-1.96(4H,m),2.20-2.28(1H,m),2.49-2.51(1H,m),3.04-3.09(2H,m),3.15-3.20(1H,m),3.42-3.54(2H,m),4.01(2H,d,J=12.7Hz),4.66(1H,dd,J=7.8,15.1Hz),4.97(1H,d,J=11.2Hz),7.65(1H,d,J=1.0Hz),7.74(1H,d,J=1.0Hz),8.42(1H,d,J=2.0Hz),8.87(1H,d,J=2.2Hz),9.98(1H,brs),13.01(1H,s). |
108 | 1.05(3H,dd,J=1.5,6.4Hz),1.55-1.72(3H,m),1.90-2.00(2H,m),2.05-2.20(1H,m),2.28-2.40(1H,m),2.50-2.60(1H,m),2.70-2.80(1H,m),3.05(2H,t,J=10.8Hz),3.00-3.60(3H,m),3.95-4.05(2H,d,J=13.2Hz),4.75-4.80(2H,m),7.67-7.69(1H,m),7.72(1H,d,J=1.0Hz),8.43(1H,d,J=1.9Hz),8.83(1H,d,J=1.9Hz),10.75-10.95(1H,brd),12.97(1H,s).. |
109 | 1.05(3H,d,J=,6.3Hz),1.64-1.72(3H,m),1.91-1.96(2H,m),2.08-2.33(2H,m),2.50-2.51(1H,m),2.73-2.80(1H,m),3.03-3.08(2H,m),3.25-3.63(3H,m),4.01(2H,d,J=13.2Hz),4.76-4.86(2H,m),7.68(1H,d,J=1.5Hz),7.73(1H,d,J=1.5Hz),8.43(1H,d,J=1.9Hz),8.87(1H,d,J=1.9Hz),10.73(1H,brs),12.99(1H,s). |
110 | 1.05-1.13(3H,m),1.62-1.72(2H,m),1.91-1.98(2H,m),2.50-2.56(1H,m),2.76-2.84(3H,m),3.00-3.10(2H,m),3.30-3.60(5H,m),3.76-3.93(1H,m),3.96-4.40(2H,m),4.62-4.85(2H,m),7.64(1H,d,J=3.9),7.74(1H,s),8.43(1H,d,J=1.9Hz),8.87(1H,d,J=2.0Hz),9.76-10.04(1H,m),13.00(1H,s). |
Ex | Data |
111 | 1.05-1.13(3H,m),1.62-1.72(2H,m),1.91-1.96(2H,m),2.50-2.55(1H,m),2.76-2.84(3H,m),3.00-3.10(2H,m),3.25-3.60(5H,m),3.76-3.93(1H,m),3.96-4.40(2H,m),4.62-4.85(2H,m),7.61-7.65(1H,m).74(1H,s),8.43(1H,d,J=1.9Hz),8.87(1H,d,J=2.4Hz),9.66-9.93(1H,m),12.27(1H,brs),13.01(1H,s). |
150 | 0.87(3H,t,J=7.3Hz),1.17-1.34(4H,m),1.58-1.72(3H,m),1.78(2H,d,J=13.2Hz),2.73(3H,d,J=4.4Hz),2.92(2H,t,J=11.5Hz),2.96-3.18(2H,m),3.31(2H,d,J=6.3Hz),4.11(2H,d,J=12.7Hz),4.62-4.83(2H,m),7.70(1H,s),7.74(1H,s),8.41(1H,d,J=2.0Hz),8.86(1H,d,J=2.0Hz),10.62(1H,brs),12.97(1H,s). |
(表27,续)
Ex | Data |
151 | 0.87(3H,t,J=7.3Hz),1.16-1.34(2H,m),1.57-1.80(4H,m),2.72(3H,d,J=4.4Hz),2.94-3.17(2H,m),3.45-3.60(4H,m),4.60-4.80(2H,m),7.50(1H,brs),7.70(1H,s),7.73(1H,s),8.32(1H,d,J=2.0Hz),8.77(1H,d,J=2.0Hz),10.86(1H,brs),12.79(1H,s). |
153 | 0.87(3H,t,J=7.3Hz),1.18-1.32(2H,m),1.57-1.72(2H,m),2.74(3H,d,J=4.4Hz),2.96-3.19(2H,m),3.32(2H,brs),3.73-4.09(4H,m),4.62-4.84(2H,m),7.70(1H,d,J=1.0Hz),7.74(1H,d,J=1.0Hz),8.07(1H,s),8.48(1H,d,J=2.0Hz),8.89(1H,d,J=2.0Hz),10.39(1H,brs),13.05(1H,s). |
221 | 1.44(3H,d,J=6.3Hz),1.62-1.72(1H,m),1.87-1.97(2H,m),2.18-2.26(1H,m),2.66(2H,d,J=7.4Hz),2.92-2.99(1H,m),3.12-3.20(1H,m),3.49-3.57(3H,m),4.01-4.05(2H,m),4.46(1H,t,8.8Hz),4.62(1H,dd,J=7.3,15.1Hz),4.91(1H,dJ=14.7Hz).68(1H,d,J=1.0Hz),7.73(1H,d,J=1.4Hz),8.27(1H,d,J=2.0Hz),8.77(1H,d,J=2.0Hz),10.56(1H,brs),12.84(1H,s). |
222 | 1.43(3H,d,J=6.4Hz),1.62-1.71(1H,m),1.87-1.98(2H,m),2.18-2.23(1H,m),2.66(2H,d,J=7.8Hz),2.89-2.99(1H,m),3.12-3.21(1H,m),3.48-3.57(3H,m),4.01-4.05(2H,m),4.43-4.48(1H,m),4.60-4.66(1H,m),4.92(1H,d,J=12.2Hz),7.67(1H,s),7.74(1H,d,J=1.0Hz),8.27(1H,d,J=2.0Hz),8.77(1H,d,J=2.0Hz),10.42(1H,brs),12.84(1H,s). |
225 | 1.42(3H,d,J=,6.4Hz),1.60-1.70(1H,m),1.86-1.97(4H,m),2.23-2.26(3H,m),3.13(3H,s),3.15-3.20(1H,m),3.40-3.60(4H,m),4.62-4.67(1H,m),4.95(1H,d,J=15.1Hz),7.65(1H,d,J=0.9Hz),7.74(1H,d,J=1.5Hz),8.38(1H,d,J=1.9Hz),8.82(1H,d,J=2.4Hz),10.08(1H,brs),12.93(1H,s). |
Ex | Data |
226 | 1.45(3H,d,J=,6.3Hz),1.63-1.73(1H,m),1.84-1.97(4H,m),2.18-2.27(3H,m),3.13(3H,s),3.16-3.20(1H,m),3.39-3.59(4H,m),4.63(1H,dd,J=7.3,15.1Hz),4.90(1H,d,J=12.2Hz),7.68(1H,d,J=1.0Hz),7.74(1H,d,J=1.0Hz),8.39(1H,d,J=2.0Hz),8.82(1H,d,J=1.9Hz),10.75(1H,brs),12.92(1H,s). |
227 | 1.22(3H,d,J=,6.9Hz),1.32(3H,d,J=6.3Hz),1.84-1.91(2H,m),2.23-2.27(2H,m),2.65(3H,d,J=4.9Hz),3.13(3H,s),3.56-3.61(3H,m),4.58(1H,dd,J=5.9,15.2Hz),4.76(1H,dd,J=3.9,4.7Hz).67(1H,s),7.74(1H,s),8.39(1H,d,J=2.0Hz),8.82(1H,d,J=1.9Hz),10.57(1H,brs),12.91(1H,s). |
271 | 1.19(3H,d,J=6.9Hz),1.30(3H,d,J=6.3Hz),1.60-1.72(2H,m),1.90-1.98(2H,m),2.28(3H,s),2.52-2.58(1H,m),2.65(3H,d,J=5.3Hz),3.05(2H,t,J=11.2Hz),3.52-3.64(1H,m),4.00(2H,d,J=13.2Hz),4.55-4.80(2H,m),7.30(1H,s),7.40(1H,s),842(1H,d,J=2.5Hz),8.75(1H,d,J=2.0Hz),9.80-9.90(1H,brs),12.97(1H,s). |
314 | 1.45(3H,d,J=6.3Hz),1.55-1.72(3H,m),1.90-2.00(4H,m),2.15-2.25(1H,m),2.55-2.65(1H.m),3.20-3.32(3H,m),3.45-3.55(2H,m),4.45(2H,d,J=13.2Hz),4.59-4.67(1H,m),4.85-4.95(1H,m),7.69(1H,d,J=1.5Hz),7.72(1H,d,J=1.4Hz),8.14(1H,dd,J=1.9,15.1Hz),8.75(1H,t,J=0.9Hz),10.75(1H,brs),12.90(1Hs). |
315 | 1.42(3H,d,J=6.4Hz),1.55-1.70(3H,m),1.85-2.00(4H,m),2.15-2.25(1H,m),2.54-2.65(1H,m),3.10-3.22(3H,m),3.45-3.60(2H,m),4.23(2H,d,J=13.2Hz),4.55-4.65(1H,m),4.85-4.95(1H,m),7.65(1H,d,J=1.0Hz),7.75(1H,s),8.13(1H,dd,J=2.0,15.1Hz),8.75(1H,s),10.67(1H,brs),12.90(1H,s). |
下面表28至41列出本发明其它化合物的结构。这些化合物可采用在制备例和实施例所述的方法,或本领域技术人员公知的方法或经改进的这些方法方便地制备。
(表28)
No | R<sup>1</sup> | R<sup>2</sup> | No | R<sup>1</sup> | R<sup>2</sup> |
A1 | EtN(Me)- | 4-Cl-2-The | A40 | 2-Me-pyrr | 4-Cl-2-The |
A2 | nPrN(Me)- | 4-Cl-2-The | A41 | 3-Me-pyrr | 4-Cl-2-The |
A3 | iPrN(Me)- | 4-Cl-2-The | A42 | 3,4-diMe-pyrr | 4-Cl-2-The |
A4 | iBuN(Me)- | 4-Cl-2-The | A43 | 3,3-diMe-pyrr | 4-Cl-2-The |
A5 | sBuN(Me)- | 4-Cl-2-The | A44 | 2-Me-pipe | 4-Cl-2-The |
A6 | tBuN(Me)- | 4-Cl-2-The | A45 | 3-Me-pipe | 4-Cl-2-The |
A7 | tBuCH<sub>2</sub>N(Me)- | 4-Cl-2-The | A46 | 4-Me-pipe | 4-Cl-2-The |
A8 | cPenN(Me)- | 4-Cl-2-The | A47 | 3,3-diMe-pipe | 4-Cl-2-The |
A9 | cPrCH<sub>2</sub>N(Me)- | 4-Cl-2-The | A48 | 4,4-diMe-pipe | 4-Cl-2-The |
A10 | cBuCH<sub>2</sub>N(Me)- | 4-Cl-2-The | A49 | EtN(Me)- | 4-Me-2-The |
A11 | MeOH(Me)CH<sub>2</sub>N(Me)- | 4-Cl-2-The | A50 | nPrN(Me)- | 4-Me-2-The |
A12 | nPrN(Et)- | 4-Cl-2-The | A51 | sBuN(Me)- | 4-Me-2-The |
A13 | nBuN(Et)- | 4-Cl-2-The | A52 | tBuN(Me)- | 4-Me-2-The |
A14 | iPrN(Et)- | 4-Cl-2-The | A53 | tBuCH<sub>2</sub>N(Me)- | 4-Me-2-The |
A15 | iBuN(Et)- | 4-Cl-2-The | A54 | cPrN(Me)- | 4-Me-2-The |
A16 | sBuN(Et)- | 4-Cl-2-The | A55 | cPenN(Me)- | 4-Me-2-The |
No | R<sup>1</sup> | R<sup>2</sup> | No | R<sup>1</sup> | R<sup>2</sup> |
A17 | tBuN(Et)- | 4-Cl-2-The | A56 | cPrCH<sub>2</sub>N(Me)- | 4-Me-2-The |
A18 | tBuCH<sub>2</sub>N(Et)- | 4-Cl-2-The | A57 | cBuCH<sub>2</sub>N(Me)- | 4-Me-2-The |
A19 | cPrN(Et)- | 4-Cl-2-The | A58 | MeO(CH<sub>2</sub>)<sub>2</sub>N(Me)- | 4-Me-2-The |
A20 | cBuN(Et)- | 4-Cl-2-The | A59 | MeOCH<sub>2</sub>CH(Me)N(Me)- | 4-Me-2-The |
A21 | cPenN(Et)- | 4-Cl-2-The | A60 | MeOCH(Me)CH<sub>2</sub>N(Me)- | 4-Me-2-The |
A22 | cHexN(Et)- | 4-Cl-2-The | A61 | EtO(CH<sub>2</sub>)<sub>2</sub>N(Me)- | 4-Me-2-The |
A23 | cPrCH<sub>2</sub>N(Et)- | 4-Cl-2-The | A62 | nPrO(CH<sub>2</sub>)<sub>2</sub>N(Me)- | 4-Me-2-The |
A24 | cBuCH<sub>2</sub>N(Et)- | 4-Cl-2-The | A63 | iPrO(CH<sub>2</sub>)<sub>2</sub>N(Me)- | 4-Me-2-The |
A25 | MeO(CH<sub>2</sub>)<sub>2</sub>N(Et)- | 4-Cl-2-The | A64 | MeO(CH<sub>2</sub>)<sub>3</sub>N(Me)- | 4-Me-2-The |
A26 | MeOCH<sub>2</sub>CH(Me)N(Et)- | 4-Cl-2-The | A65 | Et<sub>2</sub>N- | 4-Me-2-The |
A27 | MeOCH(Me)CH<sub>2</sub>N(Et)- | 4-Cl-2-The | A66 | nPrN(Et)- | 4-Me-2-The |
A28 | (MeO(CH<sub>2</sub>)<sub>2</sub>)<sub>2</sub>N- | 4-Cl-2-The | A67 | nBuN(Et)- | 4-Me-2-The |
A29 | MeO(CH<sub>2</sub>)<sub>2</sub>-N(cPr)- | 4-Cl-2-The | A68 | iPrN(Et)- | 4-Me-2-The |
A30 | MeO(CH<sub>2</sub>)<sub>2</sub>-N(cBu)- | 4-Cl-2-The | A69 | iBuN(Et)- | 4-Me-2-The |
A31 | EtO(CH<sub>2</sub>)<sub>2</sub>N(Et)- | 4-Cl-2-The | A70 | sBuN(Et)- | 4-Me-2-The |
A32 | nPrO(CH<sub>2</sub>)<sub>2</sub>N(Et)- | 4-Cl-2-The | A71 | tBuN(Et)- | 4-Me-2-The |
A33 | iPrO(CH<sub>2</sub>)<sub>2</sub>N(Et)- | 4-Cl-2-The | A72 | tBuCH<sub>2</sub>N(Et)- | 4-Me-2-The |
A34 | MeO(CH<sub>2</sub>)<sub>3</sub>N(Et)- | 4-Cl-2-The | A73 | cPrN(Et)- | 4-Me-2-The |
A35 | 2-Me-azet | 4-Cl-2-The | A74 | cBuN(Et)- | 4-Me-2-The |
A36 | 3-Me-azet | 4-Cl-2-The | A75 | cPenN(Et)- | 4-Me-2-The |
No | R<sup>1</sup> | R<sup>2</sup> | No | R<sup>1</sup> | R<sup>2</sup> |
A37 | 3,3-diMe-azet | 4-Cl-2-The | A76 | cHexN(Et)- | 4-Me-2-The |
A38 | cPrCH<sub>2</sub>N(Et)- | 4-Me-2-The | A77 | MeO(CH<sub>2</sub>)<sub>2</sub>N(Me)- | 4-Br-2-The |
A39 | cBuCH<sub>2</sub>N(Et)- | 4-Me-2-The | A78 | pipe | 4-Br-2-The |
(表28,续)
No | R<sup>1</sup> | R<sup>2</sup> | No | R<sup>1</sup> | R<sup>2</sup> |
A79 | MeO(CH<sub>2</sub>)<sub>2</sub>N(Et)- | 4-Me-2-The | A123 | Me<sub>2</sub>N- | 4-F-2-The |
A80 | MeOCH<sub>2</sub>CH(Me)N(Et)- | 4-Me-2-The | A124 | nBuN(Me)- | 4-F-2-The |
A81 | MeOCH(Me)CH<sub>2</sub>N(Et)- | 4-Me-2-The | A125 | cHexN(Me)- | 4-F-2-The |
A82 | EtO(CH<sub>2</sub>)<sub>2</sub>N(Et)- | 4-Me-2-The | A126 | MeO(CH<sub>2</sub>)<sub>2</sub>N(Me)- | 4-F-2-The |
A83 | nPrO(CH<sub>2</sub>)<sub>2</sub>N(Et)- | 4-Me-2-The | A127 | pipe | 4-F-2-The |
A84 | iPrO(CH<sub>2</sub>)<sub>2</sub>N(Et)- | 4-Me-2-The | A128 | Me<sub>2</sub>N- | 4-Et-2-The |
A85 | MeO(CH<sub>2</sub>)<sub>3</sub>N(Et)- | 4-Me-2-The | A129 | nBuN(Me)- | 4-Et-2-The |
A86 | azet | 4-Me-2-The | A130 | cHexN(Me)- | 4-Et-2-The |
A87 | pyrr | 4-Me-2-The | A131 | MeO(CH<sub>2</sub>)<sub>2</sub>N(Me)- | 4-Et-2-The |
A88 | pipe | 4-Me-2-The | A132 | pipe | 4-Et-2-The |
A89 | 氮杂环庚烷-1-基 | 4-Me-2-The | A133 | Me<sub>2</sub>N- | 5-Cl-2-The |
A90 | 氮杂环辛烷-1-基 | 4-Me-2-The | A134 | nBuN(Me)- | 5-Cl-2-The |
A91 | 2-Me-azet | 4-Me-2-The | A135 | cHexN(Me)- | 5-Cl-2-The |
A92 | 3-Me-azet | 4-Me-2-The | A136 | MeO(CH<sub>2</sub>)<sub>2</sub>N(Me)- | 5-Cl-2-The |
A93 | 3,3-diMe-azet | 4-Me-2-The | A137 | pipe | 5-Cl-2-The |
No | R<sup>1</sup> | R<sup>2</sup> | No | R<sup>1</sup> | R<sup>2</sup> |
A94 | 2-Me-pyrr | 4-Me-2-The | A138 | Me<sub>2</sub>N- | 4-F-Ph |
A95 | 3-Me-pyrr | 4-Me-2-The | A139 | cHexN(Me)- | 4-F-Ph |
A96 | 3,4-diMe-pyrr | 4-Me-2-The | A140 | MeO(CH<sub>2</sub>)<sub>2</sub>N(Me)- | 4-F-Ph |
A97 | 3,3-diMe-pyrr | 4-Me-2-The | A141 | Me<sub>2</sub>N- | 3-Cl-Ph |
A98 | 2-Me-pipe | 4-Me-2-The | A142 | nBuN(Me)- | 3-Cl-Ph |
A99 | 3-Me-pipe | 4-Me-2-The | A143 | cHex(Me)- | 3-Cl-Ph |
A100 | 4-Me-pipe | 4-Me-2-The | A144 | MeO(CH<sub>2</sub>)<sub>2</sub>N(Me)- | 3-Cl-Ph |
A101 | 3,3-diMe-pipe | 4-Me-2-The | A145 | pipe | 3-Cl-Ph |
A102 | 4,4-diMe-pipe | 4-Me-2-The | A146 | Me<sub>2</sub>N- | 3-F<sub>3</sub>C-Ph |
A103 | Me<sub>2</sub>N- | 4-Br-2-The | A147 | nBuN(Me)- | 3-F<sub>3</sub>C-Ph |
A104 | nBuN(Me)- | 4-Br-2-The | A148 | cHexN(Me)- | 3-F<sub>3</sub>C-Ph |
A105 | cHexN(Me)- | 4-Br-2-The | A149 | MeO(CH<sub>2</sub>)<sub>2</sub>N(Me)- | 3-F<sub>3</sub>C-Ph |
A106 | 2-Et-azet | 4-Cl-2-The | A150 | 2-Et-azet | 4-Me-2-The |
A107 | 3-Et-azet | 4-Cl-2-The | A151 | 3-Et-azet | 4-Me-2-The |
A108 | 2-Et-pyrr | 4-Cl-2-The | A152 | 2-Et-pyrr | 4-Me-2-The |
A109 | 3-Et-pyrr | 4-Cl-2-The | A153 | 3-Et-pyrr | 4-Me-2-The |
A110 | 2-Et-pipe | 4-Cl-2-The | A154 | 2-Et-pipe | 4-Me-2-The |
A111 | 3-Et-pipe | 4-Cl-2-The | A155 | 3-Et-pipe | 4-Me-2-The |
A112 | 4-Et-pipe | 4-Cl-2-The | A156 | 4-Et-pipe | 4-Me-2-The |
A113 | 2-MeOCH<sub>2</sub>-azet | 4-Cl-2-The | A157 | 2-MeOCH<sub>2</sub>-azet | 4-Me-2-The |
No | R<sup>1</sup> | R<sup>2</sup> | No | R<sup>1</sup> | R<sup>2</sup> |
A114 | 3-MeOCH<sub>2</sub>-azet | 4-Cl-2-The | A158 | 3-MeOCH<sub>2</sub>-azet | 4-Me-2-The |
A115 | 2-MeOCH<sub>2</sub>-pyrr | 4-Cl-2-The | A159 | 2-MeOCH<sub>2</sub>-pyrr | 4-Me-2-The |
A116 | 3-MeOCH<sub>2</sub>-pyrr | 4-Cl-2-The | A160 | 3-MeOCH<sub>2</sub>-pyrr | 4-Me-2-The |
A117 | 2-MeOCH<sub>2</sub>-pipe | 4-Cl-2-The | A161 | 2-MeOCH<sub>2</sub>-pipe | 4-Me-2-The |
A118 | 3-MeOCH<sub>2</sub>-pipe | 4-Cl-2-The | A162 | 3-MeOCH<sub>2</sub>-pipe | 4-Me-2-The |
A119 | 4-MeOCH<sub>2</sub>-pipe | 4-Cl-2-The | A163 | 4-MeOCH<sub>2</sub>-pipe | 4-Me-2-The |
A120 | 3-MeO-azet | 4-Cl-2-The | A164 | 3-MeO-azet | 4-Me-2-The |
A121 | 3-MeO-pyrr | 4-Cl-2-The | A165 | 3-MeO-pyrr | 4-Me-2-The |
A122 | 3-MeO-pipe | 4-Cl-2-The | A166 | 3-MeO-pipe | 4-Me-2-The |
(表28,续)
No | R<sup>1</sup> | R<sup>2</sup> | No | R<sup>1</sup> | R<sup>2</sup> |
A167 | 4-MeO-pipe | 4-Cl-2-The | A172 | 4-MeO-pipe | 4-Me-2-The |
A168 | 3-F-azet | 4-Cl-2-The | A173 | 3-F-azet | 4-Me-2-The |
A169 | 3-F-pyrr | 4-Cl-2-The | A174 | 3-F-pyrr | 4-Me-2-The |
A170 | 3-F-pipe | 4-Cl-2-The | A175 | 3-F-pipe | 4-Me-2-The |
A171 | 4-F-pipe | 4-Cl-2-The | A176 | 4-F-pipe | 4-Me-2-The |
(表29)
(表30)
(表31)
No | X | R | No | X | R |
D1 | Cl | 3-HO<sub>2</sub>C-pipe | D21 | Cl | HO<sub>2</sub>C(CH<sub>2</sub>)<sub>3</sub>N(Me)- |
D2 | Cl | 4-HO<sub>2</sub>CCH<sub>2</sub>-pipe | D22 | Cl | HO<sub>2</sub>C(CH<sub>2</sub>)<sub>2</sub>N(Me)- |
No | X | R | No | X | R |
D3 | Cl | 4-HO<sub>2</sub>CCH<sub>2</sub>-pipa | D23 | Cl | HO<sub>2</sub>CCH<sub>2</sub>N(Me)- |
D4 | Cl | 3-HO<sub>2</sub>CCH<sub>2</sub>-pyrr | D24 | Cl | HO<sub>2</sub>C(CH<sub>2</sub>)<sub>3</sub>O- |
D5 | Cl | 3-HO<sub>2</sub>CCH<sub>2</sub>-azet | D25 | Cl | HO<sub>2</sub>C(CH<sub>2</sub>)<sub>2</sub>O- |
D6 | Cl | 4-HO-pipe | D26 | Cl | HO<sub>2</sub>CCH<sub>2</sub>O- |
D7 | Cl | 3-HO-pipe | D27 | F | 4-HO<sub>2</sub>C-pipe |
D8 | Cl | 3-HO-pyrr | D28 | F | 3-HO<sub>2</sub>C-pipe |
D9 | Cl | 4-HOCH<sub>2</sub>-pipe | D29 | F | 3-HO<sub>2</sub>C-pyrr |
D10 | Cl | 3-HO-4-HO<sub>2</sub>C-pipe | D30 | F | 4-HO<sub>2</sub>CCH<sub>2</sub>-pipe |
D11 | Cl | 4-HO-4-HO<sub>2</sub>C-pipe | D31 | F | 4-HO<sub>2</sub>CCH<sub>2</sub>-pipa |
D12 | Cl | 4-HO-4-HO<sub>2</sub>CCH<sub>2</sub>-pipe | D32 | F | 3-HO<sub>2</sub>CCH<sub>2</sub>-pyrr |
D13 | Cl | 4-HO<sub>2</sub>CCH(OH)-pipe | D33 | F | 3-HO<sub>2</sub>CCH<sub>2</sub>-azet |
D14 | Cl | HO(CH<sub>2</sub>)<sub>2</sub>NH- | D34 | F | 4-HO-pipe |
D15 | Cl | HO(CH<sub>2</sub>)<sub>3</sub>N(Me)- | D35 | F | 3-HO-pipe |
D16 | Cl | HO(CH<sub>2</sub>)<sub>2</sub>N(Me)- | D36 | F | 3-HO-pyrr |
D17 | Cl | HO(CH<sub>2</sub>)<sub>3</sub>O- | D37 | F | 4-HOCH<sub>2</sub>-pipe |
D18 | Cl | HO(CH<sub>2</sub>)<sub>2</sub>O- | D38 | F | 4-HO<sub>2</sub>CCH<sub>2</sub>O-pipe |
D19 | Cl | HO<sub>2</sub>C(CH<sub>2</sub>)<sub>2</sub>NH- | D39 | F | 3-HO-4-HO<sub>2</sub>C-pipe |
D20 | Cl | HO<sub>2</sub>CCH<sub>2</sub>NH- | D40 | F | 4-HO-4-HO<sub>2</sub>C-pipe |
(表31,续)
No | X | R | No | X | R |
D41 | F | 4-HO-4-HO<sub>2</sub>CCH<sub>2</sub>-pipe | D85 | F | HO<sub>2</sub>C(CH<sub>2</sub>)<sub>2</sub>NH- |
D42 | F | 4-HO<sub>2</sub>CCH(OH)-pipe | D86 | F | HO<sub>2</sub>CCH<sub>2</sub>NH- |
D43 | F | HO(CH<sub>2</sub>)<sub>3</sub>NH- | D87 | F | HO<sub>2</sub>C(CH<sub>2</sub>)<sub>3</sub>N(Me)- |
D44 | F | HO(CH<sub>2</sub>)<sub>2</sub>NH- | D88 | F | HO<sub>2</sub>C(CH<sub>2</sub>)<sub>2</sub>N(Me)- |
D45 | F | HO(CH<sub>2</sub>)<sub>3</sub>N(Me)- | D89 | F | HO<sub>2</sub>CCH<sub>2</sub>N(Me)- |
D46 | F | HO(CH<sub>2</sub>)<sub>2</sub>N(Me)- | D90 | F | HO<sub>2</sub>C(CH<sub>2</sub>)<sub>3</sub>O- |
D47 | F | HO(CH<sub>2</sub>)<sub>3</sub>O- | D91 | F | HO<sub>2</sub>C(CH<sub>2</sub>)<sub>2</sub>O- |
D48 | F | HO(CH<sub>2</sub>)<sub>2</sub>O- | D92 | F | HO<sub>2</sub>CCH<sub>2</sub>O- |
D49 | F | HO<sub>2</sub>C(CH<sub>2</sub>)<sub>3</sub>NH- | D93 | Me | 4-HO<sub>2</sub>C-pipe |
D50 | H | 4-HO<sub>2</sub>C-pipe | D94 | Me | 3-HO<sub>2</sub>C-pipe |
D51 | H | 3-HO<sub>2</sub>C-pipe | D95 | Me | 3-HO<sub>2</sub>C-pyrr |
D52 | H | 3-HO<sub>2</sub>C-pyrr | D96 | Me | 3-HO<sub>2</sub>C-azet |
D53 | H | 3-HO<sub>2</sub>C-azet | D97 | Me | 4-HO<sub>2</sub>CCH<sub>2</sub>-pipe |
D54 | H | 4-HO<sub>2</sub>CCH<sub>2</sub>-pipe | D98 | Me | 4-HO<sub>2</sub>CCH<sub>2</sub>-pipa |
D55 | H | 4-HO<sub>2</sub>CCH<sub>2</sub>-pipa | D99 | Me | 3-HO<sub>2</sub>CCH<sub>2</sub>-pyrr |
D56 | H | 3-HO<sub>2</sub>CCH<sub>2</sub>-pyrr | D100 | Me | 3-HO<sub>2</sub>CCH<sub>2</sub>-azet |
D57 | H | 3-HO<sub>2</sub>CCH<sub>2</sub>-azet | D101 | Me | HO<sub>2</sub>C(CH<sub>2</sub>)<sub>3</sub>NH- |
D58 | H | HO<sub>2</sub>C(CH<sub>2</sub>)<sub>3</sub>NH- | D102 | Me | HO<sub>2</sub>C(CH<sub>2</sub>)<sub>2</sub>NH- |
D59 | H | HO<sub>2</sub>C(CH<sub>2</sub>)<sub>2</sub>NH- | D103 | Me | HO<sub>2</sub>CCH<sub>2</sub>NH- |
D60 | H | HO<sub>2</sub>CCH<sub>2</sub>NH- | D104 | Me | HO<sub>2</sub>C(CH<sub>2</sub>)<sub>3</sub>N(Me)- |
No | X | R | No | X | R |
D61 | H | HO<sub>2</sub>C(CH<sub>2</sub>)<sub>3</sub>N(Me)- | D105 | Me | HO<sub>2</sub>C(CH<sub>2</sub>)<sub>2</sub>N(Me)- |
D62 | H | HO<sub>2</sub>C(CH<sub>2</sub>)<sub>2</sub>N(Me)- | D106 | Me | HO<sub>2</sub>CCH<sub>2</sub>N(Me)- |
D63 | H | HO<sub>2</sub>CCH<sub>2</sub>N(Me)- | D107 | Me | HO<sub>2</sub>C(CH<sub>2</sub>)<sub>3</sub>O- |
D64 | H | HO<sub>2</sub>C(CH<sub>2</sub>)<sub>3</sub>O- | D108 | Me | HO<sub>2</sub>C(CH<sub>2</sub>)<sub>2</sub>O- |
D65 | H | HO<sub>2</sub>C(CH<sub>2</sub>)<sub>2</sub>O- | D109 | Me | HO<sub>2</sub>CCH<sub>2</sub>O- |
D66 | H | HO<sub>2</sub>CCH<sub>2</sub>O- | D110 | MeO | 4-HO<sub>2</sub>C-pipe |
D67 | Br | 4-HO<sub>2</sub>C-pipe | D111 | MeO | 3-HO<sub>2</sub>C-pipe |
D68 | Br | 3-HO<sub>2</sub>C-pipe | D112 | MeO | 3-HO<sub>2</sub>C-pyrr |
D69 | Br | 3-HO<sub>2</sub>C-pyrr | D113 | MeO | 3-HO<sub>2</sub>C-azet |
D70 | Br | 3-HO<sub>2</sub>C-azet | D114 | MeO | 4-HO<sub>2</sub>CCH<sub>2</sub>-pipe |
D71 | Br | 4-HO<sub>2</sub>CCH<sub>2</sub>-pipe | D115 | MeO | 4-HO<sub>2</sub>CCH<sub>2</sub>-pipa |
D72 | Br | 4-HO<sub>2</sub>CCH<sub>2</sub>-pipa | D116 | MeO | 3-HO<sub>2</sub>CCH<sub>2</sub>-pyrr |
D73 | Br | 3-HO<sub>2</sub>CCH<sub>2</sub>-pyrr | D117 | MeO | 3-HO<sub>2</sub>CCH<sub>2</sub>-azet |
D74 | Br | 3-HO<sub>2</sub>CCH<sub>2</sub>-azet | D118 | MeO | HO<sub>2</sub>C(CH<sub>2</sub>)<sub>3</sub>NH- |
D75 | Br | HO<sub>2</sub>C(CH<sub>2</sub>)<sub>3</sub>NH- | D119 | MeO | HO<sub>2</sub>C(CH<sub>2</sub>)<sub>2</sub>NH- |
D76 | Br | HO<sub>2</sub>C(CH<sub>2</sub>)<sub>2</sub>NH- | D120 | MeO | HO<sub>2</sub>CCH<sub>2</sub>NH- |
D77 | Br | HO<sub>2</sub>CCH<sub>2</sub>NH- | D121 | CF<sub>3</sub> | 3-HO<sub>2</sub>C-pipe |
D78 | Br | HO<sub>2</sub>C(CH<sub>2</sub>)<sub>3</sub>N(Me)- | D122 | CF<sub>3</sub> | 3-HO<sub>2</sub>C-pyrr |
D79 | Br | HO<sub>2</sub>C(CH<sub>2</sub>)<sub>2</sub>N(Me)- | D123 | CF<sub>3</sub> | 3-HO<sub>2</sub>C-azet |
D80 | Br | HO<sub>2</sub>CCH<sub>2</sub>N(Me)- | D124 | CF<sub>3</sub> | 4-HO<sub>2</sub>CCH<sub>2</sub>-pipe |
No | X | R | No | X | R |
D81 | Br | HO<sub>2</sub>C(CH<sub>2</sub>)<sub>3</sub>O- | D125 | CF<sub>3</sub> | 4-HO<sub>2</sub>CCH<sub>2</sub>-pipa |
D82 | Br | HO<sub>2</sub>C(CH<sub>2</sub>)<sub>2</sub>O- | D126 | CF<sub>3</sub> | 3-HO<sub>2</sub>CCH<sub>2</sub>-pyrr |
D83 | Br | HO<sub>2</sub>CCH<sub>2</sub>O- | D127 | CF<sub>3</sub> | 3-HO<sub>2</sub>CCH<sub>2</sub>-azet |
D84 | CF<sub>3</sub> | 4-HO<sub>2</sub>C-pipe | D128 | CF<sub>3</sub> | HO<sub>2</sub>C(CH<sub>2</sub>)<sub>3</sub>NH- |
(表31,续)
No | X | R | No | X | R |
D129 | CF<sub>3</sub> | HO<sub>2</sub>C(CH<sub>2</sub>)<sub>2</sub>NH- | D137 | MeO | HO<sub>2</sub>C(CH<sub>2</sub>)<sub>3</sub>N(Me)- |
D130 | CF<sub>3</sub> | HO<sub>2</sub>CCH<sub>2</sub>NH- | D138 | MeO | HO<sub>2</sub>C(CH<sub>2</sub>)<sub>2</sub>N(Me)- |
D131 | CF<sub>3</sub> | HO<sub>2</sub>C(CH<sub>2</sub>)<sub>3</sub>N(Me)- | D139 | MeO | HO<sub>2</sub>CCH<sub>2</sub>N(Me)- |
D132 | CF<sub>3</sub> | HO<sub>2</sub>C(CH<sub>2</sub>)<sub>2</sub>N(Me)- | D140 | MeO | HO<sub>2</sub>C(CH<sub>2</sub>)<sub>3</sub>O- |
D133 | CF<sub>3</sub> | HO<sub>2</sub>CCH<sub>2</sub>N(Me)- | D141 | MeO | HO<sub>2</sub>C(CH<sub>2</sub>)<sub>2</sub>O- |
D134 | CF<sub>3</sub> | HO<sub>2</sub>C(CH<sub>2</sub>)<sub>3</sub>O- | D142 | MeO | HO<sub>2</sub>CCH<sub>2</sub>O- |
D135 | CF<sub>3</sub> | HO<sub>2</sub>C(CH<sub>2</sub>)<sub>2</sub>O- | D143 | Cl | 3-HO<sub>2</sub>C-azet |
D136 | CF<sub>3</sub> | HO<sub>2</sub>CCH<sub>2</sub>O- | D144 | F | 3-HO<sub>2</sub>C-azet |
(表32)
No | X | Y | R | No | X | Y | R |
E1 | F | H | HO(CH<sub>2</sub>)<sub>3</sub>NH- | E27 | F | F | HO(CH<sub>2</sub>)<sub>2</sub>NH- |
No | X | Y | R | No | X | Y | R |
E2 | F | H | HO(CH<sub>2</sub>)<sub>2</sub>NH- | E28 | F | F | HO(CH<sub>2</sub>)<sub>3</sub>N(Me)- |
E3 | F | H | HO(CH<sub>2</sub>)<sub>3</sub>N(Me)- | E29 | F | F | HO(CH<sub>2</sub>)<sub>2</sub>N(Me)- |
E4 | F | H | HO(CH<sub>2</sub>)<sub>2</sub>N(Me)- | E30 | F | F | HO(CH<sub>2</sub>)<sub>3</sub>O- |
E5 | F | H | HO(CH<sub>2</sub>)<sub>3</sub>O- | E31 | F | F | HO(CH<sub>2</sub>)<sub>2</sub>O- |
E6 | F | H | HO(CH<sub>2</sub>)<sub>2</sub>O- | E32 | F | F | HO<sub>2</sub>C(CH<sub>2</sub>)<sub>3</sub>NH- |
E7 | F | H | HO<sub>2</sub>C(CH<sub>2</sub>)<sub>3</sub>NH- | E33 | F | F | HO<sub>2</sub>C(CH<sub>2</sub>)<sub>2</sub>NH- |
E8 | F | H | HO<sub>2</sub>C(CH<sub>2</sub>)<sub>2</sub>NH- | E34 | F | F | HO<sub>2</sub>CCH<sub>2</sub>NH- |
E9 | F | H | HO<sub>2</sub>CCH<sub>2</sub>NH- | E35 | F | F | HO<sub>2</sub>C(CH<sub>2</sub>)<sub>3</sub>N(Me)- |
E10 | F | H | HO<sub>2</sub>C(CH<sub>2</sub>)<sub>3</sub>N(Me)- | E36 | F | F | HO<sub>2</sub>C(CH<sub>2</sub>)<sub>2</sub>N(Me)- |
E11 | F | H | HO<sub>2</sub>C(CH<sub>2</sub>)<sub>2</sub>N(Me)- | E37 | F | F | HO<sub>2</sub>CCH<sub>2</sub>N(Me)- |
E12 | F | H | HO<sub>2</sub>CCH<sub>2</sub>N(Me)- | E38 | F | F | HO<sub>2</sub>C(CH<sub>2</sub>)<sub>3</sub>O- |
E13 | F | H | HO<sub>2</sub>C(CH<sub>2</sub>)<sub>2</sub>O- | E39 | F | F | HO<sub>2</sub>C(CH<sub>2</sub>)<sub>2</sub>O- |
E14 | F | H | HO<sub>2</sub>CCH<sub>2</sub>O- | E40 | F | F | HO<sub>2</sub>CCH<sub>2</sub>O- |
E15 | Cl | H | HO(CH<sub>2</sub>)<sub>3</sub>NH- | E41 | Cl | F | HO(CH<sub>2</sub>)<sub>3</sub>NH- |
E16 | Cl | H | HO(CH<sub>2</sub>)<sub>2</sub>NH- | E42 | Cl | F | HO(CH<sub>2</sub>)<sub>2</sub>NH- |
E17 | Cl | H | HO(CH<sub>2</sub>)<sub>3</sub>N(Me)- | E43 | Cl | F | HO(CH<sup>2</sup>)<sub>3</sub>N(Me)- |
E18 | Cl | H | HO(CH<sub>2</sub>)<sub>2</sub>N(Me)- | E44 | Cl | F | HO(CH<sub>2</sub>)<sub>2</sub>N(Me)- |
E19 | Cl | H | HO(CH<sub>2</sub>)<sub>3</sub>O- | E45 | Cl | F | HO(CH<sub>2</sub>)<sub>3</sub>O- |
E20 | Cl | H | HO(CH<sub>2</sub>)<sub>2</sub>O- | E46 | Cl | F | HO(CH<sub>2</sub>)<sub>2</sub>O- |
E21 | Cl | H | HO<sub>2</sub>C(CH<sub>2</sub>)<sub>3</sub>NH- | E47 | Cl | F | HO<sub>2</sub>C(CH<sub>2</sub>)<sub>3</sub>NH- |
No | X | Y | R | No | X | Y | R |
E22 | Cl | H | HO<sub>2</sub>C(CH<sub>2</sub>)<sub>2</sub>NH- | E48 | Cl | F | HO<sub>2</sub>C(CH<sub>2</sub>)<sub>2</sub>NH- |
E23 | Cl | H | HO<sub>2</sub>CCH<sub>2</sub>NH- | E49 | Cl | F | HO<sub>2</sub>CCH<sub>2</sub>NH- |
E24 | Cl | H | HO<sub>2</sub>C(CH<sub>2</sub>)<sub>3</sub>N(Me)- | E50 | Cl | F | HO<sub>2</sub>C(CH<sub>2</sub>)<sub>3</sub>N(Me)- |
E25 | Cl | H | HO<sub>2</sub>C(CH<sub>2</sub>)<sub>2</sub>N(Me)- | E51 | Cl | F | HO<sub>2</sub>C(CH<sub>2</sub>)<sub>2</sub>N(Me)- |
E26 | Cl | H | HO<sub>2</sub>CCH<sub>2</sub>N(Me)- | E52 | Cl | F | HO<sub>2</sub>CCH<sub>2</sub>N(Me)- |
(表32,续)
No | X | Y | R | No | X | Y | R |
E53 | Cl | H | HO<sub>2</sub>C(CH<sub>2</sub>)<sub>3</sub>O- | E97 | Cl | F | HO<sub>2</sub>C(CH<sub>2</sub>)<sub>3</sub>O- |
E54 | Cl | H | HO<sub>2</sub>C(CH<sub>2</sub>)<sub>2</sub>O- | E98 | Cl | F | HO<sub>2</sub>C(CH<sub>2</sub>)<sub>2</sub>O- |
E55 | Cl | H | HO<sub>2</sub>CCH<sub>2</sub>O- | E99 | Cl | F | HO<sub>2</sub>CCH<sub>2</sub>O- |
E56 | F | F | HO(CH<sub>2</sub>)<sub>3</sub>NH- | E100 | Me | H | 4-HO<sub>2</sub>C-pipe |
E57 | H | H | 4-HO<sub>2</sub>C-pipe | E101 | Me | H | 3-HO<sub>2</sub>C-pipe |
E58 | H | H | 3-HO<sub>2</sub>C-pipe | E102 | Me | H | 3-HO<sub>2</sub>C-pyrr |
E59 | H | H | 3-HO<sub>2</sub>C-pyrr | E103 | Me | H | 3-HO<sub>2</sub>C-azet |
E60 | H | H | 3-HO<sub>2</sub>C-azet | E104 | Me | H | 4-HO<sub>2</sub>CCH<sub>2</sub>-pipe |
E61 | H | H | 4-HO<sub>2</sub>CCH<sub>2</sub>-pipe | E105 | Me | H | 4-HO<sub>2</sub>CCH<sub>2</sub>-pipa |
E62 | H | H | 4-HO<sub>2</sub>CCH<sub>2</sub>-pipa | E106 | Me | H | 3-HO<sub>2</sub>CCH<sub>2</sub>-pyrr |
E63 | H | H | 3-HO<sub>2</sub>CCH<sub>2</sub>-pyrr | E107 | Me | H | 3-HO<sub>2</sub>CCH<sub>2</sub>-azet |
E64 | H | H | 3-HO<sub>2</sub>CCH<sub>2</sub>-azet | E108 | Me | H | HO<sub>2</sub>C(CH<sub>2</sub>)<sub>3</sub>NH- |
E65 | H | H | HO<sub>2</sub>C(CH<sub>2</sub>)<sub>3</sub>NH- | E109 | Me | H | HO<sub>2</sub>C(CH<sub>2</sub>)<sub>2</sub>NH- |
No | X | Y | R | No | X | Y | R |
E66 | H | H | HO<sub>2</sub>C(CH<sub>2</sub>)<sub>2</sub>NH- | E110 | Me | H | HO<sub>2</sub>CCH<sub>2</sub>NH- |
E67 | H | H | HO<sub>2</sub>CCH<sub>2</sub>NH- | E111 | Me | H | HO<sub>2</sub>C(CH<sub>2</sub>)<sub>3</sub>N(Me)- |
E68 | H | H | HO<sub>2</sub>C(CH<sub>2</sub>)<sub>3</sub>N(Me)- | E112 | Me | H | HO<sub>2</sub>C(CH<sub>2</sub>)<sub>2</sub>N(Me)- |
E69 | H | H | HO<sub>2</sub>C(CH<sub>2</sub>)<sub>2</sub>N(Me)- | E113 | Me | H | HO<sub>2</sub>CCH<sub>2</sub>N(Me)- |
E70 | H | H | HO<sub>2</sub>CCH<sub>2</sub>N(Me)- | E114 | Me | H | HO<sub>2</sub>C(CH<sub>2</sub>)<sub>3</sub>O- |
E71 | H | H | HO<sub>2</sub>C(CH<sub>2</sub>)<sub>3</sub>O- | E115 | Me | H | HO<sub>2</sub>C(CH<sub>2</sub>)<sub>2</sub>O- |
E72 | H | H | HO<sub>2</sub>C(CH<sub>2</sub>)<sub>2</sub>O- | E116 | Me | H | HO<sub>2</sub>CCH<sub>2</sub>O- |
E73 | H | H | HO<sub>2</sub>CCH<sub>2</sub>O- | E117 | MeO | H | 4-HO<sub>2</sub>C-pipe |
E74 | Br | H | 4-HO<sub>2</sub>C-pipe | E118 | MeO | H | 3-HO<sub>2</sub>C-pipe |
E75 | Br | H | 3-HO<sub>2</sub>C-pipe | E119 | MeO | H | 3-HO<sub>2</sub>C-pyrr |
E76 | Br | H | 3-HO<sub>2</sub>C-pyrr | E120 | MeO | H | 3-HO<sub>2</sub>C-azet |
E77 | Br | H | 3-HO<sub>2</sub>C-azet | E121 | MeO | H | 4-HO<sub>2</sub>CCH<sub>2</sub>-pipe |
E78 | Br | H | 4-HO<sub>2</sub>CCH<sub>2</sub>-pipe | E122 | MeO | H | 4-HO<sub>2</sub>CCH<sub>2</sub>-pipa |
E79 | Br | H | 4-HO<sub>2</sub>CCH<sub>2</sub>-pipa | E123 | MeO | H | 3-HO<sub>2</sub>CCH<sub>2</sub>-pyrr |
E80 | Br | H | 3-HO<sub>2</sub>CCH<sub>2</sub>-pyrr | E124 | MeO | H | 3-HO<sub>2</sub>CCH<sub>2</sub>-azet |
E81 | Br | H | 3-HO<sub>2</sub>CCH<sub>2</sub>-azet | E125 | MeO | H | HO<sub>2</sub>C(CH<sub>2</sub>)<sub>3</sub>NH- |
E82 | Br | H | HO<sub>2</sub>C(CH<sub>2</sub>)<sub>3</sub>NH- | E126 | MeO | H | HO<sub>2</sub>C(CH<sub>2</sub>)<sub>2</sub>NH- |
E83 | Br | H | HO<sub>2</sub>C(CH<sub>2</sub>)<sub>2</sub>NH- | E127 | MeO | H | HO<sub>2</sub>CCH<sub>2</sub>NH- |
E84 | Br | H | HO<sub>2</sub>CCH<sub>2</sub>NH- | E128 | MeO | H | HO<sub>2</sub>C(CH<sub>2</sub>)<sub>3</sub>N(Me)- |
E85 | Br | H | HO<sub>2</sub>C(CH<sub>2</sub>)<sub>3</sub>N(Me)- | E129 | MeO | H | HO<sub>2</sub>C(CH<sub>2</sub>)<sub>2</sub>N(Me)- |
No | X | Y | R | No | X | Y | R |
E86 | Br | H | HO<sub>2</sub>C(CH<sub>2</sub>)<sub>2</sub>N(Me)- | E130 | MeO | H | HO<sub>2</sub>CCH<sub>2</sub>N(Me)- |
E87 | Br | H | HO<sub>2</sub>CCH<sub>2</sub>N(Me)- | E131 | MeO | H | HO<sub>2</sub>C(CH<sub>2</sub>)<sub>3</sub>O- |
E88 | Br | H | HO<sub>2</sub>C(CH<sub>2</sub>)<sub>3</sub>O- | E132 | MeO | H | HO<sub>2</sub>C(CH<sub>2</sub>)<sub>2</sub>O- |
E89 | Br | H | HO<sub>2</sub>C(CH<sub>2</sub>)<sub>2</sub>O- | E133 | MeO | H | HO<sub>2</sub>CCH<sub>2</sub>O- |
E90 | Br | H | HO<sub>2</sub>CCH<sub>2</sub>O- | E134 | Cl | H | 4-HO<sub>2</sub>C-pipe |
E91 | CF<sub>3</sub> | H | 4-HO<sub>2</sub>C-pipe | E135 | Cl | H | 3-HO<sub>2</sub>C-pipe |
E92 | CF<sub>3</sub> | H | 3-HO<sub>2</sub>C-pipe | E136 | Cl | H | 3-HO<sub>2</sub>C-pyrr |
E93 | CF<sub>3</sub> | H | 3-HO<sub>2</sub>C-pyrr | E137 | Cl | H | 3-HO<sub>2</sub>C-azet |
E94 | CF<sub>3</sub> | H | 3-HO<sub>2</sub>C-azet | E138 | Cl | H | 4-HO<sub>2</sub>CCH<sub>2</sub>-pipe |
E95 | CF<sub>3</sub> | H | 4-HO<sub>2</sub>CCH<sub>2</sub>-pipe | E139 | Cl | H | 4-HO<sub>2</sub>CCH<sub>2</sub>-pipa |
E96 | CF<sub>3</sub> | H | 4-HO<sub>2</sub>CCH<sub>2</sub>-pipa | E140 | Cl | H | 3-HO<sub>2</sub>CCH<sub>2</sub>-pyrr |
(表32,续)
No | X | Y | R | No | X | Y | R |
E141 | CF<sub>3</sub> | H | 3-HO<sub>2</sub>CCH<sub>2</sub>-pyrr | E151 | Cl | H | 3-HO<sub>2</sub>CCH<sub>2</sub>-azet |
E142 | CF<sub>3</sub> | H | 3-HO<sub>2</sub>CCH<sub>2</sub>-azet | E152 | F | H | 4-HO<sub>2</sub>C-pipe |
E143 | CF<sub>3</sub> | H | HO<sub>2</sub>C(CH<sub>2</sub>)<sub>3</sub>NH- | E153 | F | H | 3-HO<sub>2</sub>C-pipe |
E144 | CF<sub>3</sub> | H | HO<sub>2</sub>C(CH<sub>2</sub>)<sub>2</sub>NH- | E154 | F | H | 3-HO<sub>2</sub>C-pyrr |
E145 | CF<sub>3</sub> | H | HO<sub>2</sub>CCH<sub>2</sub>NH- | E155 | CF<sub>3</sub> | H | HO<sub>2</sub>C(CH<sub>2</sub>)<sub>3</sub>N(Me)- |
E146 | CF<sub>3</sub> | H | HO<sub>2</sub>C(CH<sub>2</sub>)<sub>2</sub>N(Me)- | E156 | F | H | 3-HO<sub>2</sub>C-azet |
E147 | CF<sub>3</sub> | H | HO<sub>2</sub>CCH<sub>2</sub>N(Me)- | E157 | F | H | 4-HO<sub>2</sub>CCH<sub>2</sub>-pipe |
No | X | Y | R | No | X | Y | R |
E148 | CF<sub>3</sub> | H | HO<sub>2</sub>C(CH<sub>2</sub>)<sub>3</sub>O- | E158 | F | H | 4-HO<sub>2</sub>CCH<sub>2</sub>-pipa |
E149 | CF<sub>3</sub> | H | HO<sub>2</sub>C(CH<sub>2</sub>)<sub>2</sub>O- | E159 | F | H | 3-HO<sub>2</sub>CCH<sub>2</sub>-pyrr |
E150 | CF<sub>3</sub> | H | HO<sub>2</sub>CCH<sub>2</sub>O- | E160 | F | H | 3-HO<sub>2</sub>CCH<sub>2</sub>-azet |
(表33)
No | R<sup>1</sup> | No | R<sup>1</sup> |
F1 | 1-Me-哌啶-2-基 | F8 | 1-Me-4-F-哌啶-2-基 |
F2 | 1-Me-吡咯烷-2-基 | F9 | 1,5-diMe-哌啶-2-基 |
F3 | 1-Me-氮杂环庚烷-2-基 | F10 | 1-Me-5-nPr-哌啶-2-基 |
F4 | 1-Et-哌啶-2-基 | F11 | 1-Me-5-nPrO-哌啶-2-基 |
F5 | 1,4-diMe-哌啶-2-基 | F12 | 1-Me-5-F-哌啶-2-基 |
F6 | 1-Me-4-nPr-哌啶-2-基 | F13 | 1,6-diMe-哌啶-2-基 |
F7 | 1-Me-4-nPrO-哌啶-2-基 | F14 | 1-Me-6-nPr-哌啶-2-基 |
(表34)
No | R<sup>1</sup> | R | No | R<sup>1</sup> | R |
G1 | 2-Me-pyrr | 4-HO<sub>2</sub>C-pipe | G9 | 3-Me-pyrr | 4-HO<sub>2</sub>C-pipe |
G2 | 2-Me-pyrr | 3-HO<sub>2</sub>C-pipe | G10 | 3-Me-pyrr | 3-HO<sub>2</sub>C-pipe |
G3 | 2-Me-pyrr | 3-HO<sub>2</sub>C-pyrr | G11 | 3-Me-pyrr | 3-HO<sub>2</sub>C-pyrr |
G4 | 2-Me-pyrr | 3-HO<sub>2</sub>C-azet | G12 | 3-Me-pyrr | 3-HO<sub>2</sub>C-azet |
G5 | 2-Me-pyrr | 4-HO<sub>2</sub>CCH<sub>2</sub>-pipe | G13 | 3-Me-pyrr | 4-HO<sub>2</sub>CCH<sub>2</sub>-pipe |
G6 | 2-Me-pyrr | 4-HO<sub>2</sub>CCH<sub>2</sub>-pipa | G14 | 3-Me-pyrr | 4-HO<sub>2</sub>CCH<sub>2</sub>-pipa |
G7 | 2-Me-pyrr | 3-HO<sub>2</sub>CCH<sub>2</sub>-pyrr | G15 | 3-Me-pyrr | 3-HO<sub>2</sub>CCH<sub>2</sub>-pyrr |
G8 | 2-Me-pyrr | 3-HO<sub>2</sub>CCH<sub>2</sub>-azet | G16 | 3-Me-pyrr | 3-HO<sub>2</sub>CCH<sub>2</sub>-azet |
(表34,续)
No | R<sup>1</sup> | R | No | R<sup>1</sup> | R |
G17 | 2-Me-pyrr | HO<sub>2</sub>C(CH<sub>2</sub>)<sub>3</sub>NH- | G60 | 3-Me-pyrr | HO<sub>2</sub>C(CH<sub>2</sub>)<sub>3</sub>NH- |
G18 | 2-Me-pyrr | HO<sub>2</sub>C(CH<sub>2</sub>)<sub>2</sub>NH- | G61 | 3-Me-pyrr | HO<sub>2</sub>C(CH<sub>2</sub>)<sub>2</sub>NH- |
G19 | 2-Me-pyrr | HO<sub>2</sub>CCH<sub>2</sub>NH- | G62 | 3-Me-pyrr | HO<sub>2</sub>CCH<sub>2</sub>NH- |
G20 | 2-Me-pyrr | HO<sub>2</sub>C(CH<sub>2</sub>)<sub>3</sub>N(Me)- | G63 | 3-Me-pyrr | HO<sub>2</sub>C(CH<sub>2</sub>)<sub>3</sub>N(Me)- |
G21 | 2-Me-pyrr | HO<sub>2</sub>C(CH<sub>2</sub>)<sub>2</sub>N(Me)- | G64 | 3-Me-pyrr | HO<sub>2</sub>C(CH<sub>2</sub>)<sub>2</sub>N(Me)- |
G22 | 2-Me-pyrr | HO<sub>2</sub>CCH<sub>2</sub>N(Me)- | G65 | 3-Me-pyrr | HO<sub>2</sub>CCH<sub>2</sub>N(Me)- |
G23 | 2-Me-pyrr | HO<sub>2</sub>C(CH<sub>2</sub>)<sub>3</sub>O- | G66 | 3-Me-pyrr | HO<sub>2</sub>C(CH<sub>2</sub>)<sub>3</sub>O- |
G24 | 2-Me-pyrr | HO<sub>2</sub>C(CH<sub>2</sub>)<sub>2</sub>O- | G67 | 3-Me-pyrr | HO<sub>2</sub>C(CH<sub>2</sub>)<sub>2</sub>O- |
G25 | 2-Me-pyrr | HO<sub>2</sub>CCH<sub>2</sub>O- | G68 | 3-Me-pyrr | HO<sub>2</sub>CCH<sub>2</sub>O- |
G26 | iBuN(Me)- | 4-HO<sub>2</sub>C-pipe | G69 | cBuN(Me)- | 4-HO<sub>2</sub>C-pipe |
No | R<sup>1</sup> | R | No | R<sup>1</sup> | R |
G27 | iBuN(Me)- | 3-HO<sub>2</sub>C-pipe | G70 | cBuN(Me)- | 3-HO<sub>2</sub>C-pipe |
G28 | iBuN(Me)- | 3-HO<sub>2</sub>C-pyrr | G71 | cBuN(Me)- | 3-HO<sub>2</sub>C-pyrr |
G29 | iBuN(Me)- | 3-HO<sub>2</sub>C-azet | G72 | cBuN(Me)- | 3-HO<sub>2</sub>C-azet |
G30 | iBuN(Me)- | 4-HO<sub>2</sub>CCH<sub>2</sub>-pipe | G73 | cBuN(Me)- | 4-HO<sub>2</sub>CCH<sub>2</sub>-pipe |
G31 | iBuN(Me)- | 4-HO<sub>2</sub>CCH<sub>2</sub>-pipa | G74 | cBuN(Me)- | 4-HO<sub>2</sub>CCH<sub>2</sub>-pipa |
G32 | iBuN(Me)- | 3-HO<sub>2</sub>CCH<sub>2</sub>-pyrr | G75 | cBuN(Me)- | 3-HO<sub>2</sub>CCH<sub>2</sub>-pyrr |
G33 | iBuN(Me)- | 3-HO<sub>2</sub>CCH<sub>2</sub>-azet | G76 | cBuN(Me)- | 3-HO<sub>2</sub>CCH<sub>2</sub>-azet |
G34 | iBuN(Me)- | HO<sub>2</sub>C(CH<sub>2</sub>)<sub>3</sub>NH- | G77 | cBuN(Me)- | HO<sub>2</sub>C(CH<sub>2</sub>)<sub>3</sub>NH- |
G35 | iBuN(Me)- | HO<sub>2</sub>C(CH<sub>2</sub>)<sub>2</sub>NH- | G78 | cBuN(Me)- | HO<sub>2</sub>C(CH<sub>2</sub>)<sub>2</sub>NH- |
G36 | iBuN(Me)- | HO<sub>2</sub>CCH<sub>2</sub>NH- | G79 | cBuN(Me)- | HO<sub>2</sub>C CH<sub>2</sub>NH- |
G37 | iBuN(Me)- | HO<sub>2</sub>C(CH<sub>2</sub>)<sub>3</sub>N(Me)- | G80 | cBuN(Me)- | HO<sub>2</sub>C(CH<sub>2</sub>)<sub>3</sub>N(Me)- |
G38 | iBuN(Me)- | HO<sub>2</sub>C(CH<sub>2</sub>)<sub>2</sub>N(Me)- | G81 | cBuN(Me)- | HO<sub>2</sub>C(CH<sub>2</sub>)<sub>2</sub>N(Me)- |
G39 | iBuN(Me)- | HO<sub>2</sub>CCH<sub>2</sub>N(Me)- | G82 | cBuN(Me)- | HO<sub>2</sub>CCH<sub>2</sub>N(Me)- |
G40 | iBuN(Me)- | HO<sub>2</sub>C(CH<sub>2</sub>)<sub>3</sub>O- | G83 | cB uN(Me)- | HO<sub>2</sub>C(CH<sub>2</sub>)<sub>3</sub>O- |
G41 | iBuN(Me)- | HO<sub>2</sub>C(CH<sub>2</sub>)<sub>2</sub>O- | G84 | cBuN(Me)- | HO<sub>2</sub>C(CH<sub>2</sub>)<sub>2</sub>O- |
G42 | iBuN(Me)- | HO<sub>2</sub>CCH<sub>2</sub>O- | G85 | cBuN(Me)- | HO<sub>2</sub>CCH<sub>2</sub>O- |
G43 | iPrN(Me)- | 4-HO<sub>2</sub>C-pipe | G86 | Me<sub>2</sub>N- | 4-HO<sub>2</sub>C-pipe |
G44 | iPrN(Me)- | 3-HO<sub>2</sub>C-pipe | G87 | Me<sub>2</sub>N- | 3-HO<sub>2</sub>C-pipe |
G45 | iPrN(Me)- | 3-HO<sub>2</sub>C-pyrr | G88 | Me<sub>2</sub>N- | 3-HO<sub>2</sub>C-pyrr |
G46 | iPrN(Me)- | 3-HO<sub>2</sub>C-azet | G89 | Me<sub>2</sub>N- | 3-HO<sub>2</sub>C-azet |
No | R<sup>1</sup> | R | No | R<sup>1</sup> | R |
G47 | iPrN(Me)- | 4-HO<sub>2</sub>CCH<sub>2</sub>-pipe | G90 | Me<sub>2</sub>N- | 4-HO<sub>2</sub>CCH<sub>2</sub>-pipe |
G48 | iPrN(Me)- | 4-HO<sub>2</sub>CCH<sub>2</sub>-pipa | G91 | Me<sub>2</sub>N- | 4-HO<sub>2</sub>CCH<sub>2</sub>-pipa |
G49 | iPrN(Me)- | 3-HO<sub>2</sub>CCH<sub>2</sub>-pyrr | G92 | Me<sub>2</sub>N- | 3-HO<sub>2</sub>CCH<sub>2</sub>-pyrr |
G50 | iPrN(Me)- | 3-HO<sub>2</sub>CCH<sub>2</sub>-azet | G93 | Me<sub>2</sub>N- | 3-HO<sub>2</sub>CCH<sub>2</sub>-azet |
G51 | iPrN(Me)- | HO<sub>2</sub>C(CH<sub>2</sub>)<sub>3</sub>NH- | G94 | Me<sub>2</sub>N- | HO<sub>2</sub>C(CH<sub>2</sub>)<sub>3</sub>NH- |
G52 | iprN(Me)- | HO<sub>2</sub>C(CH<sub>2</sub>)<sub>2</sub>NH- | G95 | Me<sub>2</sub>N- | HO<sub>2</sub>C(CH<sub>2</sub>)<sub>2</sub>NH- |
G53 | iPrN(Me)- | HO<sub>2</sub>CCH<sub>2</sub>NH- | G96 | Me<sub>2</sub>N- | HO<sub>2</sub>CCH<sub>2</sub>NH- |
G54 | iPrN(Me)- | HO<sub>2</sub>C(CH<sub>2</sub>)<sub>3</sub>N(Me)- | G97 | Me<sub>2</sub>N- | HO<sub>2</sub>C(CH<sub>2</sub>)<sub>3</sub>N(Me)- |
G55 | iPrN(Me)- | HO<sub>2</sub>C(CH<sub>2</sub>)<sub>2</sub>N(Me)- | G98 | Me<sub>2</sub>N- | HO<sub>2</sub>C(CH<sub>2</sub>)<sub>2</sub>N(Me)- |
G56 | iPrN(Me)- | HO<sub>2</sub>CCH<sub>2</sub>N(Me)- | G99 | Me<sub>2</sub>N- | HO<sub>2</sub>CCH<sub>2</sub>N(Me)- |
G57 | iPrN(Me)- | HO<sub>2</sub>C(CH<sub>2</sub>)<sub>3</sub>O- | G100 | Me<sub>2</sub>N- | HO<sub>2</sub>C(CH<sub>2</sub>)<sub>3</sub>O- |
G58 | iPrN(Me)- | HO<sub>2</sub>C(CH<sub>2</sub>)<sub>2</sub>O- | G101 | Me<sub>2</sub>N- | HO<sub>2</sub>C(CH<sub>2</sub>)<sub>2</sub>O- |
G59 | iPrN(Me)- | HO<sub>2</sub>CCH<sub>2</sub>O- | G102 | Me<sub>2</sub>N- | HO<sub>2</sub>CCH<sub>2</sub>O- |
(表35)
No | R<sup>1</sup> | R | No | R<sup>1</sup> | R |
H1 | 2-Me-pyrr | 4-HO<sub>2</sub>C-pipe | H40 | 3-Me-pyrr | 4-HO<sub>2</sub>C-pipe |
H2 | 2-Me-pyrr | 3-HO<sub>2</sub>C-pipe | H41 | 3-Me-pyrr | 3-HO<sub>2</sub>C-pipe |
No | R<sup>1</sup> | R | No | R<sup>1</sup> | R |
H3 | 2-Me-pyrr | 3-HO<sub>2</sub>C-pyrr | H42 | 3-Me-pyrr | 3-HO<sub>2</sub>C-pyrr |
H4 | 2-Me-pyrr | 3-HO<sub>2</sub>C-azet | H43 | 3-Me-pyrr | 3-HO<sub>2</sub>C-azet |
H5 | 2-Me-pyrr | 4-HO<sub>2</sub>CCH<sub>2</sub>-pipe | H44 | 3-Me-pyrr | 4-HO<sub>2</sub>CCH<sub>2</sub>-pipe |
H6 | 2-Me-pyrr | 4-HO<sub>2</sub>CCH<sub>2</sub>-pipa | H45 | 3-Me-pyrr | 4-HO<sub>2</sub>CCH<sub>2</sub>-pipa |
H7 | 2-Me-pyrr | 3-HO<sub>2</sub>CCH<sub>2</sub>-pyrr | H46 | 3-Me-pyrr | 3-HO<sub>2</sub>CCH<sub>2</sub>-pyrr |
H8 | 2-Me-pyrr | 3-HO<sub>2</sub>CCH<sub>2</sub>-azet | H47 | 3-Me-pyrr | 3-HO<sub>2</sub>CCH<sub>2</sub>-azet |
H9 | 2-Me-pyrr | HO<sub>2</sub>C(CH<sub>2</sub>)<sub>3</sub>NH- | H48 | 3-Me-pyrr | HO<sub>2</sub>C(CH<sub>2</sub>)<sub>3</sub>NH- |
H10 | 2-Me-pyrr | HO<sub>2</sub>C(CH<sub>2</sub>)<sub>2</sub>NH- | H49 | 3-Me-pyrr | HO<sub>2</sub>C(CH<sub>2</sub>)<sub>2</sub>NH- |
H11 | 2-Me-pyrr | HO<sub>2</sub>CCH<sub>2</sub>NH- | H50 | 3-Me-pyrr | HO<sub>2</sub>CCH<sub>2</sub>NH- |
H12 | 2-Me-pyrr | HO<sub>2</sub>C(CH<sub>2</sub>)<sub>3</sub>N(Me)- | H51 | 3-Me-pyrr | HO<sub>2</sub>C(CH<sub>2</sub>)<sub>3</sub>N(Me- |
H13 | 2-Me-pyrr | HO<sub>2</sub>C(CH<sub>2</sub>)<sub>2</sub>N(Me)- | H52 | 3-Me-pyrr | HO<sub>2</sub>C(CH<sub>2</sub>)<sub>2</sub>N(Me)- |
H14 | 2-Me-pyrr | HO<sub>2</sub>CCH<sub>2</sub>N(Me)- | H53 | 3-Me-pyrr | HO<sub>2</sub>CCH<sub>2</sub>N(Me)- |
H15 | 2-Me-pyrr | HO<sub>2</sub>C(CH<sub>2</sub>)<sub>3</sub>O- | H54 | 3-Me-pyrr | HO<sub>2</sub>C(CH<sub>2</sub>)<sub>3</sub>O- |
H16 | 2-Me-pyrr | HO<sub>2</sub>C(CH<sub>2</sub>)<sub>2</sub>O- | H55 | 3-Me-pyrr | HO<sub>2</sub>C(CH<sub>2</sub>)<sub>2</sub>O- |
H17 | 2-Me-pyrr | HO<sub>2</sub>CCH<sub>2</sub>O- | H56 | 3-Me-pyrr | HO<sub>2</sub>CCH<sub>2</sub>O- |
H18 | iBuN(Me)- | 4-HO<sub>2</sub>C-pipe | H57 | cBuN(Me)- | 4-HO<sub>2</sub>C-pipe |
H19 | iBuN(Me)- | 3-HO<sub>2</sub>C-pipe | H58 | cBuN(Me)- | 3-HO<sub>2</sub>C-pipe |
H20 | iBuN(Me)- | 3-HO<sub>2</sub>C-pyrr | H59 | cBuN(Me)- | 3-HO<sub>2</sub>C-pyrr |
H21 | iBuN(Me)- | 3-HO<sub>2</sub>C-azet | H60 | cBuN(Me)- | 3-HO<sub>2</sub>C-azet |
H22 | iBuN(Me)- | 4-HO<sub>2</sub>CCH<sub>2</sub>-pipe | H61 | cBuN(Me)- | 4-HO<sub>2</sub>CCH<sub>2</sub>-pipe |
No | R<sup>1</sup> | R | No | R<sup>1</sup> | R |
H23 | iBuN(Me)- | 4-HO<sub>2</sub>CCH<sub>2</sub>-pipa | H62 | cBuN(Me)- | 4-HO<sub>2</sub>CCH<sub>2</sub>-pipa |
H24 | iBuN(Me)- | 3-HO<sub>2</sub>CCH<sub>2</sub>-pyrr | H63 | cBuN(Me)- | 3-HO<sub>2</sub>CCH<sub>2</sub>-pyrr |
H25 | iBuN(Me)- | 3-HO<sub>2</sub>CCH<sub>2</sub>-azet | H64 | cBuN(Me)- | 3-HO<sub>2</sub>CCH<sub>2</sub>-azet |
H26 | iBuN(Me)- | HO<sub>2</sub>C(CH<sub>2</sub>)<sub>3</sub>NH- | H65 | cBuN(Me)- | HO<sub>2</sub>C(CH<sub>2</sub>)<sub>3</sub>NH- |
H27 | iBuN(Me)- | HO<sub>2</sub>C(CH<sub>2</sub>)<sub>2</sub>NH- | H66 | cBuN(Me)- | HO<sub>2</sub>C(CH<sub>2</sub>)<sub>2</sub>NH- |
H28 | iBuN(Me)- | HO<sub>2</sub>CCH<sub>2</sub>NH- | H67 | cBuN(Me)- | HO<sub>2</sub>CCH<sub>2</sub>NH- |
H29 | iBuN(Me)- | HO<sub>2</sub>C(CH<sub>2</sub>)<sub>3</sub>N(Me)- | H68 | cBuN(Me)- | HO<sub>2</sub>C(CH<sub>2</sub>)<sub>3</sub>N(Me)- |
H30 | iBuN(Me)- | HO<sub>2</sub>C(CH<sub>2</sub>)<sub>2</sub>N(Me)- | H69 | cBuN(Me)- | HO<sub>2</sub>C(CH<sub>2</sub>)<sub>2</sub>N(Me)- |
H31 | iBuN(Me)- | HO<sub>2</sub>CCH<sub>2</sub>N(Me)- | H70 | cBuN(Me)- | HO<sub>2</sub>CCH<sub>2</sub>N(Me)- |
H32 | iBuN(Me)- | HO<sub>2</sub>C(CH<sub>2</sub>)<sub>3</sub>O- | H71 | cBuN(Me)- | HO<sub>2</sub>C(CH<sub>2</sub>)<sub>3</sub>O- |
H33 | iBuN(Me)- | HO<sub>2</sub>C(CH<sub>2</sub>)<sub>2</sub>O- | H72 | cBuN(Me)- | HO<sub>2</sub>C(CH<sub>2</sub>)<sub>2</sub>O- |
H34 | iBuN(Me)- | HO<sub>2</sub>CCH<sub>2</sub>O- | H73 | cBuN(Me)- | HO<sub>2</sub>CCH<sub>2</sub>O- |
H35 | iPrN(Me)- | 4-HO<sub>2</sub>C-pipe | H74 | Me<sub>2</sub>N- | 4-HO<sub>2</sub>C-pipe |
H36 | iPrN(Me)- | 3-HO<sub>2</sub>C-pipe | H75 | Me<sub>2</sub>N- | 3-HO<sub>2</sub>C-pipe |
H37 | iPrN(Me)- | 3-HO<sub>2</sub>C-pyrr | H76 | Me<sub>2</sub>N- | 3-HO<sub>2</sub>C-pyrr |
H38 | iPrN(Me)- | 3-HO<sub>2</sub>C-azet | H77 | Me<sub>2</sub>N- | 3-HO<sub>2</sub>C-azet |
H39 | iPrN(Me)- | 4-HO<sub>2</sub>CCH<sub>2</sub>-pipe | H78 | Me<sub>2</sub>N- | 4-HO<sub>2</sub>CCH<sub>2</sub>-pipe |
(表35)
No | R<sup>1</sup> | R | No | R<sup>1</sup> | R |
H79 | iPrN(Me)- | 4-HO<sub>2</sub>CCH<sub>2</sub>-pipa | H91 | Me<sub>2</sub>N- | 4-HO<sub>2</sub>CCH<sub>2</sub>-pipa |
No | R<sup>1</sup> | R | No | R<sup>1</sup> | R |
H80 | iPrN(Me)- | 3-HO<sub>2</sub>CCH<sub>2</sub>-pyrr | H92 | Me<sub>2</sub>N- | 3-HO<sub>2</sub>CCH<sub>2</sub>-pyrr |
H81 | iPrN(Me)- | 3-HO<sub>2</sub>CCH<sub>2</sub>-azet | H93 | Me<sub>2</sub>N- | 3-HO<sub>2</sub>CCH<sub>2</sub>-azet |
H82 | iPrN(Me)- | HO<sub>2</sub>C(CH<sub>2</sub>)<sub>3</sub>NH- | H94 | Me<sub>2</sub>N- | HO<sub>2</sub>C(CH<sub>2</sub>)<sub>3</sub>NH- |
H83 | iPrN(Me)- | HO<sub>2</sub>C(CH<sub>2</sub>)<sub>2</sub>NH- | H95 | Me<sub>2</sub>N- | HO<sub>2</sub>C(CH<sub>2</sub>)<sub>2</sub>NH- |
H84 | iPrN(Me)- | HO<sub>2</sub>CCH<sub>2</sub>NH- | H96 | Me<sub>2</sub>N- | HO<sub>2</sub>CCH<sub>2</sub>NH- |
H85 | iPrN(Me)- | HO<sub>2</sub>C(CH<sub>2</sub>)<sub>3</sub>N(Me)- | H97 | Me<sub>2</sub>N- | HO<sub>2</sub>C(CH<sub>2</sub>)<sub>3</sub>N(Me)- |
H86 | iPrN(Me)- | HO<sub>2</sub>C(CH<sub>2</sub>)<sub>2</sub>N(Me)- | H98 | Me<sub>2</sub>N- | HO<sub>2</sub>C(CH<sub>2</sub>)<sub>2</sub>N(Me)- |
H87 | iPrN(Me)- | HO<sub>2</sub>CCH<sub>2</sub>N(Me)- | H99 | Me<sub>2</sub>N- | HO<sub>2</sub>CCH<sub>2</sub>N(Me)- |
H88 | iPrN(Me)- | HO<sub>2</sub>C(CH<sub>2</sub>)<sub>3</sub>O- | H100 | Me<sub>2</sub>N- | HO<sub>2</sub>C(CH<sub>2</sub>)<sub>3</sub>O- |
H89 | iPrN(Me)- | HO<sub>2</sub>C(CH<sub>2</sub>)<sub>2</sub>O- | H101 | Me<sub>2</sub>N- | HO<sub>2</sub>C(CH<sub>2</sub>)<sub>2</sub>O- |
H90 | iPrN(Me)- | HO<sub>2</sub>CCH<sub>2</sub>O- | H102 | Me<sub>2</sub>N- | HO<sub>2</sub>CCH<sub>2</sub>O- |
(表36)
No | R<sup>2</sup> | X | Y | R |
I1 | 4-Cl-2-The | N | Cl | 4-HO(CH<sub>2</sub>)<sub>2</sub>-pipe |
I2 | 4-Cl-2-The | N | Cl | 4-MeO-pipe |
I3 | 4-Cl-2-The | N | Cl | MeO(CH<sub>2</sub>)<sub>3</sub>O- |
I4 | 4-Cl-2-The | N | Cl | MeO(CH<sub>2</sub>)<sub>2</sub>O- |
No | R<sup>2</sup> | X | Y | R |
I5 | 4-Cl-2-The | N | Cl | H<sub>2</sub>O<sub>3</sub>P-(CH<sub>2</sub>)<sub>3</sub>NH- |
I6 | 4-Cl-2-The | N | Cl | 4-H<sub>2</sub>O<sub>3</sub>P-pipe |
I7 | 4-Cl-2-The | N | Cl | (EtO)<sub>2</sub>(O)P-(CH<sub>2</sub>)<sub>3</sub>NH- |
I8 | 4-Cl-2-The | N | Cl | 4-(EtO)<sub>2</sub>(O)P-pipe |
I9 | 4-Cl-2-The | N | Cl | 4-NC-pipe |
I10 | 4-C l-2-The | N | Cl | 3-氧代-pipa |
I11 | 4-Cl-2-The | C-H | Cl | 4-HO-pipe |
I12 | 4-Cl-2-The | C-H | Cl | 4-HOCH<sub>2</sub>-pipe |
I13 | 4-Cl-2-The | C-H | Cl | 4-HO(CH<sub>2</sub>)<sub>2</sub>-pipe |
I14 | 4-Cl-2-The | C-H | Cl | 4-MeO-pipe |
I15 | 4-Cl-2-The | C-H | Cl | MeO(CH<sub>2</sub>)<sub>3</sub>O- |
I16 | 4-Cl-2-The | C-H | Cl | MeO(CH<sub>2</sub>)<sub>2</sub>O- |
I17 | 4-Cl-2-The | C-H | Cl | H<sub>2</sub>O<sub>3</sub>P-(CH<sub>2</sub>)<sub>3</sub>NH- |
I18 | 4-Cl-2-The | C-H | Cl | 4-H<sub>2</sub>O<sub>3</sub>P-pipe |
I19 | 4-Cl-2-The | C-H | Cl | (EtO)<sub>2</sub>(O)P-(CH<sub>2</sub>)<sub>3</sub>NH- |
I20 | 4-Cl-2-The | C-H | Cl | 4-(EtO)<sub>2</sub>(O)P-pipe |
I21 | 4-Cl-2-The | C-H | Cl | 4-NC-pipe |
I22 | 4-Cl-2-The | C-H | Cl | 3-氧代-pipa |
I23 | 4-Cl-2-The | C-F | F | 4-HO-pipe |
(表36,续)
No | R<sup>2</sup> | X | Y | R |
I24 | 4-Cl-2-The | C-F | F | 4-HOCH<sub>2</sub>-pipe |
I25 | 4-C1-2-The | C-F | F | 4-HO(CH<sub>2</sub>)<sub>2</sub>-pipe |
I26 | 4-Cl-2-The | C-F | F | 4-MeO-pipe |
I27 | 4-Cl-2-The | C-F | F | MeO(CH<sub>2</sub>)<sub>3</sub>O- |
I28 | 4-Cl-2-The | C-F | F | MeO(CH<sub>2</sub>)<sub>2</sub>O- |
I29 | 4-Cl-2-The | C-F | F | H<sub>2</sub>O<sub>3</sub>P-(CH<sub>2</sub>)<sub>3</sub>NH- |
I30 | 4-C1-2-The | C-F | F | 4-H<sub>2</sub>O<sub>3</sub>P-pipe |
I31 | 4-Cl-2-The | C-F | F | (EtO)<sub>2</sub>(O)P-(CH<sub>2</sub>)<sub>3</sub>NH- |
I32 | 4-Cl-2-The | C-F | F | 4-(EtO)<sub>2</sub>(O)P-pipe |
I33 | 4-Cl-2-The | C-F | F | 4-NC-pipe |
I34 | 4-Cl-2-The | C-F | F | 3-氧代-pipa |
I35 | 4-Me-2-The | N | Cl | HO(CH<sub>2</sub>)<sub>3</sub>NH- |
I36 | 4-Me-2-The | N | Cl | HO(CH<sub>2</sub>)<sub>3</sub>N(Me)- |
I37 | 4-Me-2-The | N | Cl | HO(CH<sub>2</sub>)<sub>3</sub>O- |
I38 | 4-Me-2-The | N | Cl | HO(CH<sub>2</sub>)<sub>2</sub>O- |
I39 | 4-Me-2-The | N | Cl | 4-HO-pipe |
I40 | 4-Me-2-The | N | Cl | 4-HOCH<sub>2</sub>-pipe |
I41 | 4-Me-2-The | N | Cl | 4-HO(CH<sub>2</sub>)<sub>2</sub>-pipe |
I42 | 4-Me-2-The | N | Cl | 4-MeO-pipe |
I43 | 4-Me-2-The | N | Cl | MeO(CH<sub>2</sub>)<sub>3</sub>O- |
No | R<sup>2</sup> | X | Y | R |
I44 | 4-Me-2-The | N | Cl | MeO(CH<sub>2</sub>)<sub>2</sub>O- |
I45 | 4-Me-2-The | N | Cl | H<sub>2</sub>O<sub>3</sub>P-(CH<sub>2</sub>)<sub>3</sub>NH- |
I46 | 4-Me-2-The | N | Cl | 4-H<sub>2</sub>O<sub>3</sub>P-pipe |
I47 | 4-Me-2-The | N | Cl | (EtO)<sub>2</sub>(O)P-(CH<sub>2</sub>)<sub>3</sub>NH- |
I48 | 4-Me-2-The | N | Cl | 4-(EtO)<sub>2</sub>(O)P-pipe |
I49 | 4-Me-2-The | N | Cl | 4-NC-pipe |
I50 | 4-Me-2-The | N | Cl | 3-氧代-pipa |
I51 | 4-Me-2-The | C-H | Cl | HO(CH<sub>2</sub>)<sub>3</sub>NH- |
I52 | 4-Me-2-The | C-H | Cl | HO(CH<sub>2</sub>)<sub>3</sub>N(Me)- |
I53 | 4-Me-2-The | C-H | Cl | HO(CH<sub>2</sub>)<sub>3</sub>O- |
I54 | 4-Me-2-The | C-H | Cl | HO(CH<sub>2</sub>)<sub>2</sub>O- |
I55 | 4-Me-2-The | C-H | Cl | 4-HO-pipe |
I56 | 4-Me-2-The | C-H | Cl | 4-HOCH<sub>2</sub>-pipe |
I57 | 4-Me-2-The | C-H | Cl | 4-HO(CH<sub>2</sub>)<sub>2</sub>-pipe |
I58 | 4-Me-2-The | C-H | Cl | 4-MeO-pipe |
I59 | 4-Me-2-The | C-H | Cl | MeO(CH<sub>2</sub>)<sub>3</sub>O- |
I60 | 4-Me-2-The | C-H | Cl | MeO(CH<sub>2</sub>)<sub>2</sub>O- |
I61 | 4-Me-2-The | C-H | Cl | H<sub>2</sub>O<sub>3</sub>P-(CH<sub>2</sub>)<sub>3</sub>NH- |
I62 | 4-Me-2-The | C-H | Cl | 4-H<sub>2</sub>O<sub>3</sub>P-pipe |
I63 | 4-Me-2-The | C-H | Cl | (EtO)<sub>2</sub>(O)P-(CH<sub>2</sub>)<sub>3</sub>NH- |
No | R<sup>2</sup> | X | Y | R |
I64 | 4-Me-2-The | C-H | Cl | 4-(EtO)<sub>2</sub>(O)P-pipe |
I65 | 4-Me-2-The | C-H | Cl | 4-NC-pipe |
I66 | 4-Me-2-The | C-H | Cl | 3-氧代-pipa |
I67 | 4-Me-2-The | C-F | F | HO(CH<sub>2</sub>)<sub>3</sub>NH- |
(表36,续)
No | R<sup>2</sup> | X | Y | R |
I68 | 4-Me-2-The | C-F | F | HO(CH<sub>2</sub>)<sub>3</sub>N(Me)- |
I69 | 4-Me-2-The | C-F | F | HO(CH<sub>2</sub>)<sub>3</sub>O- |
I70 | 4-Me-2-The | C-F | F | HO(CH<sub>2</sub>)<sub>2</sub>O- |
I71 | 4-Me-2-The | C-F | F | 4-HO-pipe |
I72 | 4-Me-2-The | C-F | F | 4-HOCH<sub>2</sub>-pipe |
I73 | 4-Me-2-The | C-F | F | 4-HO(CH<sub>2</sub>)<sub>2</sub>-pipe |
I74 | 4-Me-2-The | C-F | F | 4-MeO-pipe |
I75 | 4-Me-2-The | C-F | F | MeO(CH<sub>2</sub>)<sub>3</sub>O- |
I76 | 4-Me-2-The | C-F | F | MeO(CH<sub>2</sub>)<sub>2</sub>O- |
I77 | 4-Me-2-The | C-F | F | H<sub>2</sub>O<sub>3</sub>P-(CH<sub>2</sub>)<sub>3</sub>NH- |
I78 | 4-Me-2-The | C-F | F | 4-H<sub>2</sub>O<sub>3</sub>P-pipe |
I79 | 4-Me-2-The | C-F | F | (EtO)<sub>2</sub>(O)P-(CH<sub>2</sub>)<sub>3</sub>NH- |
I80 | 4-Me-2-The | C-F | F | 4-(EtO)<sub>2</sub>(O)P-pipe |
I81 | 4-Me-2-The | C-F | F | 4-NC-pipe |
No | R<sup>2</sup> | X | Y | R |
I82 | 4-Me-2-The | C-F | F | 3-氧代-pipa |
I83 | 3-F<sub>3</sub>C-Ph | N | Cl | HO(CH<sub>2</sub>)<sub>3</sub>NH- |
I84 | 3-F<sub>3</sub>C-Ph | N | Cl | HO(CH<sub>2</sub>)<sub>3</sub>N(Me)- |
I85 | 3-F<sub>3</sub>C-Ph | N | Cl | HO(CH<sub>2</sub>)<sub>3</sub>O- |
I86 | 3-F<sub>3</sub>C-Ph | N | Cl | HO(CH<sub>2</sub>)<sub>2</sub>O- |
I87 | 3-F<sub>3</sub>C-Ph | N | Cl | 4-HO-pipe |
I88 | 3-F<sub>3</sub>C-Ph | N | Cl | 4-HOCH<sub>2</sub>-pipe |
I89 | 3-F<sub>3</sub>C-Ph | N | Cl | 4-HO(CH<sub>2</sub>)<sub>2</sub>-pipe |
I90 | 3-F<sub>3</sub>C-Ph | N | Cl | 4-MeO-pipe |
I91 | 3-F<sub>3</sub>C-Ph | N | Cl | MeO(CH<sub>2</sub>)<sub>3</sub>O- |
I92 | 3-F<sub>3</sub>C-Ph | N | Cl | MeO(CH<sub>2</sub>)<sub>2</sub>O- |
I93 | 3-F<sub>3</sub>C-Ph | N | Cl | H<sub>2</sub>O<sub>3</sub>P-(CH<sub>2</sub>)<sub>3</sub>NH- |
I94 | 3-F<sub>3</sub>C-Ph | N | Cl | 4-H<sub>2</sub>O<sub>3</sub>P-pipe |
I95 | 3-F<sub>3</sub>C-Ph | N | Cl | (EtO)<sub>2</sub>(O)P-(CH<sub>2</sub>)<sub>3</sub>NH- |
I96 | 3-F<sub>3</sub>C-Ph | N | Cl | 4-(EtO)<sub>2</sub>(O)P-pipe |
I97 | 3-F<sub>3</sub>C-Ph | N | Cl | 4-NC-pipe |
I98 | 3-F<sub>3</sub>C-Ph | N | Cl | 3-氧代-pipa |
I99 | 3-F<sub>3</sub>C-Ph | C-H | Cl | HO(CH<sub>2</sub>)<sub>3</sub>NH- |
I100 | 3-F<sub>3</sub>C-Ph | C-H | Cl | HO(CH<sub>2</sub>)<sub>3</sub>N(Me)- |
I101 | 3-F<sub>3</sub>C-Ph | C-H | Cl | HO(CH<sub>2</sub>)<sub>3</sub>O- |
No | R<sup>2</sup> | X | Y | R |
I102 | 3-F<sub>3</sub>C-Ph | C-H | Cl | HO(CH<sub>2</sub>)<sub>2</sub>O- |
I103 | 3-F<sub>3</sub>C-Ph | C-H | Cl | 4-HO-pipe |
I104 | 3-F<sub>3</sub>C-Ph | C-H | Cl | 4-HOCH<sub>2</sub>-pipe |
I105 | 3-F<sub>3</sub>C-Ph | C-H | Cl | 4-HO(CH<sub>2</sub>)<sub>2</sub>-pipe |
I106 | 3-F<sub>3</sub>C-Ph | C-H | Cl | 4-MeO-pipe |
I107 | 3-F<sub>3</sub>C-Ph | C-H | Cl | MeO(CH<sub>2</sub>)<sub>3</sub>O- |
I108 | 3-F<sub>3</sub>C-Ph | C-H | Cl | MeO(CH<sub>2</sub>)<sub>2</sub>O- |
I109 | 3-F<sub>3</sub>C-Ph | C-H | Cl | H<sub>2</sub>O<sub>3</sub>P-(CH<sub>2</sub>)<sub>3</sub>NH- |
I110 | 3-F<sub>3</sub>C-Ph | C-H | Cl | 4-H<sub>2</sub>O<sub>3</sub>P-pipe |
I111 | 3-F<sub>3</sub>C-Ph | C-H | Cl | (EtO)<sub>2</sub>(O)P-(CH<sub>2</sub>)<sub>3</sub>NH- |
(表36,续)
No | R<sup>2</sup> | X | Y | R |
I112 | 3-F<sub>3</sub>C-Ph | C-H | Cl | 4-(EtO)<sub>2</sub>(O)P-pipe |
I113 | 3-F<sub>3</sub>C-Ph | C-H | Cl | 4-NC-pipe |
I114 | 3-F<sub>3</sub>C-Ph | C-H | Cl | 3-氧代-pipa |
I115 | 3-F<sub>3</sub>C-Ph | C-F | F | HO(CH<sub>2</sub>)<sub>3</sub>NH- |
I116 | 3-F<sub>3</sub>C-Ph | C-F | F | HO(CH<sub>2</sub>)<sub>3</sub>N(Me)- |
I117 | 3-F<sub>3</sub>C-Ph | C-F | F | HO(CH<sub>2</sub>)<sub>3</sub>O- |
I118 | 3-F<sub>3</sub>C-Ph | C-F | F | HO(CH<sub>2</sub>)<sub>2</sub>O- |
I119 | 3-F<sub>3</sub>C-Ph | C-F | F | 4-HO-pipe |
No | R<sup>2</sup> | X | Y | R |
I120 | 3-F<sub>3</sub>C-Ph | C-F | F | 4-HOCH<sub>2</sub>-pipe |
I121 | 3-F<sub>3</sub>C-Ph | C-F | F | 4-HO(CH<sub>2</sub>)<sub>2</sub>-pipe |
I122 | 3-F<sub>3</sub>C-Ph | C-F | F | 4-MeO-pipe |
I123 | 3-F<sub>3</sub>C-Ph | C-F | F | MeO(CH<sub>2</sub>)<sub>3</sub>O- |
I124 | 3-F<sub>3</sub>C-Ph | C-F | F | MeO(CH<sub>2</sub>)<sub>2</sub>O- |
I125 | 3-F<sub>3</sub>C-Ph | C-F | F | H<sub>2</sub>O<sub>3</sub>P-(CH<sub>2</sub>)<sub>3</sub>NH- |
I126 | 3-F<sub>3</sub>C-Ph | C-F | F | 4-H<sub>2</sub>O<sub>3</sub>P-pipe |
I127 | 3-F<sub>3</sub>C-Ph | C-F | F | (EtO)<sub>2</sub>(O)P-(CH<sub>2</sub>)<sub>3</sub>NH- |
I128 | 3-F<sub>3</sub>C-Ph | C-F | F | 4-(EtO)<sub>2</sub>(O)P-pipe |
I129 | 3-F<sub>3</sub>C-Ph | C-F | F | 4-NC-pipe |
I130 | 3-F<sub>3</sub>C-Ph | C-F | F | 3-氧代-pipa |
(表37)
No | R<sup>1</sup> | X | Y | R |
J1 | cBuN(Me)- | N | Cl | HO(CH<sub>2</sub>)<sub>3</sub>NH- |
J2 | cBuN(Me)- | N | Cl | HO(CH<sub>2</sub>)<sub>3</sub>N(Me)- |
J3 | cBuN(Me)- | N | Cl | HO(CH<sub>2</sub>)<sub>3</sub>O- |
J4 | cBuN(Me)- | N | Cl | HO(CH<sub>2</sub>)<sub>2</sub>O- |
No | R<sup>1</sup> | X | Y | R |
J5 | cBuN(Me)- | N | Cl | 4-HO-pipe |
J6 | cBuN(Me)- | N | Cl | 4-HOCH<sub>2</sub>-pipe |
J7 | cBuN(Me)- | N | Cl | 4-HO(CH<sub>2</sub>)<sub>2</sub>-pipe |
J8 | cBuN(Me)- | N | Cl | 4-MeO-pipe |
J9 | cBuN(Me)- | N | Cl | MeO(CH<sub>2</sub>)<sub>3</sub>O- |
J10 | cBuN(Me)- | N | Cl | MeO(CH<sub>2</sub>)<sub>2</sub>O- |
J11 | cBuN(Me)- | N | Cl | H<sub>2</sub>O<sub>3</sub>P-(CH<sub>2</sub>)<sub>3</sub>NH- |
J12 | cBuN(Me)- | N | Cl | 4-H<sub>2</sub>O<sub>3</sub>P-pipe |
J13 | cBuN(Me)- | N | Cl | (EtO)<sub>2</sub>(O)P-(CH<sub>2</sub>)<sub>3</sub>NH- |
J14 | cBuN(Me)- | N | Cl | 4-(EtO)<sub>2</sub>(O)P-pipe |
J15 | cBuN(Me)- | N | Cl | 4-NC-pipe |
J16 | cBuN(Me)- | N | Cl | 3-氧代-pipa |
(表37,续)
No | R<sup>1</sup> | X | Y | R |
J17 | cBuN(Me)- | C-H | Cl | HO(CH<sub>2</sub>)<sub>3</sub>NH- |
J18 | cBuN(Me)- | C-H | Cl | HO(CH<sub>2</sub>)<sub>3</sub>N(Me)- |
J19 | cBuN(Me)- | C-H | Cl | HO(CH<sub>2</sub>)<sub>3</sub>O- |
J20 | cB uN(Me)- | C-H | Cl | HO(CH<sub>2</sub>)<sub>2</sub>O- |
J21 | cBuN(Me)- | C-H | Cl | 4-HO-pipe |
J22 | cBuN(Me)- | C-H | Cl | 4-HOCH<sub>2</sub>-pipe |
No | R<sup>1</sup> | X | Y | R |
J23 | cBuN(Me)- | C-H | Cl | 4-HO(CH<sub>2</sub>)<sub>2</sub>-pipe |
J24 | cBuN(Me)- | C-H | Cl | 4-MeO-pipe |
J25 | cBuN(Me)- | C-H | Cl | MeO(CH<sub>2</sub>)<sub>3</sub>O- |
J26 | cBuN(Me)- | C-H | Cl | MeO(CH<sub>2</sub>)<sub>2</sub>O- |
J27 | cBuN(Me)- | C-H | Cl | H<sub>2</sub>O<sub>3</sub>P-(CH<sub>2</sub>)<sub>3</sub>NH- |
J28 | cBuN(Me)- | C-H | Cl | 4-H<sub>2</sub>O<sub>3</sub>P-pipe |
J29 | cBuN(Me)- | C-H | Cl | (EtO)<sub>2</sub>(O)P-(CH<sub>2</sub>)<sub>3</sub>NH- |
J30 | cBuN(Me)- | C-H | Cl | 4-(EtO)<sub>2</sub>(O)P-pipe |
J31 | cBuN(Me)- | C-H | Cl | 4-NC-pipe |
J32 | cBuN(Me)- | C-H | Cl | 3-氧代-pipa |
J33 | iBuN(Me)- | N | Cl | HO(CH<sub>2</sub>)<sub>3</sub>NH- |
J34 | iBuN(Me)- | N | Cl | HO(CH<sub>2</sub>)<sub>3</sub>N(Me)- |
J35 | iBuN(Me)- | N | Cl | HO(CH<sub>2</sub>)<sub>3</sub>O- |
J36 | iBuN(Me)- | N | Cl | HO(CH<sub>2</sub>)<sub>2</sub>O- |
J37 | iBuN(Me)- | N | Cl | 4-HO-pipe |
J38 | iBuN(Me)- | N | Cl | 4-HOCH<sub>2</sub>-pipe |
J39 | iBuN(Me)- | N | Cl | 4-HO(CH<sub>2</sub>)<sub>2</sub>-pipe |
J40 | iBuN(Me)- | N | Cl | 4-MeO-pipe |
J41 | iBuN(Me)- | N | Cl | MeO(CH<sub>2</sub>)<sub>3</sub>O- |
J42 | iBuN(Me)- | N | Cl | MeO(CH<sub>2</sub>)<sub>2</sub>O- |
No | R<sup>1</sup> | X | Y | R |
J43 | iBuN(Me)- | N | Cl | H<sub>2</sub>O<sub>3</sub>P-(CH<sub>2</sub>)<sub>3</sub>NH- |
J44 | iBuN(Me)- | N | Cl | 4-H<sub>2</sub>O<sub>3</sub>P-pipe |
J45 | iBuN(Me)- | N | Cl | (EtO)<sub>2</sub>(O)P-(CH<sub>2</sub>)<sub>3</sub>NH- |
J46 | iBuN(Me)- | N | Cl | 4-(EtO)<sub>2</sub>(O)P-pipe |
J47 | iBuN(Me)- | N | Cl | 4-NC-pipe |
J48 | iBuN(Me)- | N | Cl | 3-氧代-pipa |
J49 | iBuN(Me)- | C-H | Cl | HO(CH<sub>2</sub>)<sub>3</sub>NH- |
J50 | iBuN(Me)- | C-H | Cl | HO(CH<sub>2</sub>)<sub>3</sub>N(Me)- |
J51 | iBuN(Me)- | C-H | Cl | HO(CH<sub>2</sub>)<sub>3</sub>O- |
J52 | iBuN(Me)- | C-H | Cl | HO(CH<sub>2</sub>)<sub>2</sub>O- |
J53 | iBuN(Me)- | C-H | Cl | 4-HO-pipe |
J54 | iBuN(Me)- | C-H | Cl | 4-HOCH<sub>2</sub>-pipe |
J55 | iBuN(Me)- | C-H | Cl | 4-HO(CH<sub>2</sub>)<sub>2</sub>-pipe |
J56 | iBuN(Me)- | C-H | Cl | 4-MeO-pipe |
J57 | iBuN(Me)- | C-H | Cl | MeO(CH<sub>2</sub>)<sub>3</sub>O- |
J58 | iBuN(Me)- | C-H | Cl | MeO(CH<sub>2</sub>)<sub>2</sub>O- |
J59 | iBuN(Me)- | C-H | Cl | H<sub>2</sub>O<sub>3</sub>P-(CH<sub>2</sub>)<sub>3</sub>NH- |
J60 | iBuN(Me)- | C-H | Cl | 4-H<sub>2</sub>O<sub>3</sub>P-pipe |
(表37,续)
No | R<sup>1</sup> | X | Y | R |
J61 | iBuN(Me)- | C-H | Cl | (EtO)<sub>2</sub>(O)P-(CH<sub>2</sub>)<sub>3</sub>NH- |
J62 | iBuN(Me)- | C-H | Cl | 4-(EtO)<sub>2</sub>(O)P-pipe |
J63 | iBuN(Me)- | C-H | Cl | 4-NC-pipe |
J64 | iBuN(Me)- | C-H | Cl | 3-氧代-pipa |
J65 | pipe | N | Cl | HO(CH<sub>2</sub>)<sub>3</sub>NH- |
J66 | pipe | N | Cl | HO(CH<sub>2</sub>)<sub>3</sub>N(Me)- |
J67 | pipe | N | Cl | HO(CH<sub>2</sub>)<sub>3</sub>O- |
J68 | pipe | N | Cl | HO(CH<sub>2</sub>)<sub>2</sub>O- |
J69 | pipe | N | Cl | 4-HO-pipe |
J70 | pipe | N | Cl | 4-HOCH<sub>2</sub>-pipe |
J71 | pipe | N | Cl | 4-HO(CH<sub>2</sub>)<sub>2</sub>-pipe |
J72 | pipe | N | Cl | 4-MeO-pipe |
J73 | pipe | N | Cl | MeO(CH<sub>2</sub>)<sub>3</sub>O- |
J74 | pipe | N | Cl | MeO(CH<sub>2</sub>)<sub>2</sub>O- |
J75 | pipe | N | Cl | H<sub>2</sub>O<sub>3</sub>P-(CH<sub>2</sub>)<sub>3</sub>NH- |
J76 | pipe | N | Cl | 4-H<sub>2</sub>O<sub>3</sub>P-pipe |
J77 | pipe | N | Cl | (EtO)<sub>2</sub>(O)P-(CH<sub>2</sub>)<sub>3</sub>NH- |
J78 | pipe | N | Cl | 4-(EtO)<sub>2</sub>(O)P-pipe |
J79 | pipe | N | Cl | 4-NC-pipe |
J80 | pipe | N | Cl | 3-氧代-pipa |
No | R<sup>1</sup> | X | Y | R |
J81 | pipe | C-H | Cl | HO(CH<sub>2</sub>)<sub>3</sub>NH- |
J82 | pipe | C-H | Cl | HO(CH<sub>2</sub>)<sub>3</sub>N(Me)- |
J83 | pipe | C-H | Cl | HO(CH<sub>2</sub>)<sub>3</sub>O- |
J84 | pipe | C-H | Cl | HO(CH<sub>2</sub>)<sub>2</sub>O- |
J85 | pipe | C-H | Cl | 4-HO-pipe |
J86 | pipe | C-H | Cl | 4-HOCH<sub>2</sub>-pipe |
J87 | pipe | C-H | Cl | 4-HO(CH<sub>2</sub>)<sub>2</sub>-pipe |
J88 | pipe | C-H | Cl | 4-MeO-pipe |
J89 | pipe | C-H | Cl | MeO(CH<sub>2</sub>)<sub>3</sub>O- |
J90 | pipe | C-H | Cl | MeO(CH<sub>2</sub>)<sub>2</sub>O- |
J91 | pipe | C-H | Cl | H<sub>2</sub>O<sub>3</sub>P-(CH<sub>2</sub>)<sub>3</sub>NH- |
J92 | pipe | C-H | Cl | 4-H<sub>2</sub>O<sub>3</sub>P-pipe |
J93 | pipe | C-H | Cl | (EtO)<sub>2</sub>(O)P-(CH<sub>2</sub>)<sub>3</sub>NH- |
J94 | pipe | C-H | Cl | 4-(EtO)<sub>2</sub>(O)P-pipe |
J95 | pipe | C-H | Cl | 4-NC-pipe |
J96 | pipe | C-H | Cl | 3-氧代-pipa |
J97 | 2-Me-pyrr | N | Cl | HO(CH<sub>2</sub>)<sub>3</sub>NH- |
J98 | 2-Me-pyrr | N | Cl | HO(CH<sub>2</sub>)<sub>3</sub>N(Me)- |
J99 | 2-Me-pyrr | N | Cl | HO(CH<sub>2</sub>)<sub>3</sub>O- |
J100 | 2-Me-pyrr | N | Cl | HO(CH<sub>2</sub>)<sub>2</sub>O- |
No | R<sup>1</sup> | X | Y | R |
J101 | 2-Me-pyrr | N | Cl | 4-HO-pipe |
J102 | 2-Me-pyrr | N | Cl | 4-HOCH<sub>2</sub>-pipe |
J103 | 2-Me-pyrr | N | Cl | 4-HO(CH<sub>2</sub>)<sub>2</sub>-pipe |
J104 | 2-Me-pyrr | N | Cl | 4-MeO-pipe |
(表37,续)
No | R<sup>1</sup> | X | Y | R |
J105 | 2-Me-pyrr | N | Cl | MeO(CH<sub>2</sub>)<sub>3</sub>O- |
J106 | 2-Me-pyrr | N | Cl | MeO(CH<sub>2</sub>)<sub>2</sub>O- |
J107 | 2-Me-pyrr | N | Cl | H<sub>2</sub>O<sub>3</sub>P-(CH<sub>2</sub>)<sub>3</sub>NH- |
J108 | 2-Me-pyrr | N | Cl | 4-H<sub>2</sub>O<sub>3</sub>P-pipe |
J109 | 2-Me-pyrr | N | Cl | (EtO)<sub>2</sub>(O)P-(CH<sub>2</sub>)<sub>3</sub>NH- |
J110 | 2-Me-pyrr | N | Cl | 4-(EtO)<sub>2</sub>(O)P-pipe |
J111 | 2-Me-pyrr | N | Cl | 4-NC-pipe |
J112 | 2-Me-pyrr | N | Cl | 3-氧代-pipa |
J113 | 2-Me-pyrr | C-H | Cl | HO(CH<sub>2</sub>)<sub>3</sub>NH- |
J114 | 2-Me-pyrr | C-H | Cl | HO(CH<sub>2</sub>)<sub>3</sub>N(Me)- |
J115 | 2-Me-pyrr | C-H | Cl | HO(CH<sub>2</sub>)<sub>3</sub>O- |
J116 | 2-Me-pyrr | C-H | Cl | HO(CH<sub>2</sub>)<sub>2</sub>O- |
J117 | 2-Me-pyrr | C-H | Cl | 4-HO-pipe |
J118 | 2-Me-pyrr | C-H | Cl | 4-HOCH<sub>2</sub>-pipe |
No | R<sup>1</sup> | X | Y | R |
J119 | 2-Me-pyrr | C-H | Cl | 4-HO(CH<sub>2</sub>)<sub>2</sub>-pipe |
J120 | 2-Me-pyrr | C-H | Cl | 4-MeO-pipe |
J121 | 2-Me-pyrr | C-H | Cl | MeO(CH<sub>2</sub>)<sub>3</sub>O- |
J122 | 2-Me-pyrr | C-H | Cl | MeO(CH<sub>2</sub>)<sub>2</sub>O- |
J123 | 2-Me-pyrr | C-H | Cl | H<sub>2</sub>O<sub>3</sub>P-(CH<sub>2</sub>)<sub>3</sub>NH- |
J124 | 2-Me-pyrr | C-H | Cl | 4-H<sub>2</sub>O<sub>3</sub>P-pipe |
J125 | 2-Me-pyrr | C-H | Cl | (EtO)<sub>2</sub>(O)P-(CH<sub>2</sub>)<sub>3</sub>NH- |
J126 | 2-Me-pyrr | C-H | Cl | 4-(EtO)<sub>2</sub>(O)P-pipe |
J127 | 2-Me-pyrr | C-H | Cl | 4-NC-pipe |
J128 | 2-Me-pyrr | C-H | Cl | 3-氧代-pipa |
J129 | 3-Me-pyrr | N | Cl | HO(CH<sub>2</sub>)<sub>3</sub>NH- |
J130 | 3-Me-pyrr | N | Cl | HO(CH<sub>2</sub>)<sub>3</sub>N(Me)- |
J131 | 3-Me-pyrr | N | Cl | HO(CH<sub>2</sub>)<sub>3</sub>O- |
J132 | 3-Me-pyrr | N | Cl | HO(CH<sub>2</sub>)<sub>2</sub>O- |
J133 | 3-Me-pyrr | N | Cl | 4-HO-pipe |
J134 | 3-Me-pyrr | N | Cl | 4-HOCH<sub>2</sub>-pipe |
J135 | 3-Me-pyrr | N | Cl | 4-HO(CH<sub>2</sub>)<sub>2</sub>-pipe |
J136 | 3-Me-pyrr | N | Cl | 4-MeO-pipe |
J137 | 3-Me-pyrr | N | Cl | MeO(CH<sub>2</sub>)<sub>3</sub>O- |
J138 | 3-Me-pyrr | N | Cl | MeO(CH<sub>2</sub>)<sub>2</sub>O- |
No | R<sup>1</sup> | X | Y | R |
J139 | 3-Me-pyrr | N | Cl | H<sub>2</sub>O<sub>3</sub>P-(CH<sub>2</sub>)<sub>3</sub>NH- |
J140 | 3-Me-pyrr | N | Cl | 4-H<sub>2</sub>O<sub>3</sub>P-pipe |
J141 | 3-Me-pyrr | N | Cl | (EtO)<sub>2</sub>(O)P-(CH<sub>2</sub>)<sub>3</sub>NH- |
J142 | 3-Me-pyrr | N | Cl | 4-(EtO)<sub>2</sub>(O)P-pipe |
J143 | 3-Me-pyrr | N | Cl | 4-NC-pipe |
J144 | 3-Me-pyrr | N | Cl | 3-氧代-pipa |
J145 | 3-Me-pyrr | C-H | Cl | HO(CH<sub>2</sub>)<sub>3</sub>NH- |
J146 | 3-Me-pyrr | C-H | Cl | HO(CH<sub>2</sub>)<sub>3</sub>N(Me)- |
J147 | 3-Me-pyrr | C-H | Cl | HO(CH<sub>2</sub>)<sub>3</sub>O- |
J148 | 3-Me-pyrr | C-H | Cl | HO(CH<sub>2</sub>)<sub>2</sub>O- |
(表37,续)
No | R<sup>1</sup> | X | Y | R |
J149 | 3-Me-pyrr | C-H | Cl | 4-HO-pipe |
J150 | 3-Me-pyrr | C-H | Cl | 4-HOCH<sub>2</sub>-pipe |
J151 | 3-Me-pyrr | C-H | Cl | 4-HO(CH<sub>2</sub>)<sub>2</sub>-pipe |
J152 | 3-Me-pyrr | C-H | Cl | 4-MeO-pipe |
J153 | 3-Me-pyrr | C-H | Cl | MeO(CH<sub>2</sub>)<sub>3</sub>O- |
J154 | 3-Me-pyrr | C-H | Cl | MeO(CH<sub>2</sub>)<sub>2</sub>O- |
J155 | 3-Me-pyrr | C-H | Cl | H<sub>2</sub>O<sub>3</sub>P-(CH<sub>2</sub>)<sub>3</sub>NH- |
J156 | 3-Me-pyrr | C-H | Cl | 4-H<sub>2</sub>O<sub>3</sub>P-pipe |
No | R<sup>1</sup> | X | Y | R |
J157 | 3-Me-pyrr | C-H | Cl | (EtO)<sub>2</sub>(O)P-(CH<sub>2</sub>)<sub>3</sub>NH- |
J158 | 3-Me-pyrr | C-H | Cl | 4-(EtO)<sub>2</sub>(O)P-pipe |
J159 | 3-Me-pyrr | C-H | Cl | 4-NC-pipe |
J160 | 3-Me-pyrr | C-H | Cl | 3-氧代-pipa |
J161 | iPrN(Me)- | N | Cl | HO(CH<sub>2</sub>)<sub>3</sub>NH- |
J162 | iPrN(Me)- | N | Cl | HO(CH<sub>2</sub>)<sub>3</sub>N(Me)- |
J163 | iPrN(Me)- | N | Cl | HO(CH<sub>2</sub>)<sub>3</sub>O- |
J164 | iPrN(Me)- | N | Cl | HO(CH<sub>2</sub>)<sub>2</sub>O- |
J165 | iPrN(Me)- | N | Cl | 4-HO-pipe |
J166 | iPrN(Me)- | N | Cl | 4-HOCH<sub>2</sub>-pipe |
J167 | iPrN(Me)- | N | Cl | 4-HO(CH<sub>2</sub>)<sub>2</sub>-pipe |
J168 | iPrN(Me)- | N | Cl | 4-MeO-pipe |
J169 | iPrN(Me)- | N | Cl | MeO(CH<sub>2</sub>)<sub>3</sub>O- |
J170 | iPrN(Me)- | N | Cl | MeO(CH<sub>2</sub>)<sub>2</sub>O- |
J171 | iPrN(Me)- | N | Cl | H<sub>2</sub>O<sub>3</sub>P-(CH<sub>2</sub>)<sub>3</sub>NH- |
J172 | iPrN(Me)- | N | Cl | 4-H<sub>2</sub>O<sub>3</sub>P-pipe |
J173 | iPrN(Me)- | N | Cl | (EtO)<sub>2</sub>(O)P-(CH<sub>2</sub>)<sub>3</sub>NH- |
J174 | iPrN(Me)- | N | Cl | 4-(EtO)<sub>2</sub>(O)P-pipe |
J175 | iPrN(Me)- | N | Cl | 4-NC-pipe |
J176 | iPrN(Me)- | N | Cl | 3-氧代-pipa |
No | R<sup>1</sup> | X | Y | R |
J177 | iPrN(Me)- | C-H | Cl | HO(CH<sub>2</sub>)<sub>3</sub>NH- |
J178 | iPrN(Me)- | C-H | Cl | HO(CH<sub>2</sub>)<sub>3</sub>N(Me)- |
J179 | iPrN(Me)- | C-H | Cl | HO(CH<sub>2</sub>)<sub>3</sub>O- |
J180 | iPrN(Me)- | C-H | Cl | HO(CH<sub>2</sub>)<sub>2</sub>O- |
J181 | iPrN(Me)- | C-H | Cl | 4-HO-pipe |
J182 | iPrN(Me)- | C-H | Cl | 4-HOCH<sub>2</sub>-pipe |
J183 | iPrN(Me)- | C-H | Cl | 4-HO(CH<sub>2</sub>)<sub>2</sub>-pipe |
J184 | iPrN(Me)- | C-H | Cl | 4-MeO-pipe |
J185 | iPrN(Me)- | C-H | Cl | MeO(CH<sub>2</sub>)<sub>3</sub>O- |
J186 | iPrN(Me)- | C-H | Cl | MeO(CH<sub>2</sub>)<sub>2</sub>O- |
J187 | iPrN(Me)- | C-H | Cl | H<sub>2</sub>O<sub>3</sub>P-(CH<sub>2</sub>)<sub>3</sub>NH- |
J188 | iPrN(Me)- | C-H | Cl | 4-H<sub>2</sub>O<sub>3</sub>P-pipe |
J189 | iPrN(Me)- | C-H | Cl | (EtO)<sub>2</sub>(O)P-(CH<sub>2</sub>)<sub>3</sub>NH- |
J190 | iPrN(Me)- | C-H | Cl | 4-(EtO)<sub>2</sub>(O)P-pipe |
J191 | iPrN(Me)- | C-H | Cl | 4-NC-pipe |
J192 | iPrN(Me)- | C-H | Cl | 3-氧代-pipa |
(表37,续)
No | R<sup>1</sup> | X | Y | R |
J193 | Me<sub>2</sub>N- | N | Cl | HO(CH<sub>2</sub>)<sub>3</sub>NH- |
J194 | Me<sub>2</sub>N- | N | Cl | HO(CH<sub>2</sub>)<sub>3</sub>N(Me)- |
No | R<sup>1</sup> | X | Y | R |
J195 | Me<sub>2</sub>N- | N | Cl | HO(CH<sub>2</sub>)<sub>3</sub>O- |
J196 | Me<sub>2</sub>N- | N | Cl | HO(CH<sub>2</sub>)<sub>2</sub>O- |
J197 | Me<sub>2</sub>N- | N | Cl | 4-HO-pipe |
J198 | Me<sub>2</sub>N- | N | Cl | 4-HOCH<sub>2</sub>-pipe |
J199 | Me<sub>2</sub>N- | N | Cl | 4-HO(CH<sub>2</sub>)<sub>2</sub>-pipe |
J200 | Me<sub>2</sub>N- | N | Cl | 4-MeO-pipe |
J201 | Me<sub>2</sub>N- | N | Cl | MeO(CH<sub>2</sub>)<sub>3</sub>O- |
J202 | Me<sub>2</sub>N- | N | Cl | MeO(CH<sub>2</sub>)<sub>2</sub>O- |
J203 | Me<sub>2</sub>N- | N | Cl | H<sub>2</sub>O<sub>3</sub>P-(CH<sub>2</sub>)<sub>3</sub>NH- |
J204 | Me<sub>2</sub>N- | N | Cl | 4-H<sub>2</sub>O<sub>3</sub>P-pipe |
J205 | Me<sub>2</sub>N- | N | Cl | (EtO)<sub>2</sub>(O)P-(CH<sub>2</sub>)<sub>3</sub>NH- |
J206 | Me<sub>2</sub>N- | N | Cl | 4-(EtO)<sub>2</sub>(O)P-pipe |
J207 | Me<sub>2</sub>N- | N | Cl | 4-NC-pipe |
J208 | Me<sub>2</sub>N- | N | Cl | 3-氧代-pipa |
J209 | Me<sub>2</sub>N- | C-H | Cl | HO(CH<sub>2</sub>)<sub>3</sub>NH- |
J210 | Me<sub>2</sub>N- | C-H | Cl | HO(CH<sub>2</sub>)<sub>3</sub>N(Me)- |
J211 | Me<sub>2</sub>N- | C-H | Cl | HO(CH<sub>2</sub>)<sub>3</sub>O- |
J212 | Me<sub>2</sub>N- | C-H | Cl | HO(CH<sub>2</sub>)<sub>2</sub>O- |
J213 | Me<sub>2</sub>N- | C-H | Cl | 4-HO-pipe |
J214 | Me<sub>2</sub>N- | C-H | Cl | 4-HOCH<sub>2</sub>-pipe |
No | R<sup>1</sup> | X | Y | R |
J215 | Me<sub>2</sub>N- | C-H | Cl | 4-HO(CH<sub>2</sub>)<sub>2</sub>-pipe |
J216 | Me<sub>2</sub>N- | C-H | Cl | 4-MeO-pipe |
J217 | Me<sub>2</sub>N- | C-H | Cl | MeO(CH<sub>2</sub>)<sub>3</sub>O- |
J218 | Me<sub>2</sub>N- | C-H | Cl | MeO(CH<sub>2</sub>)<sub>2</sub>O- |
J219 | Me<sub>2</sub>N- | C-H | Cl | H<sub>2</sub>O<sub>3</sub>P-(CH<sub>2</sub>)<sub>3</sub>NH- |
J220 | Me<sub>2</sub>N- | C-H | Cl | 4-H<sub>2</sub>O<sub>3</sub>P-pipe |
J221 | Me<sub>2</sub>N- | C-H | Cl | (EtO)<sub>2</sub>(O)P-(CH<sub>2</sub>)<sub>3</sub>NH- |
J222 | Me<sub>2</sub>N- | C-H | Cl | 4-(EtO)<sub>2</sub>(O)P-pipe |
J223 | Me<sub>2</sub>N- | C-H | Cl | 4-NC-pipe |
J224 | Me<sub>2</sub>N- | C-H | Cl | 3-氧代-pipa |
(表38)
No | R<sup>1</sup> | X | Y | R |
K1 | nBuN(Me)- | C-H | Cl | 4-H<sub>2</sub>NOC-pipe |
K2 | nBuN(Me)- | C-F | F | 4-H<sub>2</sub>NOC-pipe |
K3 | cBuN(Me)- | C-H | Cl | 4-HO-pipe |
K4 | cBuN(Me)- | C-H | Cl | 4-MeO-pipe |
K5 | cBuN(Me)- | C-H | Cl | 4-H<sub>2</sub>O<sub>3</sub>P-pipe |
No | R<sup>1</sup> | X | Y | R |
K6 | cBuN(Me)- | C-H | Cl | 4-(EtO)<sub>2</sub>(O)P-pipe |
K7 | cBuN(Me)- | C-H | Cl | 4-NC-pipe |
K8 | cBuN(Me)- | C-H | Cl | 4-H<sub>2</sub>NOC-pipe |
K9 | cBuN(Me)- | C-F | F | 4-HO-pipe |
K10 | cBuN(Me)- | C-F | F | 4-MeO-pipe |
K11 | cBuN(Me)- | C-F | F | 4-H<sub>2</sub>O<sub>3</sub>P-pipe |
K12 | cBuN(Me)- | C-F | F | 4-(EtO)<sub>2</sub>(O)P-pipe |
K13 | cBuN(Me)- | C-F | F | 4-NC-pipe |
K14 | cBuN(Me)- | C-F | F | 4-H<sub>2</sub>NOC-pipe |
K15 | iBuN(Me)- | C-H | Cl | 4-HO-pipe |
K16 | iBuN(Me)- | C-H | Cl | 4-MeO-pipe |
K17 | iBuN(Me)- | C-H | Cl | 4-H<sub>2</sub>O<sub>3</sub>P-pipe |
K18 | iBuN(Me)- | C-H | Cl | 4-(EtO)<sub>2</sub>(O)P-pipe |
K19 | iBuN(Me)- | C-H | Cl | 4-NC-pipe |
K20 | iBuN(Me)- | C-H | Cl | 4-H<sub>2</sub>NOC-pipe |
K21 | iBuN(Me)- | C-F | F | 4-HO-pipe |
K22 | iBuN(Me)- | C-F | F | 4-MeO-pipe |
K23 | iBuN(Me)- | C-F | F | 4-H<sub>2</sub>O<sub>3</sub>P-pipe |
K24 | iBuN(Me)- | C-F | F | 4-(EtO)<sub>2</sub>(O)P-pipe |
K25 | iBuN(Me)- | C-F | F | 4-NC-pipe |
No | R<sup>1</sup> | X | Y | R |
K26 | iBuN(Me)- | C-F | F | 4-H<sub>2</sub>NOC-pipe |
K27 | pipe | C-H | Cl | 4-HO-pipe |
K28 | pipe | C-H | Cl | 4-MeO-pipe |
K29 | pipe | C-H | Cl | 4-H<sub>2</sub>O<sub>3</sub>P-pipe |
K30 | pipe | C-H | Cl | 4-(EtO)<sub>2</sub>(O)P-pipe |
K31 | pipe | C-H | Cl | 4-NC-pipe |
K32 | pipe | C-H | Cl | 4-H<sub>2</sub>NOC-pipe |
K33 | pipe | C-F | F | 4-HO-pipe |
K34 | pipe | C-F | F | 4-MeO-pipe |
K35 | pipe | C-F | F | 4-H<sub>2</sub>O<sub>3</sub>P-pipe |
K36 | pipe | C-F | F | 4-(EtO)<sub>2</sub>(O)P-pipe |
K37 | pipe | C-F | F | 4-NC-pipe |
(表38,续)
No | R<sup>1</sup> | X | Y | R |
K38 | pipe | C-F | F | 4-H<sub>2</sub>NOC-pipe |
K39 | 2-Me-pyrr | C-H | Cl | 4-HO-pipe |
K40 | 2-Me-pyrr | C-H | Cl | 4-MeO-pipe |
K41 | 2-Me-pyrr | C-H | Cl | 4-H<sub>2</sub>O<sub>3</sub>P-pipe |
K42 | 2-Me-pyrr | C-H | Cl | 4-(EtO)<sub>2</sub>(O)P-pipe |
K43 | 2-Me-pyrr | C-H | Cl | 4-NC-pipe |
No | R<sup>1</sup> | X | Y | R |
K44 | 2-Me-pyrr | C-H | Cl | 4-H<sub>2</sub>NOC-pipe |
K45 | 2-Me-pyrr | C-F | F | 4-HO-pipe |
K46 | 2-Me-pyrr | C-F | F | 4-MeO-pipe |
K47 | 2-Me-pyrr | C-F | F | 4-H<sub>2</sub>O<sub>3</sub>P-pipe |
K48 | 2-Me-pyrr | C-F | F | 4-(EtO)<sub>2</sub>(O)P-pipe |
K49 | 2-Me-pyrr | C-F | F | 4-NC-pipe |
K50 | 2-Me-pyrr | C-F | F | 4-H<sub>2</sub>NOC-pipe |
K51 | 3-Me-pyrr | C-H | Cl | 4-HO-pipe |
K52 | 3-Me-pyrr | C-H | Cl | 4-MeO-pipe |
K53 | 3-Me-pyrr | C-H | Cl | 4-H<sub>2</sub>O<sub>3</sub>P-pipe |
K54 | 3-Me-pyrr | C-H | Cl | 4-(EtO)<sub>2</sub>(O)P-pipe |
K55 | 3-Me-pyrr | C-H | Cl | 4-NC-pipe |
K56 | 3-Me-pyrr | C-H | Cl | 4-H<sub>2</sub>NOC-pipe |
K57 | 3-Me-pyrr | C-F | F | 4-HO-pipe |
K58 | 3-Me-pyrr | C-F | F | 4-MeO-pipe |
K59 | 3-Me-pyrr | C-F | F | 4-H<sub>2</sub>O<sub>3</sub>P-pipe |
K60 | 3-Me-pyrr | C-F | F | 4-(EtO)<sub>2</sub>(O)P-pipe |
K61 | 3-Me-pyrr | C-F | F | 4-NC-pipe |
K62 | 3-Me-pyrr | C-F | F | 4-H<sub>2</sub>NOC-pipe |
K63 | iPrN(Me)- | C-H | Cl | 4-HO-pipe |
No | R<sup>1</sup> | X | Y | R |
K64 | iPrN(Me)- | C-H | Cl | 4-MeO-p ipe |
K65 | iPrN(Me)- | C-H | Cl | 4-H<sub>2</sub>O<sub>3</sub>P-pipe |
K66 | iPrN(Me)- | C-H | Cl | 4-(EtO)<sub>2</sub>(O)P-pipe |
K67 | iPrN(Me)- | C-H | Cl | 4-NC-pipe |
K68 | iPrN(Me)- | C-H | Cl | 4-H<sub>2</sub>NOC-pipe |
K69 | iPrN(Me)- | C-F | F | 4-HO-pipe |
K70 | iPrN(Me)- | C-F | F | 4-MeO-pipe |
K71 | iPrN(Me)- | C-F | F | 4-H<sub>2</sub>O<sub>3</sub>P-pipe |
K72 | iPrN(Me)- | C-F | F | 4-(EtO)<sub>2</sub>(O)P-pipe |
K73 | iPrN(Me)- | C-F | F | 4-NC-pipe |
K74 | iPrN(Me)- | C-F | F | 4-H<sub>2</sub>NOC-pipe |
K75 | Me<sub>2</sub>N- | C-H | Cl | 4-HO-pipe |
K76 | Me<sub>2</sub>N- | C-H | Cl | 4-MeO-pipe |
K77 | Me<sub>2</sub>N- | C-H | Cl | 4-H<sub>2</sub>0<sub>3</sub>P-pipe |
K78 | Me<sub>2</sub>N- | C-H | Cl | 4-(EtO)<sub>2</sub>(O)P-pipe |
K79 | Me<sub>2</sub>N- | C-H | Cl | 4-NC-pipe |
K80 | Me<sub>2</sub>N- | C-H | Cl | 4-H<sub>2</sub>NOC-pipe |
K81 | Me<sub>2</sub>N- | C-F | F | 4-HO-pipe |
(表38,续)
No | R<sup>1</sup> | X | Y | R |
K82 | Me<sub>2</sub>N- | C-F | F | 4-MeO-pipe |
K83 | Me<sub>2</sub>N- | C-F | F | 4-H<sub>2</sub>O<sub>3</sub>P-pipe |
K84 | Me<sub>2</sub>N- | C-F | F | 4-(EtO)<sub>2</sub>(O)P-pipe |
K85 | Me<sub>2</sub>N- | C-F | F | 4-NC-pipe |
K86 | Me<sub>2</sub>N- | C-F | F | 4-H<sub>2</sub>NOC-pipe |
(表39)
No | R | No | R |
L1 | 3-HOCH<sub>2</sub>-pyrr | L29 | 3-H<sub>2</sub>O<sub>3</sub>P(CH<sub>2</sub>)<sub>2</sub>-pyrr |
L2 | 3-HO(CH<sub>2</sub>)<sub>2</sub>-pyrr | L30 | 3-H<sub>2</sub>O<sub>3</sub>P CH<sub>2</sub>-azet |
L3 | 3-HOCH<sub>2</sub>-azet | L31 | 3-H<sub>2</sub>O<sub>3</sub>P(CH<sub>2</sub>)<sub>2</sub>-azet |
L4 | 3-HO(CH<sub>2</sub>)<sub>2</sub>-azet | L32 | (EtO)<sub>2</sub>(O)P-(CH<sub>2</sub>)<sub>2</sub>NH- |
L5 | 3-HO-azet | L33 | (EtO)<sub>2</sub>(O)P-(CH<sub>2</sub>)<sub>3</sub>N(Me)- |
L6 | MeO(CH<sub>2</sub>)<sub>3</sub>NH- | L34 | (EtO)<sub>2</sub>(O)P-(CH<sub>2</sub>)<sub>2</sub>N(Me)- |
L7 | MeO(CH<sub>2</sub>)<sub>2</sub>NH- | L35 | (EtO<sub>2</sub>(O)P-(CH<sub>2</sub>)<sub>3</sub>O- |
L8 | MeO(CH<sub>2</sub>)<sub>3</sub>N(Me)- | L36 | (EtO)<sub>2</sub>(O)P-(CH<sub>2</sub>)<sub>2</sub>O- |
L9 | MeO(CH<sub>2</sub>)<sub>2</sub>N(Me)- | L37 | 3-(EtO)<sub>2</sub>(O)P-pipe |
L10 | 3-MeO-pipe | L38 | 3-(EtO)<sub>2</sub>(O)P-pyrr |
No | R | No | R |
L11 | 3-MeO-pyrr | L39 | 4-(EtO)<sub>2</sub>(O)P-CH<sub>2</sub>-pipe |
L12 | 4-MeOCH<sub>2</sub>-pipe | L40 | 4-(EtO)<sub>2</sub>(O)P-(CH<sub>2</sub>)<sub>2</sub>-pipe |
L13 | 4-MeO(CH<sub>2</sub>)<sub>2</sub>-pipe | L41 | 3-(EtO)<sub>2</sub>(O)P-CH<sub>2</sub>-pyrr |
L14 | 3-MeOCH<sub>2</sub>-pyrr | L42 | 3-(EtO)<sub>2</sub>(O)P-(CH<sub>2</sub>)<sub>2</sub>-pyrr |
L15 | 3-MeO(CH<sub>2</sub>)<sub>2</sub>-pyrr | L43 | 3-(EtO)<sub>2</sub>(O)P-CH<sub>2</sub>-azet |
L16 | 3-MeOCH<sub>2</sub>-azet | L44 | 3-(EtO<sub>2</sub>(O)P-(CH<sub>2</sub>)<sub>2</sub>-azet |
L17 | 3-MeO(CH<sub>2</sub>)<sub>2</sub>-azet | L45 | HOCH(Me)(CH<sub>2</sub>)<sub>2</sub>NH- |
L18 | NC-(CH<sub>2</sub>)<sub>3</sub>NH- | L46 | HOCH(Me)CH<sub>2</sub>NH- |
L19 | NC-(CH<sub>2</sub>)<sub>2</sub>NH- | L47 | HOCH<sub>2</sub>CH(OH)CH<sub>2</sub>NH- |
L20 | NC-(CH<sub>2</sub>)<sub>3</sub>N(Me)- | L48 | HOCH(Me)(CH<sub>2</sub>)<sub>2</sub>N(Me)- |
L21 | NC-(CH<sub>2</sub>)<sub>2</sub>N(Me)- | L49 | HOCH(Me)CH<sub>2</sub>N(Me)- |
L22 | NC-(CH<sub>2</sub>)<sub>3</sub>O- | L50 | HOCH<sub>2</sub>CH(OH)CH<sub>2</sub>N(Me)- |
L23 | NC-(CH<sub>2</sub>)<sub>2</sub>O- | L51 | HOCH(Me)(CH<sub>2</sub>)<sub>2</sub>O- |
L24 | 3-NC-pipe | L52 | HOCH(Me)CH<sub>2</sub>O- |
L25 | 3-NC-pyrr | L53 | HOCH<sub>2</sub>CH(OH)CH<sub>2</sub>O- |
L26 | 4-NC-CH<sub>2</sub>-pipe | L54 | Mor |
L27 | 4-NC-(CH<sub>2</sub>)<sub>2</sub>-pipe | L55 | MsNH(CH<sub>2</sub>)<sub>3</sub>-NH- |
L28 | 3-NCCH<sub>2</sub>-pyrr | L56 | MsNH(CH<sub>2</sub>)<sub>2</sub>-N(Me)- |
(表39,续)
No | R | No | R |
L57 | 3-NC(CH<sub>2</sub>)<sub>2</sub>-pyrr | L73 | MsNH(CH<sub>2</sub>)<sub>3</sub>-N(Me)- |
L58 | 3-NCCH<sub>2</sub>-azet | L74 | HO<sub>3</sub>S-(CH<sub>2</sub>)<sub>3</sub>-NH- |
L59 | 3-NC(CH<sub>2</sub>)<sub>2</sub>-azet | L75 | HO<sub>3</sub>S-(CH<sub>2</sub>)<sub>2</sub>-N(Me)- |
L60 | 4-Me-3-氧代-pipa | L76 | HO<sub>3</sub>S-(CH<sub>2</sub>)<sub>3</sub>-N(Me)- |
L61 | 5-氧代-1,4-二氮杂环庚烷-1-基 | L77 | 3-THP-O- |
L62 | Me2NOC-pipe | L78 | 4-THP-O- |
L63 | 3-F-pyrr | L79 | 2-THF-CH<sub>2</sub>O- |
L64 | 4-F-pipe | L80 | 3-THF-CH<sub>2</sub>O- |
L65 | 4-(四唑-5-基)-pipe | L81 | 3-THF-NH- |
L66 | 4-H<sub>2</sub>O<sub>3</sub>P-(CH<sub>2</sub>)<sub>2</sub>-pipe | L82 | 4-THP-NH- |
L67 | 3-H<sub>2</sub>O<sub>3</sub>P-CH<sub>2</sub>-pyrr | L83 | 2-THF-CH<sub>2</sub>NH- |
L68 | H<sub>2</sub>NO<sub>2</sub>S-(CH<sub>2</sub>)<sub>2</sub>-NH- | L84 | 3-THF-CH<sub>2</sub>NH- |
L69 | H<sub>2</sub>NO<sub>2</sub>S-(CH<sub>2</sub>)<sub>3</sub>-NH- | L85 | 3-THF-N(Me)- |
L70 | H<sub>2</sub>NO<sub>2</sub>S-(CH<sub>2</sub>)<sub>2</sub>-N(Me)- | L86 | 4-THP-N(Me)- |
L71 | H<sub>2</sub>NO<sub>2</sub>S-(CH<sub>2</sub>)<sub>3</sub>-N(Me)- | L87 | 2-THF-CH<sub>2</sub>N(Me)- |
L72 | HO<sub>3</sub>S-(CH<sub>2</sub>)<sub>2</sub>-NH- | L88 | 3-THF-CH<sub>2</sub>N(Me)- |
(表40)
(表41)
No | R<sup>1</sup> | X | R |
N1 | cBuN(Me)- | C-H | 4-HO-pipe |
N2 | cBuN(Me)- | C-H | mor |
N3 | cBuN(Me)- | C-H | 4-H<sub>2</sub>O<sub>3</sub>P-pipe |
N4 | cBuN(Me)- | C-H | 4-NC-pipe |
N5 | cBuN(Me)- | C-H | 3-氧代-pipa |
(表41,续)
No | R<sup>1</sup> | X | R |
N6 | cBuN(Me)- | N | 4-HO-pipe |
N7 | cBuN(Me)- | N | mor |
N8 | cBuN(Me)- | N | 4-H<sub>2</sub>O<sub>3</sub>P-pipe |
N9 | cBuN(Me)- | N | 4-NC-pipe |
N10 | cBuN(Me)- | N | 3-氧代-pipa |
N11 | iBuN(Me)- | C-H | 4-HO-pipe |
N12 | iBuN(Me)- | C-H | mor |
No | R<sup>1</sup> | X | R |
N13 | iBuN(Me)- | C-H | 4-H<sub>2</sub>O<sub>3</sub>P-pipe |
N14 | iBuN(Me)- | C-H | 4-NC-pipe |
N15 | iBuN(Me)- | C-H | 3-氧代-pipa |
N16 | iBuN(Me)- | N | 4-HO-pipe |
N17 | iBuN(Me)- | N | mor |
N18 | iBuN(Me)- | N | 4-H<sub>2</sub>O<sub>3</sub>P-pipe |
N19 | iBuN(Me)- | N | 4-NC-pipe |
N20 | iBuN(Me)- | N | 3-氧代-pipa |
N21 | 2-Me-pyrr | C-H | 4-HO-pipe |
N22 | 2-Me-pyrr | C-H | mor |
N23 | 2-Me-pyrr | C-H | 4-H<sub>2</sub>O<sub>3</sub>P-pipe |
N24 | 2-Me-pyrr | C-H | 4-NC-pipe |
N25 | 2-Me-pyrr | C-H | 3-氧代-pipa |
N26 | 2-Me-pyrr | N | 4-HO-pipe |
N27 | 2-Me-pyrr | N | mor |
N28 | 2-Me-pyrr | N | 4-H<sub>2</sub>O<sub>3</sub>P-pipe |
N29 | 2-Me-pyrr | N | 4-NC-pipe |
N30 | 2-Me-pyrr | N | 3-氧代-pipa |
N31 | iPrN(Me)- | C-H | 4-HO-pipe |
N32 | iPrN(Me)- | C-H | mor |
No | R<sup>1</sup> | X | R |
N33 | iPrN(Me)- | C-H | 4-H<sub>2</sub>O<sub>3</sub>P-pipe |
N34 | iPrN(Me)- | C-H | 4-NC-pipe |
N35 | iPrN(Me)- | C-H | 3-氧代-pipa |
N36 | iPrN(Me)- | N | 4-HO-pipe |
N37 | iPrN(Me)- | N | mor |
N38 | iPrN(Me)- | N | 4-H<sub>2</sub>O<sub>3</sub>P-pipe |
N39 | iPrN(Me)- | N | 4-NC-pipe |
N40 | iPrN(Me)- | N | 3-氧代-pipa |
Claims (13)
1.一种用化学式(I)表示的化合物或其药学上可接受的盐在制备血小板增多剂医药组合物中的应用,
式中符号具有以下含义:
A:亚甲基,
R1:式(II)表示的基团,或取代或未取代的3-8元环状胺基,
式中符号具有以下含义:
R11:取代或未取代的C1-6烷基,或取代或未取代的C3-8环烷基,
R12:取代或未取代的C1-6烷基,或取代或未取代的C3-8环烷基,
R2:取代或未取代的噻吩基,
R3:取代或未取代的吡啶基;
对于在R1中的“取代或未取代的环状胺基”,R11中的“取代或未取代的C3-8环烷基”、R12中的“取代或未取代的C3-8环烷基”和R2中的“取代或未取代的噻吩基”中所允许的取代基选自以下的(a)~(h)所示的基团;
(a)卤原子;
(b)-OH、-O-RZ、-O-芳基、-OCO-RZ、氧代基;
(c)-SH、-S-RZ、-S-芳基、-SO-RZ、-SO-芳基、-SO2-RZ、-SO2-芳基、可被1个或2个RZ取代的氨磺酰基;
(d)可被1个或2个RZ取代的氨基、-NHCO-RZ、-NHCO-芳基、-NHCO2-RZ、-NHCONH2、-NHSO2-RZ、-NHSO2-芳基、-NHSO2NH2、硝基;
(e)-CHO、-CO-RZ、-CO2H、-CO2-RZ、可被1个或2个RZ取代的氨基甲酰基、氰基;
(f)可被一个或多个选自-OH、-O-C1-6烷基、可被1个或2个C1-6烷基取代的氨基、卤原子及RZ的基团分别取代的芳基或环烷基;
(g)可被一个或多个选自-OH、-O-C1-6烷基、可被1个或2个C1-6烷基取代的氨基、卤原子及RZ的基团分别取代的芳族杂环或非芳族杂环;
(h)可被一个或多个选自上述(a)~(g)所示的取代基的基团取代的C1-6烷基;
R11中的“取代或未取代的C1-6烷基”以及R12中的“取代或未取代的C1-6烷基”中所允许的取代基选自(a)至(g)中列出的基团;
R3中的“取代或未取代的吡啶基”中所允许的取代基选自卤素、可被一个或多个卤素取代的C1-6烷基、-OH、-O-RZ、氧代、可被1个或2个RZ取代的氨基以及化学式(III)表示的基团;
-X-Y-Z (III)
式中符号具有以下含义:
X:C3-8环胺二基,可被一个或多个选自-OH、-O-C1-6烷基、卤素、氧代和RZ的基团取代;
Y:单键、-O-C1-6亚烷基或-N(C1-6烷基)-C1-6亚烷基;
Z:取代基W、-C3-8环胺二基-取代基W或-CO-C3-8环胺二基-取代基W;
“取代基W”指以下的基团:-OH、-O-RZ、-OCO-RZ、羧基、-CO2-RZ、-CO-RZ和可被一个或两个RZ取代的氨基甲酰基、氰基、可被一个或两个RZ取代的氨基、-NHCO-RZ、-NHSO2-RZ、可被一个或两个RZ取代的氨磺酰基、-SO3H、-P(O)(OH)2、-P(O)(OH)(ORZ)、-P(O)(ORZ)2、芳族杂环、非芳族杂环和RZ;
“RZ”表示C1-6烷基、C3-8环烷基或非芳族杂环,它们各自可以被一个或多个选自以下的基团取代:-OH、-O-C1-6烷基、-OCO-C1-6烷基、羧基、-CO2-C1-6烷基、-CO-C1-6烷基、可被一个或两个C1-6烷基取代的氨基甲酰基,氰基、可被一个或两个C1-6烷基取代的氨基,-NHCO-C1-6烷基、-NHSO2-C1-6烷基、可被一个或两个C1-6烷基取代的氨磺酰基、-SO3H、-P(O)(OH)2、-P(O)(OH)(O-C1-6烷基)、-P(O)(O-C1-6烷基)2、芳族杂环、非芳族杂环和卤素。
2.如权利要求1所述的应用,其特征在于,R2是未取代的或被卤素取代的噻吩基。
3.如权利要求1所述的应用,其特征在于,R1的定义中所述的取代或未取代的3-8元环状胺基未被取代或被C1-6烷基取代;R11和R12的定义中所述的取代或未取代的C1-6烷基未被取代或被C1-6烷氧基取代;R11和R12的定义中所述的取代或未取代的C3-8环烷基未被取代。
4.如权利要求1所述的应用,其特征在于,R1是-NR11R12;氮杂环庚烷-1-基和氮杂环辛烷-1-基;其中R11是取代或未取代的C1-6烷基或取代或未取代的C3-8环烷基,R12是取代或未取代的C1-6烷基或取代或未取代的C3-8环烷基,R11和R12的定义中所述的取代或未取代的C1-6烷基未被取代或被C1-6烷氧基取代;R11和R12的定义中所述的取代或未取代的C3-8环烷基未被取代。
5.如权利要求2所述的应用,其特征在于,R2是4-氯噻吩-2-基。
6.如权利要求1所述的应用,所述药物组合物是血小板减少症治疗剂。
7.一种化学式(III)表示的化合物或其药学上可接受的盐,
式中符号具有以下含义:
B:亚甲基,
R4:式(II)表示的基团,或取代或未取代的3-8元环状胺基,
R11:取代或未取代的C1-6烷基,或取代或未取代的C3-8环烷基,
R12:取代或未取代的C1-6烷基,或取代或未取代的C3-8环烷基,
R5:取代或未取代的噻吩基,
R6:取代或未取代的吡啶基;
对于在R4中的“取代或未取代的环状胺基”,R11中的“取代或未取代的C3-8环烷基”、R12中的“取代或未取代的C3-8环烷基”和R5中的“取代或未取代的噻吩基”中所允许的取代基选自以下的(a)~(h)所示的基团;
(a)卤原子;
(b)-OH、-O-RZ、-O-芳基、-OCO-RZ、氧代基;
(c)-SH、-S-RZ、-S-芳基、-SO-RZ、-SO-芳基、-SO2-RZ、-SO2-芳基、可被1个或2个RZ取代的氨磺酰基;
(d)可被1个或2个RZ取代的氨基、-NHCO-RZ、-NHCO-芳基、-NHCO2-RZ、-NHCONH2、-NHSO2-RZ、-NHSO2-芳基、-NHSO2NH2、硝基;
(e)-CHO、-CO-RZ、-CO2H、-CO2-RZ、可被1个或2个RZ取代的氨基甲酰基、氰基;
(f)可被一个或多个选自-OH、-O-C1-6烷基、可被1个或2个C1-6烷基取代的氨基、卤原子及RZ的基团分别取代的芳基或环烷基;
(g)可被一个或多个选自-OH、-O-C1-6烷基、可被1个或2个C1-6烷基取代的氨基、卤原子及RZ的基团分别取代的芳族杂环或非芳族杂环;
(h)可被一个或多个选自上述(a)~(g)所示的取代基的基团取代的C1-6烷基;
R11中的“取代或未取代的C1-6烷基”以及R12中的“取代或未取代的C1-6烷基”中所允许的取代基选自(a)至(g)中列出的基团;
R6中的“取代或未取代的吡啶基”中所允许的取代基选自卤素、可被一个或多个卤素取代的C1-6烷基、-OH、-O-RZ、氧代、可被1个或2个RZ取代的氨基以及化学式(III)表示的基团;
-X-Y-Z (III)
式中符号具有以下含义:
X:C3-8环胺二基,可被一个或多个选自-OH、-O-C1-6烷基、卤素、氧代和RZ的基团取代;
Y:单键、-O-C1-6亚烷基或-N(C1-6烷基)-C1-6亚烷基;
Z:取代基W、-C3-8环胺二基-取代基W或-CO-C3-8环胺二基-取代基W;
“取代基W”指以下的基团:-OH、-O-RZ、-OCO-RZ、羧基、-CO2-RZ、-CO-RZ和可被一个或两个RZ取代的氨基甲酰基、氰基、可被一个或两个RZ取代的氨基、-NHCO-RZ、-NHSO2-RZ、可被一个或两个RZ取代的氨磺酰基、-SO3H、-P(O)(OH)2、-P(O)(OH)(ORZ)、-P(O)(ORZ)2、芳族杂环、非芳族杂环和RZ;
“RZ”表示C1-6烷基、C3-8环烷基或非芳族杂环,它们各自可以被一个或多个选自以下的基团取代:-OH、-O-C1-6烷基、-OCO-C1-6烷基、羧基、-CO2-C1-6烷基、-CO-C1-6烷基、可被一个或两个C1-6烷基取代的氨基甲酰基,氰基、可被一个或两个C1-6烷基取代的氨基,-NHCO-C1-6烷基、-NHSO2-C1-6烷基、可被一个或两个C1-6烷基取代的氨磺酰基、-SO3H、-P(O)(OH)2、-P(O)(OH)(O-C1-6烷基)、-P(O)(O-C1-6烷基)2、芳族杂环、非芳族杂环和卤素。
8.如权利要求7所述的化合物或其药学上可接受的盐,其特征在于,R5是未取代的或被卤素取代的噻吩基。
9.如权利要求7所述的化合物或其药学上可接受的盐,其特征在于,R4的定义中所述的取代或未取代的5-8元环状胺基未被取代或被C1-6烷基取代;R11和R12的定义中所述的取代或未取代的C1-6烷基未被取代或被C1-6烷氧基取代;R11和R12的定义中所述的取代或未取代的C3-8环烷基未被取代。
10.如权利要求7所述的化合物或其药学上可接受的盐,其特征在于,R4是-NR11R12;氮杂环庚烷-1-基和氮杂环辛烷-1-基;其中R11是取代或未取代的C1-6烷基或取代或未取代的C3-8环烷基,R12是取代或未取代的C1-6烷基或取代或未取代的C3-8环烷基,R11和R12的定义中所述的取代或未取代的C1-6烷基未被取代或被C1-6烷氧基取代;R11和R12的定义中所述的取代或未取代的C3-8环烷基未被取代。
11.如权利要求8所述的化合物或其药学上可接受的盐,其特征在于,R5是4-氯噻吩-2-基。
12.如权利要求7所述的化合物,为:
1-{3-氯-5-[(4-(4-氯噻吩-2-基)-5-{[环丁基(甲基)氨基]甲基}噻唑-2-基)氨基甲酰基]-2-吡啶基}哌啶-4-羧酸,
1-(5-{[5-{(丁基(甲基)氨基]甲基}-4-(4-氯噻吩-2-基)噻唑-2-基]氨基甲酰基}-3-氯-2-吡啶基)哌啶-4-羧酸,
1-{5-[(4-(4-氯噻吩-2-基)-5-{[(2R)-2-甲基吡咯烷-1-基]甲基}噻唑-2-基)氨基甲酰基]-3-氟-2-吡啶基}哌啶-4-羧酸,
1-{3-氯-5-[(4-(4-氯噻吩-2-基)-5-{[(2S)-2-甲基吡咯烷-1-基]甲基}噻唑-2-基)氨基甲酰基]-2-吡啶基}哌啶-4-羧酸,
1-(3-氯-5-{[4-(4-氯噻吩-2-基)-5-(二甲基氨基甲基)噻唑-2-基]氨基甲酰基}-2-吡啶基)哌啶-4-羧酸,
1-{3-氯-5-[(4-(4-氯噻吩-2-基)-5-{[异丙基(甲基)氨基]甲基}噻唑-2-基)氨基甲酰基]-2-吡啶基}哌啶-4-羧酸,
4-[{3-氯-5-[(4-(4-氯噻吩-2-基)-5-{[异丙基(甲基)氨基]甲基}噻唑-2-基)氨基甲酰基]-2-吡啶基}(甲基)氨基]丁酸,
1-{3-氯-5-[(4-(4-氯噻吩-2-基)-5-{[(3S)-3-甲基吡咯烷-1-基]甲基}噻唑-2-基)氨基甲酰基]-2-吡啶基}哌啶-4-羧酸,
1-{3-氯-5-[(4-(4-氯噻吩-2-基)-5-{[[(2S)-2-甲氧基丙基](甲基)氨基]甲基}噻唑-2-基)氨基甲酰基]-2-吡啶基}哌啶-4-羧酸,
N-[5-{[丁基(甲基)氨基]甲基}-4-(4-氯噻吩-2-基)噻唑-2-基]-5-氯-6-[(3-羟基丙基)氨基]烟酰胺,
N-[5-{[丁基(甲基)氨基]甲基}-4-(4-氯噻吩-2-基)噻唑-2-基]-5-氯-6-(3-氧代哌嗪-1-基)烟酰胺,
N-[5-{[丁基(甲基)氨基]甲基}-4-(4-氯噻吩-2-基)噻唑-2-基]-5-氯-6-[4-(羟甲基)哌啶子基]烟酰胺,
或它们的药学上可接受的盐。
13.一种药物组合物,包含权利要求7-12中任一项所述的化合物作为活性成分。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP275718/2003 | 2003-07-17 | ||
JP2003275718 | 2003-07-17 | ||
PCT/JP2004/010440 WO2005007651A1 (ja) | 2003-07-17 | 2004-07-15 | 2-アシルアミノチアゾール誘導体又はその塩 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1835948A CN1835948A (zh) | 2006-09-20 |
CN1835948B true CN1835948B (zh) | 2010-05-26 |
Family
ID=34074565
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2004800204978A Expired - Fee Related CN1835948B (zh) | 2003-07-17 | 2004-07-15 | 2-酰基氨基噻唑衍生物或其盐 |
Country Status (8)
Country | Link |
---|---|
US (1) | US7361658B2 (zh) |
EP (1) | EP1647553A4 (zh) |
JP (1) | JP4324791B2 (zh) |
KR (1) | KR100907317B1 (zh) |
CN (1) | CN1835948B (zh) |
CA (1) | CA2529686C (zh) |
MX (1) | MXPA06000441A (zh) |
WO (1) | WO2005007651A1 (zh) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2610611T3 (es) * | 2002-01-18 | 2017-04-28 | Astellas Pharma Inc. | Derivado de 2-acilaminotiazol o sal del mismo |
JP4774995B2 (ja) * | 2005-01-12 | 2011-09-21 | アステラス製薬株式会社 | アシルアミノチアゾール誘導体を有効成分とする医薬組成物 |
WO2007046867A2 (en) * | 2005-05-19 | 2007-04-26 | Xenon Pharmaceuticals Inc. | Piperidine derivatives and their uses as therapeutic agents |
WO2007004038A1 (en) * | 2005-07-05 | 2007-01-11 | Pfizer Products Inc. | Aminothiazole derivatives as agonists of the thrombopoietin receptor |
WO2007036769A1 (en) * | 2005-07-05 | 2007-04-05 | Pfizer Products Inc. | Aminothiazole derivatives as agonists of the thrombopoietin receptor |
KR20080074166A (ko) * | 2005-11-08 | 2008-08-12 | 아스테라스 세이야쿠 가부시키가이샤 | 혈소판감소증을 치료하는 조성물 및 방법 |
EP2452674B1 (en) * | 2006-08-08 | 2014-03-26 | Akarx, Inc. | Compositions and methods for increasing blood platelet levels in humans |
BRPI0814891A2 (pt) | 2007-07-31 | 2015-08-18 | Shionogi & Co | Composição farmacêutica contendo composto oticamente ativo tendo atividade agonista de receptor de trombopoietina, e intermediário do mesmo. |
RU2490257C2 (ru) * | 2008-05-30 | 2013-08-20 | Такеда Фармасьютикал Компани Лимитед | Гетероциклическое соединение |
WO2011019990A1 (en) * | 2009-08-14 | 2011-02-17 | Eisai, Inc. | Use of e5501 for stimulating platelet production |
EP2780322B1 (en) | 2011-11-14 | 2018-05-16 | Ligand Pharmaceuticals, Inc. | Methods and compositions associated with the granulocyte colony-stimulating factor receptor |
WO2013072705A1 (en) * | 2011-11-18 | 2013-05-23 | Heptares Therapeutics Limited | Muscarinic m1 receptor agonists |
TWI647227B (zh) | 2013-02-28 | 2019-01-11 | 日商安斯泰來製藥股份有限公司 | 2-醯胺噻唑衍生物或其鹽 |
US9962370B2 (en) | 2013-03-15 | 2018-05-08 | Ligand Pharmaceuticals Incorporated | Methods of treatment associated with the granulocyte colony-stimulating factor receptor |
PL3153511T3 (pl) | 2014-06-06 | 2019-09-30 | Astellas Pharma Inc. | Pochodna 2-acyloaminotiazolu do stosowania do profilaktyki lub leczenia chorób pęcherza moczowego/dróg moczowych |
CN106573928B (zh) * | 2014-08-26 | 2020-04-14 | 安斯泰来制药株式会社 | 2-氨基噻唑衍生物或其盐 |
GB201513743D0 (en) | 2015-08-03 | 2015-09-16 | Heptares Therapeutics Ltd | Muscarinic agonists |
GB201617454D0 (en) | 2016-10-14 | 2016-11-30 | Heptares Therapeutics Limited | Pharmaceutical compounds |
GB201810239D0 (en) | 2018-06-22 | 2018-08-08 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
GB201819960D0 (en) | 2018-12-07 | 2019-01-23 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
GB202020191D0 (en) | 2020-12-18 | 2021-02-03 | Heptares Therapeutics Ltd | Pharmaceutical compounds |
AU2021288584A1 (en) * | 2020-06-09 | 2023-01-19 | Anima Biotech Inc. | Collagen 1 translation inhibitors and methods of use thereof |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1049337A (zh) * | 1989-08-07 | 1991-02-20 | 藤泽药品工业株式会社 | 噻唑衍生物,制备它们的方法,以及含有它们的药用组合物 |
US5380736A (en) * | 1991-06-05 | 1995-01-10 | Elf Sanofi | Heterocyclic substituted 2-acylamino-5-thiazoles, their preparation and pharmaceutical compositions containing them |
EP1207155A1 (en) * | 1999-07-26 | 2002-05-22 | Shionogi & Co., Ltd. | Drug compositions exhibiting thrombopoietin agonism |
WO2002062775A1 (fr) * | 2001-02-02 | 2002-08-15 | Yamanouchi Pharmaceutical Co., Ltd. | Dérivé de 2-acylaminothiazole ou son sel |
CN1419547A (zh) * | 2000-01-24 | 2003-05-21 | 盐野义制药株式会社 | 具有血小板生成素受体激动作用的化合物 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5256675A (en) | 1989-08-07 | 1993-10-26 | Fujisawa Pharmaceutical Co., Ltd. | Thiazole derivatives, processes for production thereof and pharmaceutical compositions comprising the same |
ES2610611T3 (es) | 2002-01-18 | 2017-04-28 | Astellas Pharma Inc. | Derivado de 2-acilaminotiazol o sal del mismo |
-
2004
- 2004-07-15 US US10/564,520 patent/US7361658B2/en not_active Expired - Fee Related
- 2004-07-15 CN CN2004800204978A patent/CN1835948B/zh not_active Expired - Fee Related
- 2004-07-15 JP JP2004208207A patent/JP4324791B2/ja not_active Expired - Fee Related
- 2004-07-15 KR KR1020067000994A patent/KR100907317B1/ko not_active IP Right Cessation
- 2004-07-15 EP EP04747829A patent/EP1647553A4/en not_active Withdrawn
- 2004-07-15 WO PCT/JP2004/010440 patent/WO2005007651A1/ja not_active Application Discontinuation
- 2004-07-15 MX MXPA06000441A patent/MXPA06000441A/es active IP Right Grant
- 2004-07-15 CA CA2529686A patent/CA2529686C/en not_active Expired - Fee Related
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1049337A (zh) * | 1989-08-07 | 1991-02-20 | 藤泽药品工业株式会社 | 噻唑衍生物,制备它们的方法,以及含有它们的药用组合物 |
US5380736A (en) * | 1991-06-05 | 1995-01-10 | Elf Sanofi | Heterocyclic substituted 2-acylamino-5-thiazoles, their preparation and pharmaceutical compositions containing them |
EP1207155A1 (en) * | 1999-07-26 | 2002-05-22 | Shionogi & Co., Ltd. | Drug compositions exhibiting thrombopoietin agonism |
CN1419547A (zh) * | 2000-01-24 | 2003-05-21 | 盐野义制药株式会社 | 具有血小板生成素受体激动作用的化合物 |
WO2002062775A1 (fr) * | 2001-02-02 | 2002-08-15 | Yamanouchi Pharmaceutical Co., Ltd. | Dérivé de 2-acylaminothiazole ou son sel |
Also Published As
Publication number | Publication date |
---|---|
CA2529686A1 (en) | 2005-01-27 |
EP1647553A1 (en) | 2006-04-19 |
CA2529686C (en) | 2010-06-15 |
JP4324791B2 (ja) | 2009-09-02 |
WO2005007651A1 (ja) | 2005-01-27 |
MXPA06000441A (es) | 2006-04-05 |
US20060194844A1 (en) | 2006-08-31 |
KR100907317B1 (ko) | 2009-07-13 |
US7361658B2 (en) | 2008-04-22 |
CN1835948A (zh) | 2006-09-20 |
JP2005047905A (ja) | 2005-02-24 |
EP1647553A4 (en) | 2008-12-31 |
KR20060039908A (ko) | 2006-05-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1835948B (zh) | 2-酰基氨基噻唑衍生物或其盐 | |
CA2974853C (en) | 4h-pyrrolo[3,2-c]pyridin-4-one derivatives | |
JP2023071767A (ja) | Brm標的化化合物および関連使用方法 | |
KR102013512B1 (ko) | 신규 3-인돌 치환 유도체, 제약 조성물 및 사용 방법 | |
CA2895404A1 (en) | Bet-protein-inhibiting dihydropyridopyrazinones | |
JP6925435B2 (ja) | ピリミジニル−ピリジルオキシ−ナフチル化合物及びire1関連疾患及び障害を治療する方法 | |
CA2918813A1 (en) | Substituted dihydropyrido[3,4-b]pyrazinones as dual inhibitors of bet proteins and polo-like kinases | |
EP2428508A1 (en) | Diamino heterocyclic carboxamide compound | |
CA3154073A1 (en) | Isoindolinone and indazole compounds for the degradation of egfr | |
WO2018172852A1 (en) | Substituted dihydroindene-4-carboxamides and analogs thereof, and methods using same | |
WO2003062233A1 (fr) | Derive de 2-acylaminothiazole et son sel | |
CA2994596A1 (en) | 1h-pyrrol-3-amines | |
WO2014076146A1 (en) | Triazolopyridazine | |
EP2776445A1 (en) | Therapeutically active thiazolo-pyrimidine derivatives | |
AU2018291688A1 (en) | Heteroaryldihydropyrimidine derivatives and methods of treating hepatitis B infections | |
US20220204498A1 (en) | Pyrido-pyrimidinyl compounds and methods of use | |
JP2017533206A (ja) | 腫瘍の治療のためのmidh1阻害剤としての1−シクロヘキシル−2−フェニルアミノベンゾイミダゾール | |
US12071425B2 (en) | Phenoxy-pyridyl-pyrimidine compounds and methods of use | |
US20230303509A1 (en) | Sulfonamido derivatives as cyclin-dependent kinase 2 inhibitors | |
WO2014075318A1 (zh) | 嘧啶类化合物及其应用 | |
BRPI0612678A2 (pt) | derivados de 1 - [2' , 3'-dideoxi-3' c-(hidroximentil) - beta-d-eritro-pentofuranozil] citozina como inibidores de hiv |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20100526 Termination date: 20140715 |
|
EXPY | Termination of patent right or utility model |